Pharmaceutical compounds

ABSTRACT

Compounds of Formulae Ia and Ib, and stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula Ia and Ib for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

The invention claimed herein was made as a result of activitiesundertaken within the scope of a joint research agreement betweenPiramed Limited and Genentech, Inc.

PRIORITY OF INVENTION

This application claims priority to U.S. Provisional Application No.60/795,048 that was filed on 26 Apr. 2006. The entire content of thisprovisional application is hereby incorporated herein by reference.

FIELD OF THE INVENTION

The present invention relates to pyrimidine derivatives and their use asinhibitors of phosphatidylinositol 3-kinase (PI3K).

BACKGROUND TO THE INVENTION

Phosphatidylinositol (hereinafter abbreviated as “PI”) is one of anumber of phospholipids found in cell membranes. In recent years it hasbecome clear that PI plays an important role in intracellular signaltransduction. In the late 1980s, a PI3 kinase (PI3K) was found to be anenzyme which phosphorylates the 3-position of the inositol ring ofphosphatidylinositol (D. Whitman et al, 1988, Nature, 332, 664).

PI3K was originally considered to be a single enzyme, but it has nowbeen clarified that a plurality of subtypes are present in PI3K. Eachsubtype has its own mechanism for regulating activity. Three majorclasses of PI3Ks have been identified on the basis of their in vitrosubstrate specificity (B. Vanhaesebroeck, 1997, Trend in Biol. Sci, 22,267). Substrates for class I PI3Ks are PI, PI 4-phosphate (PI4P) and PI4,5-biphosphate (PI (4,5)P2). Class I PI3Ks are further divided into twogroups, class Ia and class Ib, in terms of their activation mechanism.Class Ia PI3Ks include PI3K p110α, p110β and p110δ subtypes, whichtransmit signals from tyrosine kinase-coupled receptors. Class Ib PI3Kincludes a p110γ subtype activated by a G protein-coupled receptor. PIand PI(4)P are known as substrates for class II PI3Ks. Class II PI3Ksinclude PI3K C2α, C2β and C2γ subtypes, which are characterized bycontaining C2 domains at the C terminus. The substrate for class IIIPI3Ks is PI only.

In the PI3K subtypes, the class Ia subtype has been most extensivelyinvestigated to date. The three subtypes of class Ia are heterodimers ofa catalytic 110 kDa subunit and regulatory subunits of 85 kDa or 55 kDa.The regulatory subunits contain SH2 domains and bind to tyrosineresidues phosphorylated by growth factor receptors with a tyrosinekinase activity or oncogene products, thereby inducing the PI3K activityof the p110 catalytic subunit which phosphorylates its lipid substrate.Thus, the class Ia subtypes are considered to be associated with cellproliferation and carcinogenesis.

There continues to be a need for class I PI3 kinase inhibitors withimproved pharmacokinetic and pharmacodynamic properties. The PI3kinase/Akt/PTEN pathway is thus an attractive target for cancer drugdevelopment since such agents would be expected to inhibitproliferation, reverse the repression of apoptosis and surmountresistance to cytotoxic agents in cancer cells. PI3 kinase inhibitorshave been reported (Yaguchi et al (2006) Jour. of the Nat. Cancer Inst.98(8):545-556; U.S. Pat. No. 6,608,056; U.S. Pat. No. 6,608,053; U.S.Pat. No. 6,838,457; U.S. Pat. No. 6,770,641; U.S. Pat. No. 6,653,320;U.S. Pat. No. 6,403,588; WO 2004017950; US 2004092561; WO 2004007491; WO2004006916; WO 2003037886; US 2003149074; WO 2003035618; WO 2003034997;US 2003158212; EP 1417976; US 2004053946; JP 2001247477; JP 08175990; JP08176070). Wortmannin analogs have PI3 kinase activity in mammals (U.S.Pat. No. 6,703,414; WO 97/15658).

SUMMARY OF THE INVENTION

It has now been found that a novel class of fused pyrimidine compoundsare effective inhibitors of PI3K with drug-like physicochemical andpharmacokinetic properties. The compounds exhibit selectivity for classIa PI3Ks over class Ib, in particular for the p110α subtype.

Accordingly, the present invention provides a compound which is a fusedpyrimidine of formula (Ia) or (Ib):

and stereoisomers, geometric isomers, tautomers, solvates, metabolites,and pharmaceutically acceptable salts thereof, wherein X is O or S.Groups R¹, R² and R³ are as defined herein.

Another aspect of the invention provides a pharmaceutical compositioncomprising a thienopyrimidine or furanopyrimidine compound of FormulasIa or Ib and a pharmaceutically acceptable carrier. The pharmaceuticalcomposition may further comprise one or more additional therapeuticagents selected from anti-proliferative agents, anti-inflammatoryagents, immunomodulatory agents, neurotropic factors, agents fortreating cardiovascular disease, agents for treating liver disease,anti-viral agents, agents for treating blood disorders, agents fortreating diabetes, and agents for treating immunodeficiency disorders.

Another aspect of the invention provides methods of inhibiting PI3kinase activity, comprising contacting a PI3 kinase with an effectiveinhibitory amount of a compound of Formula Ia or Ib, or a stereoisomer,geometric isomer, tautomer, solvate, metabolite, or pharmaceuticallyacceptable salt or prodrug thereof.

Another aspect of the invention provides methods of preventing ortreating a disease or disorder modulated by PI3 kinases, comprisingadministering to a mammal in need of such treatment an effective amountof a compound of Formula Ia or Ib, or a stereoisomer, geometric isomer,tautomer, solvate, metabolite, or pharmaceutically acceptable salt orprodrug thereof. Examples of such diseases, conditions and disordersinclude, but are not limited to, hyperproliferative disorders (e.g.,cancer, including melanoma and other cancers of the skin),neurodegeneration, cardiac hypertrophy, pain, migraine, neurotraumaticdiseases, stroke, diabetes, hepatomegaly, cardiovascular disease,Alzheimer's disease, cystic fibrosis, viral diseases, autoimmunediseases, atherosclerosis, restenosis, psoriasis, allergic disorders,inflammation, neurological disorders, hormone-related diseases,conditions associated with organ transplantation, immunodeficiencydisorders, destructive bone disorders, proliferative disorders,infectious diseases, conditions associated with cell death,thrombin-induced platelet aggregation, chronic myelogenous leukemia(CML), liver disease, pathologic immune conditions involving T cellactivation, and CNS disorders.

Another aspect of the invention provides methods of preventing ortreating a hyperproliferative disorder, comprising administering to amammal in need of such treatment an effective amount of a compound ofFormula Ia or Ib, or a stereoisomer, geometric isomer, tautomer,solvate, metabolite, or pharmaceutically acceptable salt or prodrugthereof, alone or in combination with one or more additional compoundshaving anti-hyperproliferative properties.

In a further aspect the present invention provides a method of using acompound of this invention to treat a disease or condition modulated byPI3 kinase in a mammal. An additional aspect of the invention is the useof a compound of this invention in the preparation of a medicament forthe treatment or prevention of a disease or condition modulated by PI3kinase in a mammal.

Another aspect of the invention includes kits comprising a compound ofFormula Ia or Ib, or a stereoisomer, geometric isomer, tautomer,solvate, metabolite, or pharmaceutically acceptable salt or prodrugthereof, a container, and optionally a package insert or labelindicating a treatment.

DETAILED DESCRIPTION OF THE INVENTION

Compounds of formulae Ia and Ib are regioisomers, i.e. they differ bythe placement of atom X in the thienopyrimidine (X=sulphur) orfuranopyrimidine (X=oxygen) fused ring system. The four possibleregioisomeric forms of the ring systems encompassed by formulae Ia andIb are:

Compounds of the invention thus include both regioisomers of each of the4-morpholino thienopyrimidine and 4-morpholino furanopyrimidinecompounds of formulae (Ia), (Ia′), (Ia″) and (Ia′″), and (Ib), (Ib′),(Ib″) and (Ib′″).

DEFINITIONS

As used herein, the terms “treat” and “treatment” refer to boththerapeutic treatment and prophylactic or preventative measures, whereinthe object is to prevent or slow down (lessen) an undesiredphysiological change or disorder, such as the development or spread ofcancer. For purposes of this invention, beneficial or desired clinicalresults include, but are not limited to, alleviation of symptoms,diminishment of extent of disease, stabilized (i.e., not worsening)state of disease, delay or slowing of disease progression, ameliorationor palliation of the disease state, and remission (whether partial ortotal), whether detectable or undetectable. “Treatment” can also meanprolonging survival as compared to expected survival if not receivingtreatment. Those in need of treatment include those already with thecondition or disorder as well as those prone to have the condition ordisorder or those in which the condition or disorder is to be prevented.

The phrase “therapeutically effective amount” means an amount of acompound of the present invention that (i) treats or prevents theparticular disease, condition, or disorder, (ii) attenuates,ameliorates, or eliminates one or more symptoms of the particulardisease, condition, or disorder, or (iii) prevents or delays the onsetof one or more symptoms of the particular disease, condition, ordisorder described herein. In the case of cancer, the therapeuticallyeffective amount of the drug may reduce the number of cancer cells;reduce the tumor size; inhibit (i.e., slow to some extent and preferablystop) cancer cell infiltration into peripheral organs; inhibit (i.e.,slow to some extent and preferably stop) tumor metastasis; inhibit, tosome extent, tumor growth; and/or relieve to some extent one or more ofthe symptoms associated with the cancer. To the extent the drug mayprevent growth and/or kill existing cancer cells, it may be cytostaticand/or cytotoxic. For cancer therapy, efficacy can be measured, forexample, by assessing the time to disease progression (TTP) and/ordetermining the response rate (RR).

The phrase “pharmaceutically acceptable” indicates that the substance orcomposition must be compatible chemically and/or toxicologically, withthe other ingredients comprising a formulation, and/or the mammal beingtreated therewith.

The terms “cancer” and “cancerous” refer to or describe thephysiological condition in mammals that is typically characterized byunregulated cell growth. A “tumor” comprises one or more cancerouscells. Examples of cancer include, but are not limited to, carcinoma,lymphoma, blastoma, sarcoma, and leukemia or lymphoid malignancies. Moreparticular examples of such cancers include squamous cell cancer (e.g.,epithelial squamous cell cancer), lung cancer including small-cell lungcancer, non-small cell lung cancer (“NSCLC”), adenocarcinoma of the lungand squamous carcinoma of the lung, cancer of the peritoneum,hepatocellular cancer, gastric or stomach cancer includinggastrointestinal cancer, pancreatic cancer, glioblastoma, cervicalcancer, ovarian cancer, liver cancer, bladder cancer, hepatoma, breastcancer, colon cancer, rectal cancer, colorectal cancer, endometrial oruterine carcinoma, salivary gland carcinoma, kidney or renal cancer,prostate cancer, vulval cancer, thyroid cancer, hepatic carcinoma, analcarcinoma, penile carcinoma, as well as head and neck cancer.

A “chemotherapeutic agent” is a chemical compound useful in thetreatment of cancer. Examples of chemotherapeutic agents includeErlotinib (TARCEVA®, Genentech/OSI Pharm.), Bortezomib (VELCADE®,Millennium Pharm.), Fulvestrant (FASLODEX®, AstraZeneca), Sutent(SU11248, Pfizer), Letrozole (FEMARA®, Novartis), Imatinib mesylate(GLEEVEC®, Novartis), PTK787/ZK 222584 (Novartis), Oxaliplatin(Eloxatin®, Sanofi), 5-FU (5-fluorouracil), Leucovorin, Rapamycin(Sirolimus, RAPAMUNE®, Wyeth), Lapatinib (TYKERB®, GSK572016, GlaxoSmith Kline), Lonafarnib (SCH 66336), Sorafenib (BAY43-9006, BayerLabs), and Gefitinib (IRESSA®, AstraZeneca), AG1478, AG1571 (SU 5271;Sugen), alkylating agents such as thiotepa and CYTOXAN®cyclosphosphamide; alkyl sulfonates such as busulfan, improsulfan andpiposulfan; aziridines such as benzodopa, carboquone, meturedopa, anduredopa; ethylenimines and methylamelamines including altretamine,triethylenemelamine, triethylenephosphoramide,triethylenethiophosphoramide and trimethylomelamine; acetogenins(especially bullatacin and bullatacinone); a camptothecin (including thesynthetic analog topotecan); bryostatin; callystatin; CC-1065 (includingits adozelesin, carzelesin and bizelesin synthetic analogs);cryptophycins (particularly cryptophycin 1 and cryptophycin 8);dolastatin; duocarmycin (including the synthetic analogs, KW-2189 andCB1-TM1); eleutherobin; pancratistatin; a sarcodictyin; spongistatin;nitrogen mustards such as chlorambucil, chlomaphazine,chlorophosphamide, estramustine, ifosfamide, mechlorethamine,mechlorethamine oxide hydrochloride, melphalan, novembichin,phenesterine, prednimustine, trofosfamide, uracil mustard; nitrosureassuch as carmustine, chlorozotocin, fotemustine, lomustine, nimustine,and ranimnustine; antibiotics such as the enediyne antibiotics (e.g.,calicheamicin, especially calicheamicin gamma1I and calicheamicinomegaI1 (Angew Chem. Intl. Ed. Engl. (1994) 33:183-186); dynemicin,including dynemicin A; bisphosphonates, such as clodronate; anesperamicin; as well as neocarzinostatin chromophore and relatedchromoprotein enediyne antibiotic chromophores), aclacinomysins,actinomycin, authramycin, azaserine, bleomycins, cactinomycin,carabicin, caminomycin, carzinophilin, chromomycinis, dactinomycin,daunorubicin, detorubicin, 6-diazo-5-oxo-L-norleucine, ADRIAMYCIN®(doxorubicin), morpholino-doxorubicin, cyanomorpholino-doxorubicin,2-pyrrolino-doxorubicin and deoxydoxorubicin), epirubicin, esorubicin,idarubicin, marcellomycin, mitomycins such as mitomycin C, mycophenolicacid, nogalamycin, olivomycins, peplomycin, porfiromycin, puromycin,quelamycin, rodorubicin, streptonigrin, streptozocin, tubercidin,ubenimex, zinostatin, zorubicin; anti-metabolites such as methotrexateand 5-fluorouracil (5-FU); folic acid analogs such as denopterin,methotrexate, pteropterin, trimetrexate; purine analogs such asfludarabine, 6-mercaptopurine, thiamiprine, thioguanine; pyrimidineanalogs such as ancitabine, azacitidine, 6-azauridine, carmofur,cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine;androgens such as calusterone, dromostanolone propionate, epitiostanol,mepitiostane, testolactone; anti-adrenals such as aminoglutethimide,mitotane, trilostane; folic acid replenisher such as frolinic acid;aceglatone; aldophosphamide glycoside; aminolevulinic acid; eniluracil;amsacrine; bestrabucil; bisantrene; edatraxate; defofamine; demecolcine;diaziquone; elformithine; elliptinium acetate; an epothilone; etoglucid;gallium nitrate; hydroxyurea; lentinan; lonidainine; maytansinoids suchas maytansine and ansamitocins; mitoguazone; mitoxantrone; mopidanmol;nitraerine; pentostatin; phenamet; pirarubicin; losoxantrone;podophyllinic acid; 2-ethylhydrazide; procarbazine; PSK® polysaccharidecomplex (JHS Natural Products, Eugene, Oreg.); razoxane; rhizoxin;sizofiran; spirogermanium; tenuazonic acid; triaziquone;2,2′,2″-trichlorotriethylamine; trichothecenes (especially T-2 toxin,verracurin A, roridin A and anguidine); urethan; vindesine; dacarbazine;mannomustine; mitobronitol; mitolactol; pipobroman; gacytosine;arabinoside (“Ara-C”); cyclophosphamide; thiotepa; taxoids, e.g., TAXOL®(paclitaxel; Bristol-Myers Squibb Oncology, Princeton, N.J.), ABRAXANE™(Cremophor-free), albumin-engineered nanoparticle formulations ofpaclitaxel (American Pharmaceutical Partners, Schaumberg, Ill.), andTAXOTERE® (doxetaxel; Rhône-Poulenc Rorer, Antony, France);chloranmbucil; GEMZAR® (gemcitabine); 6-thioguanine; mercaptopurine;methotrexate; platinum analogs such as cisplatin and carboplatin;vinblastine; etoposide (VP-16); ifosfamide; mitoxantrone; vincristine;NAVELBINE® (vinorelbine); novantrone; teniposide; edatrexate;daunomycin; aminopterin; capecitabine (XELODA®); ibandronate; CPT-11;topoisomerase inhibitor RFS 2000; difluoromethylornithine (DMFO);retinoids such as retinoic acid; and pharmaceutically acceptable salts,acids and derivatives of any of the above.

Also included in the definition of “chemotherapeutic agent” are: (i)anti-hormonal agents that act to regulate or inhibit hormone action ontumors such as anti-estrogens and selective estrogen receptor modulators(SERMs), including, for example, tamoxifen (including NOLVADEX®;tamoxifen citrate), raloxifene, droloxifene, 4-hydroxytamoxifen,trioxifene, keoxifene, LY117018, onapristone, and FARESTON® (toremifinecitrate); (ii) aromatase inhibitors that inhibit the enzyme aromatase,which regulates estrogen production in the adrenal glands, such as, forexample, 4(5)-imidazoles, aminoglutethimide, MEGASE® (megestrolacetate), AROMASIN® (exemestane; Pfizer), formestanie, fadrozole,RIVISOR® (vorozole), FEMARA® (letrozole; Novartis), and ARIMIDEX®(anastrozole; AstraZeneca); (iii) anti-androgens such as flutamide,nilutamide, bicalutamide, leuprolide, and goserelin; as well astroxacitabine (a 1,3-dioxolane nucleoside cytosine analog); (iv) proteinkinase inhibitors; (v) lipid kinase inhibitors; (vi) antisenseoligonucleotides, particularly those which inhibit expression of genesin signaling pathways implicated in aberrant cell proliferation, suchas, for example, PKC-alpha, Ralf and H-Ras; (vii) ribozymes such as VEGFexpression inhibitors (e.g., ANGIOZYME®) and HER2 expression inhibitors;(viii) vaccines such as gene therapy vaccines, for example, ALLOVECTIN®,LEUVECTIN®, and VAXID®; PROLEUKIN® rIL-2; a topoisomerase 1 inhibitorsuch as LURTOTECAN®; ABARELIX® rmRH; (ix) anti-angiogenic agents such asbevacizumab (AVASTIN®, Genentech); and (x) pharmaceutically acceptablesalts, acids and derivatives of any of the above.

The term “prodrug” as used in this application refers to a precursor orderivative form of a compound of the invention that is less cytotoxic tocells compared to the parent compound or drug and is capable of beingenzymatically or hydrolytically activated or converted into the moreactive parent form. See, e.g., Wilman, “Prodrugs in Cancer Chemotherapy”Biochemical Society Transactions, 14, pp. 375-382, 615th Meeting Belfast(1986) and Stella et al., “Prodrugs: A Chemical Approach to TargetedDrug Delivery,” Directed Drug Delivery, Borchardt et al., (ed.), pp.247-267, Humana Press (1985). The prodrugs of this invention include,but are not limited to, phosphate-containing prodrugs,thiophosphate-containing prodrugs, sulfate-containing prodrugs,peptide-containing prodrugs, D-amino acid-modified prodrugs,glycosylated prodrugs, β-lactam-containing prodrugs, optionallysubstituted phenoxyacetamide-containing prodrugs, optionally substitutedphenylacetamide-containing prodrugs, 5-fluorocytosine and other5-fluorouridine prodrugs which can be converted into the more activecytotoxic free drug. Examples of cytotoxic drugs that can be derivatizedinto a prodrug form for use in this invention include, but are notlimited to, compounds of the invention and chemotherapeutic agents suchas described above.

A “metabolite” is a product produced through metabolism in the body of aspecified compound or salt thereof. Metabolites of a compound may beidentified using routine techniques known in the art and theiractivities determined using tests such as those described herein. Suchproducts may result for example from the oxidation, reduction,hydrolysis, amidation, deamidation, esterification, deesterification,enzymatic cleavage, and the like, of the administered compound.Accordingly, the invention includes metabolites of compounds of theinvention, including compounds produced by a process comprisingcontacting a compound of this invention with a mammal for a period oftime sufficient to yield a metabolic product thereof.

A “liposome” is a small vesicle composed of various types of lipids,phospholipids and/or surfactant which is useful for delivery of a drug(such as the PI3 kinase inhibitors disclosed herein and, optionally, achemotherapeutic agent) to a mammal. The components of the liposome arecommonly arranged in a bilayer formation, similar to the lipidarrangement of biological membranes.

The term “chiral” refers to molecules which have the property ofnon-superimposability of the mirror image partner, while the term“achiral” refers to molecules which are superimposable on their mirrorimage partner.

The term “stereoisomers” refers to compounds which have identicalchemical constitution, but differ with regard to the arrangement of theatoms or groups in space.

“Diastereomer” refers to a stereoisomer with two or more centers ofchirality and whose molecules are not mirror images of one another.Diastereomers have different physical properties, e.g. melting points,boiling points, spectral properties, and reactivities. Mixtures ofdiastereomers may separate under high resolution analytical proceduressuch as electrophoresis and chromatography.

“Enantiomers” refer to two stereoisomers of a compound which arenon-superimposable mirror images of one another.

Stereochemical definitions and conventions used herein generally followS. P. Parker, Ed., McGraw-Hill Dictionary of Chemical Terms (1984)McGraw-Hill Book Company, New York; and Eliel, E. and Wilen, S.,“Stereochemistry of Organic Compounds”, John Wiley & Sons, Inc., NewYork, 1994. The compounds of the invention may contain asymmetric orchiral centers, and therefore exist in different stereoisomeric forms.It is intended that all stereoisomeric forms of the compounds of theinvention, including but not limited to, diastereomers, enantiomers andatropisomers, as well as mixtures thereof such as racemic mixtures, formpart of the present invention. Many organic compounds exist in opticallyactive forms, i.e., they have the ability to rotate the plane ofplane-polarized light. In describing an optically active compound, theprefixes D and L, or R and S, are used to denote the absoluteconfiguration of the molecule about its chiral center(s). The prefixes dand l or (+) and (−) are employed to designate the sign of rotation ofplane-polarized light by the compound, with (−) or l meaning that thecompound is levorotatory. A compound prefixed with (+) or d isdextrorotatory. For a given chemical structure, these stereoisomers areidentical except that they are mirror images of one another. A specificstereoisomer may also be referred to as an enantiomer, and a mixture ofsuch isomers is often called an enantiomeric mixture. A 50:50 mixture ofenantiomers is referred to as a racemic mixture or a racemate, which mayoccur where there has been no stereoselection or stereospecificity in achemical reaction or process. The terms “racemic mixture” and “racemate”refer to an equimolar mixture of two enantiomeric species, devoid ofoptical activity.

The term “tautomer” or “tautomeric form” refers to structural isomers ofdifferent energies which are interconvertible via a low energy barrier.For example, proton tautomers (also known as prototropic tautomers)include interconversions via migration of a proton, such as keto-enoland imine-enamine isomerizations. Valence tautomers includeinterconversions by reorganization of some of the bonding electrons.

An alkyl group is a straight or branched chain saturated hydrocarbonradical which is unsubstituted or substituted. Typically it is C₁-C₂₀alkyl, for instance C₁-C₁₀ alkyl, such as C₁-C₆ alkyl. C₁-C₆ alkyl istypically C₁-C₄ alkyl. It may be, for example, methyl (Me, —CH₃), ethyl(Et, —CH₂CH₃), 1-propyl (n-Pr, n-propyl, —CH₂CH₂CH₃), 2-propyl (i-Pr,i-propyl, —CH(CH₃)₂), 1-butyl (n-Bu, n-butyl, —CH₂CH₂CH₂CH₃),2-methyl-1-propyl (i-Bu, i-butyl, —CH₂CH(CH₃)₂), 2-butyl (s-Bu, s-butyl,—CH(CH₃)CH₂CH₃), 2-methyl-2-propyl (t-Bu, t-butyl, —C(CH₃)₃), 1-pentyl(n-pentyl, —CH₂CH₂CH₂CH₂CH₃), 2-pentyl (—CH(CH₃)CH₂CH₂CH₃), 3-pentyl(—CH(CH₂CH₃)₂), 2-methyl-2-butyl (—C(CH₃)₂CH₂CH₃), 3-methyl-2-butyl(—CH(CH₃)CH(CH₃)₂), 3-methyl-1-butyl (—CH₂CH₂CH(CH₃)₂), 2-methyl-1-butyl(—CH₂CH(CH₃)CH₂CH₃), 1-hexyl (—CH₂CH₂CH₂CH₂CH₂CH₃), 2-hexyl(—CH(CH₃)CH₂CH₂CH₂CH₃), 3-hexyl (—CH(CH₂CH₃)(CH₂CH₂CH₃)),2-methyl-2-pentyl (—C(CH₃)₂CH₂CH₂CH₃), 3-methyl-2-pentyl(—CH(CH₃)CH(CH₃)CH₂CH₃), 4-methyl-2-pentyl (—CH(CH₃)CH₂CH(CH₃)₂),3-methyl-3-pentyl (—C(CH₃)(CH₂CH₃)₂), 2-methyl-3-pentyl(—CH(CH₂CH₃)CH(CH₃)₂), 2,3-dimethyl-2-butyl (—C(CH₃)₂CH(CH₃)₂), or3,3-dimethyl-2-butyl (—CH(CH₃)C(CH₃)₃.

When an alkyl group is substituted it typically bears one or moresubstituents R²⁰ selected from halogen, alkoxy, carbocyclyl, a 5- or6-membered saturated N-containing heterocyclic group as defined above,OH, SR, CN, nitro, NR₂, —COOR, —C(O)R, S(O)_(m)R and —CONR₂, whereineach R is H, unsubstituted alkyl or C₃-C₁₀ cycloalkyl and m is 1 or 2.It is, for instance, a hydroxyalkyl group, a haloalkyl group or a group-alk-N(R⁴)(R⁵) wherein alk is an alkylene chain and R⁴ and R⁵ form,together with the N atom to which they are attached, a 5- or 6-memberedsaturated N-containing heterocyclic group which includes 0 or 1additional heteroatoms selected from N, S and O, which may be fused to abenzene ring and which is unsubstituted or substituted.

Typically R²⁰ is selected from halogen, alkoxy, carbocyclyl, a 5- or6-membered saturated N-containing heterocyclic group as defined above,OH, CN, NR², —COOR and —CONR₂, wherein each R is H or unsubstitutedalkyl as defined above. It is, for instance, a haloalkyl group or agroup -alk-N(R⁶)(R⁵) wherein alk is an alkylene chain and R⁴ and R⁵form, together with the N atom to which they are attached, a 5- or6-membered saturated N-containing heterocyclic group as defined above.

An alkylene group is unsubstituted or substituted, straight or branchedchain saturated divalent hydrocarbon group. Typically it is C₁-C₈alkylene, for instance C₁-C₆ alkylene. Preferably it is C₁-C₄ alkylene,for example C₂-C₄ alkylene, such as methylene, ethylene, i-propylene,n-propylene, t-butylene, s-butylene or n-butylene. It may also bepentylene, hexylene, heptylene, octylene and the various branched chainisomers thereof. When the alkylene group is substituted it is typicallysubstituted by a group R²⁰ as defined above.

An alkenyl group is an unsubstituted or substituted, straight orbranched chain hydrocarbon radical having one or more double bonds.Typically it is C₂-C₈ alkenyl, for instance C₂-C₆ alkenyl, such asallyl, butenyl, butadienyl, pentenyl or hexenyl. When the alkenyl groupis substituted it is typically substituted by a group R²⁰ as definedabove or by alkyl which is unsubstituted or substituted by a group R²⁰as defined above.

An alkynyl group is an unsubstituted or substituted, straight orbranched chain hydrocarbon radical having one or more triple bonds.Typically it is C₂-C₈ alkynyl, for instance C₂-C₆ alkynyl, such asethynyl, propynyl or butynyl. When the alkynyl group is substituted itis typically substituted by a group R²⁰ as defined above or by alkylwhich is unsubstituted or substituted by a group R²⁰ as defined above.

A haloalkyl group is an alkyl group as defined above, substituted by oneor more halogen atoms. It can be a perhaloalkyl group, for instancetrifluoromethyl or perfluorohexyl.

A halogen is chlorine, fluorine, bromine or iodine. It is typicallybromine or iodine.

An alkoxy group is typically C₁-C₆ alkoxy, for instance C₁-C₄ alkoxy,such as methoxy, ethoxy, i-propoxy, n-propoxy, t-butoxy, n-butoxy ors-butoxy. It is unsubstituted or substituted, for instance by a groupR²⁰ as defined above or by alkyl which is unsubstituted or substitutedby a group R²⁰ as defined above or by alkyl which is unsubstituted orsubstituted by a group R²⁰ as defined above. Typically it is substitutedby carbocyclyl, morpholino, OH, CN, NR₂, —COOR or —CONR₂, wherein each Ris H or unsubstituted alkyl as defined above.

A carbocyclyl group is a non-aromatic saturated monocyclic; hydrocarbonring, typically having from 3 to 10 carbon atoms. It may be a C₃-C₈cycloalkyl group, or C₅-C₁₀ cycloalkyl group, for instance cyclopropyl,cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl. Acarbocyclyl group may be unsubstituted or substituted, for instance by agroup R²⁰ as defined above or by alkyl which is unsubstituted orsubstituted by a group R²⁰ as defined above. Typically it is substitutedby alkoxy, morpholino, OH, CN, NR₂, —COOR and —CONR₂, wherein each R isH or unsubstituted alkyl as defined above.

The term “cyclyl” as used herein denotes a C₃-C₆ cycloalkyl group, forinstance cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl. Inparticular, cyclyl is a cyclopropyl group.

A 5- or 6-membered saturated N-containing heterocyclic group whichincludes 0 or 1 additional heteroatoms selected from N, S and O isunsubstituted or substituted and is typically selected from morpholine,piperidine, piperazine, pyrrolidine and thiomorpholine.

When a 5- or 6-membered saturated N-containing heterocyclic group asdefined above is substituted it is typically substituted by one or moresubstituents, for instance 1, 2 or 3 substituents, typically by 1 or 2substituents. Typically the substituents are selected from alkyl whichis unsubstituted or substituted, alkoxy which is unsubstituted orsubstituted, —NR₂, —N(R′″)-alk-OR, -alk-OR, —O-alk-OR, -alk-C(O)NR₂,—C(O)NR₂, -alk-Het, —N(R)-Het, —O-Het, —N(R)—C(O)-alk-OR,—C(O)—N(R)-alk-OR, -alk-S(O)₂R, —N(R)-alk-OR, -alk-NR′R″,—N(R′″)—S(O)₂R, S(O)₂R′″, -alk-N(R)-alk-OR, —S(O)₂-alk-OR, a second 5-or 6-membered saturated N-containing heterocyclic group as definedabove, a 5- or 6-membered N-containing heteroaryl group which isunsubstituted or substituted and which may be fused to a benzene ring,—COOR, —CONR₂, oxo (═O), —SO₂NR₂, —SO₂-alk-NR₂ and —CO-alk-OR, wherein:alk is an alkylene chain as defined above; Het is a 5- or 6-memberedN-containing heteroaryl group as defined herein which is unsubstitutedor substituted; R is H or alkyl, or when two groups R are bonded to Nthey may form, together with the N atom, a saturated 5- or 6-memberedN-containing heterocyclic group as defined herein which is unsubstitutedor substituted; each of R′ and R″ is independently H, alkyl or alkoxy;and R′″ is alkyl which is unsubstituted or substituted, for instance byCF₃, NR₂, OR, a 5- or 6-membered saturated N-containing heterocyclicgroup as defined herein or a 5- or 6-membered N-containing heteroarylgroup as defined herein, the said heterocyclic and heteroaryl groupsbeing unsubstituted or substituted. It may be substituted by a group R²⁰as defined above or by alkyl which is unsubstituted or substituted by agroup R²⁰ as defined above.

Typically a 5- or 6-membered saturated N-containing heterocyclic groupas defined above is substituted by a group selected from alkyl which isunsubstituted or substituted, alkoxy which is unsubstituted orsubstituted, a second 5- or 6-membered saturated N-containingheterocyclic group as defined above, a 5- or 6-membered N-containingheteroaryl group which is unsubstituted or substituted and which may befused to a benzene ring, —COOR, —CONR₂, —CONR, oxo (═O), OH, —NSO₂R,—SO₂NR₂ or —CO(CH₂)_(n)OR wherein R is H or alkyl, —NR′R″ wherein eachof R′ and R″ is independently H, alkyl or alkoxy, and —SO₂R′″ whereinR′″ is alkyl which is unsubstituted or substituted, for instance by NR₂or a 5- or 6-membered saturated N-containing heterocyclic group asdefined above.

More typically a 5- or 6-membered saturated N-containing heterocyclicgroup is substituted by one or more substituents selected from alkyl asdefined above which is unsubstituted or substituted (for instance by R²⁰as defined above), haloalkyl as defined above, alkoxy as defined abovewhich is unsubstituted or substituted, halogen, hydroxy, CN, nitro,amino, oxo (═O), and —NR′R″ wherein each of R′ and R″ is independently Hor alkyl.

A heteroaryl group is a heteroaryl group which contains 1, 2 3 or 4 ringnitrogen atoms and 0, 1 or 2 additional heteroatoms selected from O, Nand S, which group is monocyclic or bicyclic and which is unsubstitutedor substituted. It is typically a 5- to 12-membered ring. Examples of aheteroaryl group include pyrrole, pyrazole, triazole, tetrazole,indazole, thiazole, isothiazole, oxazole, isooxazole, indole, isoindole,1,3-dihydro-indol-2-one, pyridine-2-one, pyridine, pyridin-3-ol,imidazole, 1,3-dihydro-benzimidazolone, benzimidazole, benzothiazole,benzothiadiazole, quinoline, isoquinoline, quinoxaline,pyrazolopyridine, aminopyrazolinone, imidazopyridine, pyrimidine,pyridazine, pyrazine and isatin groups. Preferred examples includeindazole, indole, pyrazole and tetrazole groups. These groups may beunsubstituted or substituted, for instance by a group R²⁰ as specifiedabove or by alkyl which is unsubstituted or substituted by a group R²⁰as defined above.

A 5- or 6-membered N containing heteroaryl group which may be fused to abenzene ring is typically selected from pyrrole, pyrazole, triazole,tetrazole, indazole, thiazole, isothiazole, oxazole, isooxazole, indole,isoindole, 1,3-dihydro-indol-2-one, pyridine-2-one, pyridine,pyridin-3-ol, imidazole, 1,3-dihydro-benzimidazolone, benzimidazole,benzothiazole, benzothiadiazole, quinoline, isoquinoline, quinoxaline,pyrazolopyridine, aminopyrazolinone, imidazopyridine, pyrimidine,pyridazine and pyrazine. When such a heteroaryl group is substituted itmay be substituted by a group R²⁰ as defined above or by alkyl which isunsubstituted or substituted by a group R²⁰ as defined above.

PI3 Kinase Inhibitor Compounds

The present invention provides fused pyrimidines which are 4-morpholinothienopyrimidine and furanopyrimidine compounds, and pharmaceuticallyacceptable salts thereof, that are potentially useful in the treatmentof diseases, conditions and/or disorders modulated by PI3 kinases. Thecompounds may inhibit p110 isoforms including alpha, beta, gamma, anddelta as pan inhibitors. The compounds may be p110 isoform selectiveinhibitors by selective inhibition of one of the p110 isoforms.

More specifically, the present invention provides a compound which is afused pyrimidine of formula Ia or Ib:

X is O or S;R¹ is a group of formula:

R² is H, halo or C₁-C₆ alkylR⁴ and R⁵ form, together with the N atom to which they are attached, agroup selected from piperazine, piperidine, pyrrolidine, oxazolidinone,diazepan and 2,5-diaza-bicyclo[2,2,1]-heptane, which group isunsubstituted or substituted by -[(alk)_(q)-NR]_(r)—S(O)₂-(alk)_(q)-Z or—C(O)-(alk)_(q)-S(O)₂Z wherein Z is R¹⁰ or —NR¹¹R¹², or by unsubstitutedC₁-C₆ alkyl, hydroxyl-C₁-C₆ alkyl, oxo (═O), -(alk)_(q)-OR,—C(O)—C(R′)₂—N(R)₂, —C(R)₂—C(O)—N(R)₂, —C(O)—(NR)_(q)-(alk)_(q)-OR,—C(O)-cyclyl, —C(O)R, —C(O)OR, —C(O)-Tet or —NR¹³R¹⁴;or one of R⁴ and R⁵ is C₁-C₆ alkyl, -(alk)_(q)-Heterocyclyl or-(alk)_(q)-OR and the other is a piperazine, piperidine, pyrrolidine,sulphonylpyran or -(alk)_(q)-Heterocyclyl group, wherein saidpiperazine, piperidine, pyrrolidine, sulphonylpyran or Heterocyclyl isunsubstituted or substituted by C₁-C₆ alkyl, -(alk)_(q)-OR or —S(O)₂R¹⁰;R is H or C₁-C₆ alkyl which is unsubstituted;each R′ is, independently, H or C₁-C₆ alkyl which is unsubstituted, orthe two groups R′ form, together with the C atom to which they areattached, a cyclyl group;R¹⁰ is H, cyclyl, C₁-C₆ alkyl which is unsubstituted or CF₃;R¹¹ and R¹² are each independently selected from H, C₁-C₆ alkyl which isunsubstituted and -(alk)_(q)-OR, or R¹¹ and R¹² together form, with theN atom to which they are attached, a 5- or 6-membered saturatedN-containing heterocyclic group containing 0 or 1 additional heteroatomsselected from O, N and S;R¹³ and R¹⁴ are each independently selected from C₁-C₆ alkyl, —S(O)₂R¹⁰,and -(alk)_(q)-OR;Tet is a tetrahydrofuranyl or tetrahydropyranyl group, which group isunsubstituted or substituted;Heterocyclyl is a 5- or 6-membered saturated N-containing heterocyclicgroup containing 0 or 1 additional heteroatoms selected from O, N and S;Cyclyl is a C₃-C₆ cycloalkyl group;each q is independently 0 or 1;r is 0 or 1;alk is C₁-C₆ alkylene; andR³ is selected from:

(a) a group of the following formula:

wherein B is a phenyl ring which is unsubstituted or substituted, and Zis selected from H, —OR, —SR, CH₂OR, —CO₂R, CF₂OH, CH(CF₃)OH, C(CF₃)₂OH,—(CH₂)_(q)OR, —(CH₂)_(q)NR₂, —C(O)N(R)₂, —NR₂, —NRC(O)R, —S(O)_(m)N(R)₂,—OC(O)R, OC(O)N(R)₂, —NRS(O)_(m)R, —NRC(O)N(R)₂, CN, halogen and —NO₂,wherein each R is independently selected from H, C₁-C₆ alkyl, C₃-C₁₀cycloalkyl and a 5- to 12-membered aryl or heteroaryl group, the groupbeing unsubstituted or substituted, m is 1 or 2 and q is 0, 1 or 2;

(b) a heteroaryl group which contains 1, 2, 3 or 4 ring nitrogen atomsand 0, 1 or 2 additional heteroatoms selected from O and S, which groupis monocyclic or bicyclic and which is unsubstituted or substituted; and

(c) a group comprising a benzene ring which is unsubstituted orsubstituted and which is fused to a heteroaryl group as defined above;

or a pharmaceutically acceptable salt thereof;

with the provisos that:

-   -   (i) when X in formula (Ia) is S, then R³ is other than an indole        or 3-hydroxyphenyl group;    -   (ii) when X in formula (Ib) is S, then R³ is other than an        indole group;    -   (iii) in formula (Ia) only, when X is S and R² is H and R³ is        indazol-4-yl, then R⁴ and R⁵ do not form: (i) piperazine which        is unsubstituted or substituted by a group selected from methyl,        —S(O)₂Me, —S(O)₂NMe₂, -alk-OH, -alk-OMe, —S(O)₂-alk-NMe₂, and        —S(O)₂-alk-morpholino; or (ii) piperidine which is substituted        by a group selected from —S(O)₂Me, —C(O)—NR-(alk)_(q)-OR,        —NMe-S(O)₂-Me, methyl, piperidine and —NR¹³R¹⁴ wherein one of        R¹³ and R¹⁴ is -(alk)_(q)-OR.

In one embodiment the invention provides a compound which is a fusedpyrimidine of formula (Ia′):

whereinX is O or S;Y is N or —CH—;R² is H, halo or C₁-C₆ alkyl;each R′ is, independently, H, C₁-C₆ alkyl or hydroxyl-C₁-C₆ alkyl, ortwo groups R′ on the same carbon atom form an oxo (═O) group; or when Yis N, two groups R′ on different carbon atoms together form a —CH₂—bridgehead;each R″ is, independently, H or C₁-C₆ alkyl, or two groups R″ on thesame carbon atom form an oxo (═O) group;Z is R¹⁰ or -(alk)_(q)-NR¹¹R¹²;R¹⁰ is H, a C₃-C₆ cycloalkyl group, C₁-C₆ alkyl which is unsubstituted,or CF₃;R¹¹ and R¹² are each independently selected from H, C₁-C₆ alkyl which isunsubstituted and -(alk)_(q)-OR, or R¹¹ and R¹² together form, with theN atom to which they are attached, a 5- or 6-membered saturatedN-containing heterocyclic group containing 0 or 1 additional heteroatomsselected from O, N and S;q is 0 or 1;r is 0 or 1;alk is C₁-C₆ alkylene; andR³ is selected from:

(a) a group of the following formula:

wherein B is a phenyl ring which is unsubstituted or substituted and Zis selected from H, —OR, —SR, CH₂OR, —CO₂R, CF₂OH, CH(CF₃)OH, C(CF₃)₂OH,—(CH₂)_(q)OR, —(CH₂)_(q)NR₂, —C(O)N(R)₂, —NR₂, —NRC(O)R, —S(O)_(m)N(R)₂,—OC(O)R,OC(O)N(R)₂, —NRS(O)_(m)R, —RC(O)N(R)₂, CN, halogen and —NO₂, whereineach R is independently selected from H, C₁-C₆ alkyl, C₃-C₁₀ cycloalkyland a 5- to 12-membered aryl or heteroaryl group, the group beingunsubstituted or substituted, m is 1 or 2 and q is 0, 1 or 2;

(b) a heteroaryl group which contains 1, 2, 3 or 4 ring nitrogen atomsand 0, 1 or 2 additional heteroatoms selected from O and S, which groupis monocyclic or bicyclic and which is unsubstituted or substituted; and

(c) a group comprising a benzene ring which is unsubstituted orsubstituted and which is fused to a heteroaryl group as defined above;

or a pharmaceutically acceptable salt thereof;

with the provisos that:

-   -   (i) R³ is other than an indole or 3-hydroxyphenyl group when X        is S;    -   (ii) Z is other than a group selected from Me, -(alk)_(q)-NMe₂        and -alk-morpholino when the following are satisfied: Y is N,        each of R′ and R″ is H, R² is H and R³ is indazol-4-yl;    -   (iii) Z is other than Me when the following are satisfied: Y is        —CH—, each of R′ and R″ is H, R² is H and R³ is indazol-4-yl.

In another embodiment the invention provides a compound which is fusedpyrimidine of formula (Ib′):

whereinX is O or S;Y is N or —CH—;R² is H, halo or C₁-C₆ alkyl;each R′ is, independently, H, C₁-C₆ alkyl or hydroxy-C₁-C₆ alkyl, or twogroups R′ on the same carbon atom form an oxo (═O) group; or when Y isN, two groups R′ on different carbon atoms together form a —CH₂—bridgehead;each R″ is, independently, H or C₁-C₆ alkyl, or two groups R″ on thesame carbon atom form an oxo (═O) group;Z is R¹⁰ or -(alk)_(q)-NR¹¹R¹²;R¹⁰ is H, a C₃-C₆ cycloalkyl group, C₁-C₆ alkyl which is unsubstituted,or CF₃;R¹¹ and R¹² are each independently selected from H, C₁-C₆ alkyl which isunsubstituted and -(alk)_(q)-OR, or R¹¹ and R¹² together form, with theN atom to which they are attached, a 5- or 6-membered saturatedN-containing heterocyclic group containing 0 or 1 additional heteroatomsselected from O, N and S;q is 0 or 1;r is 0 or 1;alk is C₁-C₆ alkylene; andR³ is selected from:

(a) a group of the following formula:

wherein B is a phenyl ring which is unsubstituted or substituted and Zis selected from H, —OR, —SR, CH₂OR, —CO₂R, CF₂OH, CH(CF₃)OH, C(CF₃)₂OH,—(CH₂)_(q)OR, —(CH₂)_(q)NR₂, —C(O)N(R)₂, —NR₂, —NRC(O)R, —S(O)_(m)N(R)₂,—OC(O)R,OC(O)N(R)₂, —NRS(O)_(m)R, —RC(O)N(R)₂, CN, halogen and —NO₂, whereineach R is independently selected from H, C₁-C₆ alkyl, C₃-C₁₀ cycloalkyland a 5- to 12-membered aryl or heteroaryl group, the group beingunsubstituted or substituted, m is 1 or 2 and q is 0, 1 or 2;

(b) a heteroaryl group which contains 1, 2, 3 or 4 ring nitrogen atomsand 0, 1 or 2 additional heteroatoms selected from O and S, which groupis monocyclic or bicyclic and which is unsubstituted or substituted; and

(c) a group comprising a benzene ring which is unsubstituted orsubstituted and which is fused to a heteroaryl group as defined above;

or a pharmaceutically acceptable salt thereof.

In a yet further embodiment the invention provides a compound which is afused pyrimidine of formula (Ia″) or (Ib″):

whereinX is O or S;R² is H, halo or C₁-C₆ alkyl;R⁴ is C₁-C₆ alkyl, -(alk)_(q)-Heterocyclyl, or -(alk)_(q)-OR;R⁵ is a piperazine, piperidine, pyrrolidine, sulphonylpyran or-(alk)_(q)-Heterocyclyl group, wherein said piperazine, piperidine,pyrrolidine, sulphonylpyran or Heterocyclyl is unsubstituted orsubstituted by C₁-C₆ alkyl, -(alk)_(q)-OR or —S(O)₂R¹⁰;R is H, C₁-C₆ alkyl which is unsubstituted;R¹⁰ is H, a C₃-C₆ cycloalkyl group, C₁-C₆ alkyl which is unsubstituted,or CF₃; Heterocyclyl is a 5- or 6-membered saturated N-containingheterocyclic group containing 0 or 1 additional heteroatoms selectedfrom O, N and S;q is 0 or 1;alk is C₁-C₆ alkylene; andR³ is selected from:

(a) a group of the following formula:

wherein B is a phenyl ring which is unsubstituted or substituted and Zis selected from H, —OR, —SR, CH₂OR, —CO₂R, CF₂OH, CH(CF₃)OH, C(CF₃)₂OH,—(CH₂)_(q)OR, —(CH₂)_(q)NR₂, —C(O)N(R)₂, —NR₂, —NRC(O)R, —S(O)_(m)N(R)₂,—OC(O)R,OC(O)N(R)₂, —NRS(O)_(m)R, —RC(O)N(R)₂, CN, halogen and —NO₂, whereineach R is independently selected from H, C₁-C₆ alkyl, C₃-C₁₀ cycloalkyland a 5- to 12-membered aryl or heteroaryl group, the group beingunsubstituted or substituted, m is 1 or 2 and q is 0, 1 or 2;

(b) a heteroaryl group which contains 1, 2, 3 or 4 ring nitrogen atomsand 0, 1 or 2 additional heteroatoms selected from O and S, which groupis monocyclic or bicyclic and which is unsubstituted or substituted; and

(c) a group comprising a benzene ring which is unsubstituted orsubstituted and which is fused to a heteroaryl group as defined above;

or a pharmaceutically acceptable salt thereof;

with the provisos that:

-   -   (i) when X in formula (Ia) is S, then R³ is other than an indole        or 3-hydroxyphenyl group; and    -   (ii) when X in formula (Ib) is S, then R³ is other than an        indole group.

In R¹, the groups R⁴ and R⁵ typically form, together with the N atom towhich they are attached, a group selected from piperidine, piperazine,pyrrolidine, oxazolidinone, diazepan and2,5-diaza-bicyclo[2,2,1]-heptane. Typically the group formed by R⁴ andR⁵ is piperidine, piperazine or pyrrolidine.

The group formed by R⁴ and R⁵ with the N atom is unsubstituted orsubstituted by -[(alk)_(q)-NR]_(r)—S(O)₂-(alk)_(q)-Z or by unsubstitutedC₁-C₆ alkyl, oxo (═O), -(alk)_(q)-OR, —C(O)—C(R)₂—N(R)₂,—C(R)₂—C(O)—N(R)₂, —C(O)—(NR)_(q)-(alk)_(q)-OR, —C(O)-cyclyl, —C(O)R,—C(O)OR, or —NR¹³R¹⁴.

Alternatively, one of R⁴ and R⁵ is C₁-C₆ alkyl, -(alk)_(q)-Heterocyclylor -(alk)_(q)-OR and the other is a piperazine, piperidine, pyrrolidine,sylphonylpyran or -(alk)_(q)-Heterocyclyl group, wherein saidpiperazine, piperidine, pyrrolidine, sulphonylpyran or Heterocyclylgroup is unsubstituted or substituted by C₁-C₆ alkyl, -(alk)_(q)-OR or—S(O)₂R¹⁰.

Examples of Heterocyclyl include piperidine, for instancepiperidin-1-yl, piperidin-2-yl, piperidin-3-yl or piperidin-4-yl, inparticular piperidin-4-yl; morpholine; and pyrrolidine, for instancepyrrolidin-2-yl or pyrrolidin-3-yl, groups.

Examples of -[(alk)_(q)-NR]_(r)—S(O)₂-(alk)_(q)-Z include —S(O)₂R¹⁰,—S(O)₂-(alk)_(q)-NR¹¹R¹² and -(alk)_(q)-NR—S(O)₂R¹⁰. Examples of—S(O)₂R¹⁰ include —S(O)₂Me and —S(O)₂-cyclopropyl.

Examples of —C(O)-(alk)_(q)-S(O)₂Z include —C(O)—CH₂—S(O)₂Me,—C(O)—CHMe-S(O)₂Me and —C(O)—C(Me)₂-S(O)₂Me.

R¹⁰ is typically H, methyl, propyl (either n-propyl or i-propyl), orCF₃.

Examples of —S(O)₂-(alk)_(q)-NR¹¹R¹² include —S(O)₂—N(Me)₂, —S(O)₂—NHMe,—S(O)₂—N(Me)(CH₂CH₂OMe), —S(O)₂—N(Me)(CH₂CH₂OH),

Examples of -(alk)_(q)-NR—S(O)₂R¹⁰ include —CH₂NH(SO₂Me),—CH₂N(Me)(SO₂Me), —NH—SO₂Me and —N(Me)(SO₂Me).

Examples of -(alk)_(q)-OR include —OH, —OMe, —CH₂OH, —CH₂OMe,—CH₂CH₂OMe, —CH₂CH₂OH, —CH₂CH₂CH₂OMe and —CH₂CH₂CH₂OH.

Examples of —C(O)—C(R′)₂—N(R)₂ include —C(O)—CH₂—N(Me)₂, —C(O)—CH₂—NHMe,—C(O)—CH₂—NH₂, —C(O)—CHMe-N(Me)₂, —C(O)—CHMe-NHMe, —C(O)—CHMe-NH₂,—C(O)—C(Me)₂-N(Me)₂, —C(O)—C(Me)₂-NHMe, —C(O)—C(Me)₂-NH₂,—C(O)—C(Me)₂-NH₂,

Examples of —C(R)₂—C(O)—N(R)₂ include —C(Me)₂-C(O)—NH₂, —CH₂—C(O)—NH₂,—CHMe-C(O)—NH₂, —C(Me)₂-C(O)—NHMe, —CH₂—C(O)—NHMe, —CHMe-C(O)—NHMe,—C(Me)₂-C(O)—N(Me)₂, —CH₂—C(O)—N(Me), and —CHMe-C(O)—N(Me)₂.

Examples of —C(O)—(NR)_(q)-(alk)_(q)-OR when each q is 1 include—C(O)—N(Me)-CH₂—OMe, —C(O)—N(Me)-CH₂—OH, —C(O)—NH—CH₂—OH, and—C(O)—NH—CH₂—OMe.

Examples of —C(O)—(NR)_(q)-(alk)_(q)-OR when one q is 0 and the other qis 1 include —C(O)—CH₂—OMe, —C(O)—CH(Me)-OMe, —C(O)—C(Me)₂-OMe,—C(O)—CH₂—OH, —C(O)—CH(Me)-OH,

—C(O)—C(Me)₂-OH and —C(O)—CH(Me)-OMe.

Examples of —C(O)-cyclyl include —C(O)-(cyclopropyl).

Examples of —C(O)R include —C(O)H, —C(O)Me, —C(O)Et, and —C(O)—C(CH₃)₃.

Examples of —C(O)OR include —C(O)OH, —C(O)OMe, —C(O)OEt, and—C(O)OC(CH₃)₃.

In the definition (a) for R³ the phenyl ring B is unsubstituted (apartfrom group Z) or substituted. When it is unsubstituted the group Z isthe sole substituent. Z may be at the 2-, 3-, 4-, 5- or 6-position onthe phenyl ring. Typically it is at the 2-, 3- or 4-position, moretypically at the 3- or 4-position. Z is most typically other than H,such that moiety —BZ is a substituted phenyl ring. Specific examples ofthe group Z include —OH, —CH₂OH, F, Cl, 1-hydroxyethyl, —NHS(O)₂Me,—NC(O)Me, —S(O)₂NH₂Me and —C(O)Me.

When the phenyl ring B is substituted it typically comprises, inaddition to group Z, one or more substituents selected from halo, alkyl,alkenyl, alkynyl, CN, NO₂, OR′, SR′, NR′₂, C(O)R′, SOR′, SO₂R′, SO₂NR′₂,NC(O)R′ and CO₂R′, wherein each R′ is independently H or C₁-C₆ alkyl.

In definition (b) for R³ the heteroaryl group is unsubstituted orsubstituted. It is typically selected from indazole, indole, pyridine,pyrimidine, benzimidazole, quinoline, isoquinoline, imidazole andpyrazole, each of which is linked via any available ring C or N atom.For instance, an indazole group may be linked as indazol-4-yl,indazol-5-yl or indazol-6-yl. Pyrimidine may be linked aspyrimidin-1-yl, pyrimidine-2-yl, pyrimidin-3-yl or pyrimidin-4-yl.Pyridine may be linked as pyridin-1-yl, pyridine-2-yl, pyridine-3-yl orpyridine-4-yl. Benzimidazole may be linked via N as benzimidazol-1-yl.Quinoline may be linked as quinolin-3-yl or quinolin-4-yl. Isoquinolinemay be linked as isoquinolin-3-yl or isoquinolin-4-yl. Imidazole may belinked via N as imidazol-1-yl

If the heteroaryl group is substituted it may be substituted by one ormore substituents selected from a group Z, R²⁰ as defined above, alkylwhich is unsubstituted or substituted by a R²⁰ as defined above, anygroup specified above as an additional substituent on the phenyl ring B,and an oxo group (═O). Typically, if substituted, the heteroaryl groupis substituted by OH, OMe, NH₂, NMe₂, F or Cl. In one embodiment theheteroaryl group is unsubstituted.

In definition (c) for R³ the benzene ring is unsubstituted orsubstituted. If it is substituted it may be substituted by one or moresubstituents selected from a group Z, R²⁰ as defined above, alkyl whichis unsubstituted or substituted by R²⁰ as defined above, and any of thegroups specified above as an additional substituent on the phenyl ringB. The heteroaryl group to which the benzene ring is fused is itselfunsubstituted or substituted, for instance by a group Z, R²⁰ or alkylwhich is unsubstituted or substituted by a group R²⁰ as defined above;by any group specified above as an option for an additional substituenton the phenyl ring B; or by an oxo group (═O). In one embodiment boththe benzene ring and the heteroaryl group are unsubstituted.

Groups included in definitions (b) and (c) for R³ as defined aboveinclude the following structures:

wherein each R¹⁰ is independently selected from H, C₁-C₆ alkyl, C₁-C₆alkoxy, C₁-C₆ acyl, —C(O)NR′R″, —S(O)_(t)NR′R″, aryl, heteroaryl,sulphonyl and halogen, wherein R′ and R″ are each independently H orC₁-C₆ alkyl and t is 1 or 2;each R¹¹ is independently selected from —OR¹⁰ and —N(R¹⁰)₂, wherein R¹⁰is as defined above;each R¹² is independently H, F or CF₃;each W is independently selected from CR¹⁰ and N, wherein R¹⁰ is asdefined above; and W′ is selected from O, S and NR¹² wherein R¹² is asdefined above.

Typical examples of R³ include

wherein P is selected from H, —OR, —NR₂, —CN, halo and C₁-C₆ alkyl.

Typically in compounds of the invention, R³ takes definition (a) or (b)as defined above.

In one aspect the invention provides a compound which is a fusedpyrimidine of formula (Ia′″) or (Ib′″):

whereinR², R³, X, Y, Z, R′ and R″ are as defined above for formulae (Ia′) and(Ib′);or a pharmaceutically acceptable salt thereof;with the provisos that, in formula (Ia′″) only:

-   -   (i) R³ is other than an indole or 3-hydroxyphenyl group when X        is S;    -   (ii) Z is other than a group selected from Me, -(alk)_(q)-NMe₂        and -alk-morpholino when the following are satisfied: Y is N,        each of R′ and R″ is H, R² is H and R³ is indazol-4-yl; and    -   (iii) Z is other than Me when the following are satisfied: Y is        —CH—, each of R′ and R″ is H, R² is H and R³ is indazol-4-yl.

In one aspect the invention provides a compound which is a fusedpyrimidine of formula (Ia) or (Ib):

whereinX is O or S;R¹ is a group of formula:

R² is H, halo or C₁-C₆ alkylR⁴ and R⁵ form, together with the N atom to which they are attached, agroup selected from piperazine, piperidine, pyrrolidine, oxazolidinone,diazepan and 2,5-diaza-bicyclo[2,2,1]-heptane, which group isunsubstituted or substituted by -[(alk)_(q)-NR]_(r)—S(O)₂-(alk)_(q)-Z or—C(O)-(alk)_(q)-S(O)₂Z wherein Z is R¹⁰ or —NR¹¹R¹², or by unsubstitutedC₁-C₆ alkyl, hydroxyl-C₁-C₆ alkyl, oxo (═O), -(alk)_(q)-OR,—C(O)—C(R′)₂—N(R)₂, —C(R)₂—C(O)—N(R)₂, —C(O)—(NR)_(q)-(alk)_(q)-OR,—C(O)-cyclyl, —C(O)R, —C(O)OR, —C(O)-Tet or —NR¹³R¹⁴, with the provisothat, in formula (Ia) only, when X is S and R² is H and R³ isindazol-4-yl, said group is other than (i) piperazine which isunsubstituted or substituted by a group selected from methyl, —S(O)₂Me,—S(O)₂NMe₂, -alk-OH, -alk-OMe, —S(O)₂-alk-NMe₂, and—S(O)₂-alk-morpholino; and (ii) piperidine which is substituted by agroup selected from —S(O)₂Me, —C(O)—NR-(alk)_(q)-OR, —NMe-S(O)₂-Me,methyl, piperidine and —NR¹³R¹⁴ wherein one of R¹³ and R¹⁴ is-(alk)_(q)-OR;or one of R⁴ and R⁵ is C₁-C₆ alkyl, -(alk)_(q)-Heterocyclyl or-(alk)_(q)-OR and the other is a piperazine, piperidine, pyrrolidine,sulphonylpyran or -(alk)_(q)-Heterocyclyl group, wherein saidpiperazine, piperidine, pyrrolidine, sulphonylpyran or Heterocyclyl isunsubstituted or substituted by C₁-C₆ alkyl, -(alk)_(q)-OR or —S(O)₂R¹⁰;R is H or C₁-C₆ alkyl which is unsubstituted;each R′ is, independently, H or C₁-C₆ alkyl which is unsubstituted, orthe two groups R′ form, together with the C atom to which they areattached, a cyclyl group;R¹⁰ is H, C₁-C₆ alkyl which is unsubstituted or CF₃;R¹¹ and R¹² are each independently selected from H, C₁-C₆ alkyl which isunsubstituted and -(alk)_(q)-OR, or R¹¹ and R¹² together form, with theN atom to which they are attached, a 5- or 6-membered saturatedN-containing heterocyclic group containing 0 or 1 additional heteroatomsselected from O, N and S;R¹³ and R¹⁴ are each independently selected from C₁-C₆ alkyl, —S(O)₂R¹⁰,and -(alk)_(q)-OR;Tet is a tetrahydrofuranyl or tetrahydropyranyl group, which group isunsubstituted or substituted;Heterocyclyl is a 5- or 6-membered saturated N-containing heterocyclicgroup containing 0 or 1 additional heteroatoms selected from O, N and S;Cyclyl is a C₃-C₆ cycloalkyl group;each q is independently 0 or 1;r is 0 or 1;alk is C₁-C₆ alkylene; andR³ is selected from:

(a) a group of the following formula:

wherein B is a phenyl ring which is unsubstituted or substituted and Zis selected from H, —OR, —SR, CH₂OR, —CO₂R, CF₂OH, CH(CF₃)OH, C(CF₃)₂OH,—(CH₂)_(q)OR, —(CH₂)_(q)NR₂, —C(O)N(R)₂, —NR₂, —NRC(O)R, —S(O)_(m)N(R)₂,—OC(O)R, OC(O)N(R)₂, —NRS(O)_(m)R, —NRC(O)N(R)₂, CN, halogen and —NO₂,wherein each R is independently selected from H, C₁-C₆ alkyl, C₃-C₁₀cycloalkyl and a 5- to 12-membered aryl or heteroaryl group, the groupbeing unsubstituted or substituted, m is 1 or 2 and q is 0, 1 or 2;

(b) a heteroaryl group which contains 1, 2, 3 or 4 ring nitrogen atomsand 0, 1 or 2 additional heteroatoms selected from O and S, which groupis monocyclic or bicyclic and which is unsubstituted or substituted; and

(c) a group comprising a benzene ring which is unsubstituted orsubstituted and which is fused to a heteroaryl group as defined above;

or a pharmaceutically acceptable salt thereof;

with the provisos that:

-   -   (i) when X in formula (Ia) is S, then R³ is other than an indole        or 3-hydroxyphenyl group; and    -   (ii) when X in formula (Ib) is S, then R³ is other than an        indole group.

In one aspect the invention provides a compound which is a fusedpyrimidine of formula (Ia′)

whereinX is O or S;Y is N or —CH—;R² is H, halo or C₁-C₆ alkyl;each R′ is, independently, H, C₁-C₆ alkyl or hydroxyl-C₁-C₆ alkyl, ortwo groups R′ on the same carbon atom form an oxo (═O) group; or when Yis N, two groups R′ on different carbon atoms together form a —CH₂—bridgehead;each R″ is, independently, H or C₁-C₆ alkyl, or two groups R″ on thesame carbon atom form an oxo (═O) group;Z is R¹⁰ or -(alk)_(q)-NR¹¹R¹²;R¹⁰ is H, C₁-C₆ alkyl which is unsubstituted, or CF₃;R¹¹ and R¹² are each independently selected from H, C₁-C₆ alkyl which isunsubstituted and -(alk)_(q)-OR, or R¹¹ and R¹² together form, with theN atom to which they are attached, a 5- or 6-membered saturatedN-containing heterocyclic group containing 0 or 1 additional heteroatomsselected from O, N and S;q is 0 or 1;alk is C₁-C₆ alkylene; andand R³ is selected from:

(a) a group of the following formula:

wherein B is a phenyl ring which is unsubstituted or substituted and Zis selected from H, —OR, —SR, CH₂OR, —CO₂R, CF₂OH, CH(CF₃)OH, C(CF₃)₂OH,—(CH₂)_(q)OR, —(CH₂)_(q)NR₂, —C(O)N(R)₂, —NR₂, —NRC(O)R, —S(O)_(m)N(R)₂,—OC(O)R, OC(O)N(R)₂, —NRS(O)_(m)R, —NRC(O)N(R)₂, CN, halogen and —NO₂,wherein each R is independently selected from H, C₁-C₆ alkyl, C₃-C₁₀cycloalkyl and a 5- to 12-membered aryl or heteroaryl group, the groupbeing unsubstituted or substituted, m is 1 or 2 and q is 0, 1 or 2;

(b) a heteroaryl group which contains 1, 2, 3 or 4 ring nitrogen atomsand 0, 1 or 2 additional heteroatoms selected from O and S, which groupis monocyclic or bicyclic and which is unsubstituted or substituted; and

(c) a group comprising a benzene ring which is unsubstituted orsubstituted and which is fused to a heteroaryl group as defined above;

or a pharmaceutically acceptable salt thereof;

with the provisos that:

-   -   (i) R³ is other than an indole or 3-hydroxyphenyl group when X        is S;    -   (ii) Z is other than a group selected from Me, -(alk)_(q)-NMe₂        and -alk-morpholino when the following are satisfied: Y is N,        each of R′ and R″ is H, R² is H and R³ is indazol-4-yl;    -   (iii) Z is other than Me when the following are satisfied: Y is        —CH—, each of R′ and R″ is H, R² is H and R³ is indazol-4-yl.

In one aspect the invention provides a compound which is fusedpyrimidine of formula (Ib′):

whereinX is O or S;Y is N or —CH—;R² is H, halo or C₁-C₆ alkyl;each R′ is, independently, H, C₁-C₆ alkyl or hydroxy-C₁-C₆ alkyl, or twogroups R′ on the same carbon atom form an oxo (═O) group; or when Y isN, two groups R′ on different carbon atoms together form a —CH₂—bridgehead;each R″ is, independently, H or C₁-C₆ alkyl, or two groups R″ on thesame carbon atom form an oxo (═O) group;Z is R¹⁰ or -(alk)_(q)-NR¹¹R¹²;R¹⁰ is H, C₁-C₆ alkyl which is unsubstituted, or CF₃;R¹¹ and R¹² are each independently selected from H, C₁-C₆ alkyl which isunsubstituted and -(alk)_(q)-OR, or R¹¹ and R¹² together form, with theN atom to which they are attached, a 5- or 6-membered saturatedN-containing heterocyclic group containing 0 or 1 additional heteroatomsselected from O, N and S;q is 0 or 1;alk is C₁-C₆ alkylene; andand R³ is selected from:

(a) a group of the following formula:

wherein B is a phenyl ring which is unsubstituted or substituted and Zis selected from H, —OR, —SR, CH₂OR, —CO₂R, CF₂OH, CH(CF₃)OH, C(CF₃)₂OH,—(CH₂)_(q)OR, —(CH₂)_(q)NR₂, —C(O)N(R)₂, —NR₂, —NRC(O)R, —S(O)_(m)N(R)₂,—OC(O)R, OC(O)N(R)₂, —NRS(O)_(m)R, —NRC(O)N(R)₂, CN, halogen and —NO₂,wherein each R is independently selected from H, C₁-C₆ alkyl, C₃-C₁₀cycloalkyl and a 5- to 12-membered aryl or heteroaryl group, the groupbeing unsubstituted or substituted, m is 1 or 2 and q is 0, 1 or 2;

(b) a heteroaryl group which contains 1, 2, 3 or 4 ring nitrogen atomsand 0, 1 or 2 additional heteroatoms selected from O and S, which groupis monocyclic or bicyclic and which is unsubstituted or substituted; and

(c) a group comprising a benzene ring which is unsubstituted orsubstituted and which is fused to a heteroaryl group as defined above;

or a pharmaceutically acceptable salt thereof.

In one aspect the invention provides a compound which is a fusedpyrimidine of formula (Ia″) or (Ib″):

whereinX is O or S;R² is H, halo or C₁-C₆ alkyl;R⁴ is C₁-C₆ alkyl, -(alk)_(q)-Heterocyclyl, or -(alk)_(q)-OR;R⁵ is a piperazine, piperidine, pyrrolidine, sulphonylpyran or-(alk)_(q)-Heterocyclyl group, wherein said piperazine, piperidine,pyrrolidine, sulphonylpyran or Heterocyclyl group is unsubstituted orsubstituted by C₁-C₆ alkyl, -(alk)_(q)-OR or —S(O)₂R¹⁰;R is H, C₁-C₆ alkyl which is unsubstituted;R¹⁰ is H, C₁-C₆ alkyl which is unsubstituted, or CF₃;Heterocyclyl is a 5- or 6-membered saturated N-containing heterocyclicgroup containing 0 or 1 additional heteroatoms selected from O, N and S;q is 0 or 1;alk is C₁-C₆ alkylene; andand R³ is selected from:

(a) a group of the following formula:

wherein B is a phenyl ring which is unsubstituted or substituted and Zis selected from H, —OR, —SR, CH₂OR, —CO₂R, CF₂OH, CH(CF₃)OH, C(CF₃)₂OH,—(CH₂)_(q)OR, —(CH₂)_(q)NR₂, —C(O)N(R)₂, —NR₂, —NRC(O)R, —S(O)_(m)N(R)₂,—OC(O)R, OC(O)N(R)₂, —NRS(O)_(m)R, —NRC(O)N(R)₂, CN, halogen and —NO₂,wherein each R is independently selected from H, C₁-C₆ alkyl, C₃-C₁₀cycloalkyl and a 5- to 12-membered aryl or heteroaryl group, the groupbeing unsubstituted or substituted, m is 1 or 2 and q is 0, 1 or 2;

(b) a heteroaryl group which contains 1, 2, 3 or 4 ring nitrogen atomsand 0, 1 or 2 additional heteroatoms selected from O and S, which groupis monocyclic or bicyclic and which is unsubstituted or substituted; and

(c) a group comprising a benzene ring which is unsubstituted orsubstituted and which is fused to a heteroaryl group as defined above;

or a pharmaceutically acceptable salt thereof;

with the provisos that:

-   -   (i) when X in formula (Ia″) is S, then R³ is other than an        indole or 3-hydroxyphenyl group; and    -   (ii) when X in formula (Ib″) is S, then R³ is other than an        indole group.

Specific examples of compounds of the invention include:

TABLE 1a Compound No. Structure Name 1

(1S,4S)-2-((2-(1H-indazol-4-yl)-4- morpholinothieno[3,2-d]pyrirnidin-6-yl)methyl)-5-methylsulfonyl-2,5- diaza-bicyclo[2.2.1]heptane 2

2-(1H-indazol-4-yl)-6-((4- methylsulfonylpiperazin-1-yl)methyl)-4-morpholinofuro[3,2- d]pyrimidine 3

2-(1H-indazol-4-yl)-6-((4-(N- morpholino)sulfonylpiperazin-1-yl)methyl)-4-morpholinothieno[3,2- d]pyrimidine 4.

2-(1H-indazol-4-yl)-6-(((3S,5R)-3- methyl-4-methylsulfonylpiperazin-1-yl)methyl)-4-morpholinothieno[3,2- d]pyrimidine 5.

6-((4-methylsulfonylpiperazin-1- yl)methyl)-4-morpholino-2-(pyrimidin-5-yl)thieno[2,3- d]pyrimidine 6.

2-(1H-indazol-4-yl)-6-(((3S,5R)-3,5- dimethyl-4-methylsulfonylpiperazin-1-yl)methyl)-4- morpholinothieno[3,2-d]pyrimidine 7.

6-(((2R,6S)-4-methylsulfonyl-2,6- dimethylpiperazin-1-yl)methyl)-2-(1H-indazol-4-yl)-4- morpholinothieno[3,2-d]pyrimidine 8.

6-(((2R,6S)-4-isopropylsulfonyl-2,6- dimethylpiperazin-1-yl)methyl)-2-(1H-indazol-4-yl)-4- morpholinothieno[3,2-d]pyrimidine 9.

6-(((2R,6S)-4- trifluoromethylsulfonyl-2,6-dimethylpiperazin-1-yl)methyl)-2- (1H-indazol-4-yl)-4-morpholinothieno[3,2-d]pyrimidine 10.

6-(((R)-4-methylsulfonyl-3- methylpiperazin-1-yl)methyl)-2-(1H-indazol-4-yl)-4- morpholinothieno[3,2-d]pyrimidine 11.

3-(6-((4-methylsulfonylpiperazin-1- yl)methyl)-4-morpholinothieno[3,2-d]pyrimidin-2- yl)benzenesulfonamide 12.

(4-(6-((4-methylsulfonylpiperazin-1- yl)methyl)-4-morpholinothieno[3,2-d]pyrimidin-2-yl)phenyl)methanol 13.

3-(6-((4-methylsulfonylpiperazin-1- yl)methyl)-4-morpholinothieno[3,2-d]pyrimidin-2-yl)benzamide 14.

1-((2-(1H-indazol-4-yl)-4- morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)-4- methylsulfonylpiperazin-2-one 15.

1-(4-((2-(1H-indazol-4-yl)-4- morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-amino-2- methyipropan-1-one 16.

2-(2-methyl-1H-benzo[d]imidazol-1- yl)-6-((4-methylsulfonylpiperazin-1-yl)methyl)-4-morpholinothieno[2,3- d]pyrimidine 17.

(3-(6-((4-methylpiperazin-1- yl)methyl)-4-morpholinothieno[2,3-d]pyrimidin-2-yl)phenyl)methanol 18.

2-(1H-indazol-4-yl)-6-((4-N-methyl- N-methoxyethyiaminosulfonylpiperidin- 1-yl)methyl)-4-morpholinothieno[3,2-d]pyrimidine 19.

2-(1H-indazol-4-yl)-6-((4-N,N- dimethylaminosulfonylpiperidin-1-yl)methyl)-4-morpholinothieno[2,3- d]pyrimidine 20.

2-(1H-indazol-4-yl)-6-((4-N,N- dimethylaminosulfonylpiperidin-1-yl)methyl)-7-methyl-4- morpholinothieno[3,2-d]pyrimidine 21.

2-(1H-indazol-4-yl)-6-((4- methylsulfonylpiperidin-1-yl)methyl)-4-morpholinothieno[2,3- d]pyrimidine 22.

2-(1H-indazol-4-yl)-6-((4-N- methylaminosulfonylpiperidin-1-yl)methyl)-4-morpholinothieno[3,2- d]pyrimidine 23.

2-(1H-indazol-4-yl)-7-methyl-6-((4- (methylsulfonyl)piperidin-1-yl)methyl)-4-morpholinothieno[3,2- d]pyrimidine 24.

2-(1H-indazol-4-yl)-6-((4-N-4- methylpiperazinosulfonylpiperidin-1-yl)methyl)-4-morpholinothieno[3,2- d]pyrimidine 25.

2-(1H-imidazol-1-yl)-6-((4- methylsulfonylpiperazin-1-yl)methyl)-4-morpholinothieno[3,2- d]pyrimidine 26.

2-(1H-benzo[d]imidazol-1-yl)-6-((4- methylsulfonylpiperazin-1-yl)methyl)-4-morpholinothieno[3,2- d]pyrimidine 27.

2-(1H-indazol-4-yl)-6-((4-N,N- dimethylaminosulfonylpiperidin-1-yl)methyl)-4-morpholinothieno[3,2- d]pyrimidine 28.

2-(1H-indazol-4-yl)-6-((4-N- morpholinosulfonylpiperazin-1-yl)methyl)-4-morpholinothieno[3,2- d]pyrimidine 29.

2-(1H-indazol-4-yl)-7-methyl-6-((4- (methylsulfonyl)piperazin-1-yl)methyl)-4-morpholinothieno[3,2- d]pyrimidine 30.

N-((2-(1H-indazol-4-yl)-4- morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)-1-methylsulfonyl-N-(2- morpholinoethyl)piperidin-4-amine 31.

2-(1H-indazol-4-yl)-6-((4- methylpiperazin-1-yl)methyl)-4-morpholinothieno[2,3-d]pyrimidine 32.

(1-((2-(1H-indazol-4-yl)-4- morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)pyrrolidin-2-yl)-N- methylsulfonylmethanamine 33.

2-chloro-5-(6-((4-methylpiperazin-1- yl)methyl)-4-morpholinothieno[3,2-d]pyrimidin-2-yl)phenol 34.

N-((2-(1H-indazol-4-yl)-4- morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)-N-(2-methoxyethyl)-1- methylsulfonylpiperidin-4-amine 35.

4-fluoro-3-(6-((4-methylpiperazin-1- yl)methyl)-4-morpholinothieno[3,2-d]pyrimidin-2-yl)phenol 36.

2,3-difluoro-5-(6-((4- methylpiperazin-1-yl)methyl)-4-morpholinothieno[3,2-d]pyrimidin-2- yl)phenol 37.

5-(6-((4-methylpiperazin-1- yl)methyl)-4-morpholinothieno[3,2-d]pyrimidin-2-yl)pyridin-3-ol 38.

2-(1H-indazol-4-yl)-6-((1- methylpiperidin-4-yl)methyl)-4-morpholinothieno[3,2-d]pyrimidine 39.

6-((4-methylpiperazin-1-yl)methyl)- 4-morpholino-2-(1H-pyrazol-4-yl)thieno[3,2-d]pyrimidine 40.

1-(3-(6-((4-methylpiperazin-1- yl)methyl)-4-morpholinothieno[3,2-d]pyrimidin-2-yl)phenyl)ethanol 41.

(3-(6-((4-methylpiperazin-1- yl)methyl)-4-morpholinothieno[3,2-d]pyrimidin-2-yl)phenyl)methanol 42.

N-((2-(1H-indazol-4-yl)-4- morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)-tetrahydro-N-methyl-2H- sulfonylpyran-4-amine 43.

2-(4-((2-(1H-indazol-4-yl)-4- morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2- methylpropanamide 44.

N-((2-(1H-indazol-4-yl)-4- morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)-1-(2-methoxyethyl)-N- methylpiperidin-4-amine 45.

N-((2-(1H-indazol-4-yl)-4- morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)-N,1-dimethylpiperidin-4- amine 46.

1-(2-hydroxyethyl)-4-((2-(3- hydroxyphenyl)-4-morpholinothieno[3,2-d]pyrimidin-6- yl)methyl)piperazin-2-one 47.

4-((2-(3-hydroxyphenyl)-4- morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)-N-(2-methoxyethyl)-N- methylpiperazine-1-carboxamide 48.

(4-((2-(1H-indazol-4-yl)-4- morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1- yl)(cyclopropyl)methanone 49.

2-(1H-indazol-4-yl)-6-((3- (methylsulfonyl)pyrrolidin-1-yl)methyl)-4-morpholinothieno[3,2- d]pyrimidine 50.

2-(1H-indazol-4-yl)-6-(((S)-2- methyl-4-methylsulfonylpiperazin-1-yl)methyl)-4-morpholinothieno[3,2- d]pyrimidine 51.

(3-(6-((4-methylsulfonylpiperazin-1- yl)methyl)-4-morpholinothieno[3,2-d]pyrimidin-2-yl)phenyl)methanol 52.

1-(4-((2-(1H-indazol-4-yl)-4- morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2,2- dimethylpropan-1-one 53.

4-((2-(1H-indazol-4-yl)-4- morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazine-1-carbaldehyde 54.

1-(4-((2-(1H-indazol-4-yl)-4- morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)ethanone 55.

ethyl 4-((2-(1H-indazol-4-yl)-4- morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazine-1-carboxylate 56.

methyl 4-((2-(1H-indazol-4-yl)-4- morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazine-1-carboxylate 57.

2-(1H-indazol-4-yl)-6-((4- methylsulfonylpiperazin-1-yl)methyl)-4-morpholinothieno[2,3-d]pyrimidine 58.

1-((2-(1H-indazol-4-yl)-4- morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)-N-methyl-N- methylsulfonylpyrrolidin-3-amine 59.

N-((2-(1H-indazol-4-yl)-4- morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)-N-methyl(1- methylsulfonylpyrrolidin-2-yl)methanamine 60.

N-((2-(1H-indazol-4-yl)-4- morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)-N-methyl-(1- methylsulfonylpyrrolidin)-3-amine 61.

1-((1-((2-(1H-indazol-4-yl)-4- morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperidin-4-yl)methyl)pyrrolidin-2- one 62.

6-((4-((1H-pyrazol-1-yl)methyl)piperidin-1-yl)methyl)-2-(1H-indazol-4-yl)-4- morpbolinothieno[3,2-d]pyrimidine 63.

1-((2-(1H-indazol-4-yl)-4- morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperidin-4-ol 64.

1-((2-(1H-indazol-4-yl)-4- morpholinothienol[3,2-d]pyrimidin-6-yl)methyl)pyrrolidin-3-ol 65.

1-((2-(1H-indazol-4-yl)-4- morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperidin-3-ol 66.

(S)-1-(4-((2-(1H-indazol-4-yl)-4- morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxypropan-1- one 67.

1-(4-((2-(1H-indazol-4-yl)-4- morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2- (dimethylamino)ethanone 68.

1-(4-((2-(1H-indazol-4-yl)-4- morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-aminoethanone 69.

6-((4-methylsulfonylpiperazin-1-yl)methyl)-2-(4-(methylsulfonyl)phenyl)-4- morpholinothieno[3,2-d]pyrimidine 70.

2-(1H-indazol-6-yl)-6-((4-methylpiperazin-1-yl)methyl)-4-morpholinothieno[3,2- d]pyrimidine 71.

N-((2-(1H-indazol-4-yl)-4- morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)-N-(2-methoxyethyl)-1- methylpiperidin-4-amine 72.

(4-((2-(1H-indazol-4-yl)-4- morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)-1-methylsulfonylpiperazin-2-yl)- N,N-dimethylmethanamine 73.

1-(2-(1H-indazol-4-yl)-4- morpholinothieno[3,2-d]pyrimidin-6-yl)pyrrolidin-2-one 74.

N-((2-(1H-indazol-4-yl)-4- morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)-N,1-dimethylpiperidin-4-amine 75.

3-(2-(1H-indazol-4-yl)-4- morpholinothieno[3,2-d]pyrimidin-6-yl)oxazolidin-2-one 76.

3-(6-((4-methylsulfonylpiperazin-1-yl)methyl)-4-morpholinothieno[3,2-d]pyrimidin-2- yl)benzenemethylsulfonylamine 77.

6-((4-methylsulfonylpiperazin-1-yl)methyl)-4-morpholino-2-(pyrimidin-5-yl)thieno[3,2- d]pyrimidine 78.

2-(6-fluoropyridin-3-yl)-6-((4- methylsulfonylpiperazin-1-yl)methyl)-4-morpholinothieno[3,2-d]pyrimidine 79.

N-methyl-3-(6-((4-methylsulfonylpiperazin-1-yl)methyl)-4-morpholinothieno[3,2- d]pyrimidin-2-yl)benzamide 80.

2-(3-fluorophenyl)-6-((4-methylpiperazin-1-yl)methyl)-4-morpholinothieno[3,2- d]pyrimidine 81.

2-(2-fluoropyridin-3-yl)-6-((4- methylsulfonylpiperazin-1-yl)methyl)-4-morpholinothieno[3,2-d]pyrimidine 82.

6-(4-Methanesulfonyl-piperazin-1-ylmethyl)-2-(2-methoxy-pyrimidin-5-yl)-4-morpholin-4-yl- thieno[2,3-d]pyrimidine 83.

{5-[6-(4-Methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[2,3-d]pyrimidin-2-yl]-pyrimidin-2-yl}-dimethyl amine 84.

6-(4-Methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-2-pyridin-3-yl-thieno[3,2- d]pyrimidine 85.

N-{4-[6-(4-Methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidin-2-yl]-phenyl}-methanesulfonamide 86.

N-{4-[6-(4-Methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidin-2-yl]-phenyl}-acetamide 87.

6-(4-Methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-2-pyridin-3-yl-thieno[2,3- d]pyrimidine 88.

6-(4-Methanesulfonyl-piperazin-1-ylmethyl)-2-(2-methyl-imidazol-1-yl)-4-morpholin-4-yl- thieno[3,2-d]pyrimidine 89.

3-[6-(4-Methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2- d]pyrimidin-2-yl]-quinoline 90.

4-[6-(4-Methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2- d]pyrimidin-2-yl]-isoquinoline91.

1-{3-[6-(4-Methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[2,3-d]pyrimidin-2-yl]-phenyl}-ethanone 92.

2-(1H-Indazol-4-yl)-6-(4-methanesulfonyl-[1,4]diazepan-1-ylmethyl)-4-morpholin-4-yl- thieno[3,2-d]pyrimidine 93.

1-{3-[6-(4-Methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[2,3- d]pyrimidin-2-yl]-phenyl}-ethanol94.

4-[6-(4-Methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[2,3- d]pyrimidin-2-yl]-isoquinoline95.

3-[6-(4-Methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[2,3- d]pyrimidin-2-yl]-quinoline 96.

2-(1H-Indazol-4-yl)-6-((S)-4-methanesulfonyl-3-methyl-piperazin-1-ylmethyl)-4-morpholin-4- yl-thieno[2,3-d]pyrimidine97.

2-(1H-Indazol-4-yl)-4-morpholin-4-yl-6-[4-(propane-2-sulfonyl)-piperazin-1-ylmethyl] thieno[2,3-d]pyrimidine 98.

2-(1H-Indazol-4-yl)-6-((R)-4-methanesulfonyl-3-methyl-piperazin-1-ylmethyl)-4-morpholin-4- yl-thieno[2,3-d]pyrimidine99.

2-(1H-Indazol-4-yl)-6-(4-methanesulfonyl-2,2-dimethyl-piperazin-1-ylmethyl)-4-morpholin-4- yl-thieno[3,2-d]pyrimidine100.

2-(1H-Indazol-4-yl)-6-(4-methanesulfonyl-3,3-dimethyl-piperazin-1-ylmethyl)-4-morpholin-4- yl-thieno[3,2-d]pyrimidine101.

6-(4-Methanesulfonyl-piperazin-1-ylmethyl)-2-(2-methyl-benzoimidazol-1-yl)-4-morpholin-4- yl-thieno[3,2-d]pyrimidine102.

2-(1H-Indazol-4-yl)-6-((2S,6R)-4-methanesulfonyl-2,6-dimethyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[2,3- d]pyrimidine 103

[2-(1H-Indazol-4-yl)-4-morpholin-4-yl-thieno[2,3-d]pyrimidin-6-ylmethyl]-methyl-(1-methyl-piperidin-4-yl)-amine 104

2-{4-[2-(1H-Indazol-4-yl)-4-morpholin-4-yl-thieno[2,3-d]pyrimidin-6-ylmethyl]-piperazin-1-yl}-N,N-dimethyl-acetamide 105

2-{4-[2-(1H-Indazol-4-yl)-4-morpholin-4-yl-thieno[2,3-d]pyrimidin-6-ylmethyl]-piperazin-1-yl}-N-methyl-isobutyramide 106

2-(1H-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-5-methyl-4-morpholin- 4-yl-thieno[2,3-d]pyrimidine107

(R)-1-(4-((2-(1H-indazol-4-yl)-4- morphoiinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxypropan-1- one 108

1-(4-((2-(1H-indazol-4-yl)-4- morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxy-2- methylpropan-1-one 109

1-(4-((2-(1H-indazol-4-yl)-4- morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxyethanone 110

1-(4-((2-(1H-indazol-4-yl)-4- morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-methoxyethanone 111

(4-((2-(1H-indazol-4-yl)-4- morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)(tetrahydrofuran-2- yl)methanone 112

(4-((2-(1H-indazol-4-yl)-4- morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)(1- aminocyclopropyl)methanone 113

(S)-1-(4-((2-(1H-indazol-4-yl)-4- morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-aminopropan-1-one 114

(R)-1-(4-((2-(1H-indazol-4-yl)-4- morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-aminopropan-1-one 115

1-(4-((2-(1H-indazol-4-yl)-4- morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2- (methylsulfonyl)ethanone 116

(5)-1-(4-((2-(1H-indazol-4-yl)-4- morpholinothieno[2,3-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxypropan-1- one 117

(R)-1-(4-((2-(1H-indazol-4-yl)-4-morpholinothieno[2,3-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxypropan-1-one 118

1-(4-((2-(1H-indazol-4-yl)-4- morpholinothieno[2,3-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxy-2- methylpropan-1-one 119

1-(4-((2-(1H-indazol-4-yl)-4- morpholinothieno[2,3-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxyethanone 120

1-(4-((2-(1H-indazol-4-yl)-4- morpholinothieno[2,3-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-methoxyethanone 121

(4-((2-(1H-indazol-4-yl)-4- morpholinothieno[2,3-d]pyrimidin-6-yl)methyl)piperazin-1-yl)(tetrahydrofuran-2- yl)methanone 122

1-(4-((2-(1H-indazol-4-yl)-4- morpholinothieno[2,3-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-amino-2- methylpropan-1-one 123

(4-((2-(1H-indazol-4-yl)-4- morpholinothieno[2,3-d]pyrimidin-6-yl)methyl)piperazin-1-yl)(1- aminocyclopropyl)methanone 124

1-(4-((2-(1H-indazol-4-yl)-4- morpholinothieno[2,3-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-aminoethanone 125

(5)-1-(4-((2-(1H-indazol-4-yl)-4- morpholinothieno[2,3-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-aminopropan-1-one 126

(R)-1-(4-((2-(1H-indazol-4-yl)-4- morpholinothieno[2,3-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-aminopropan-1-one 127

1-(4-((2-(1H-indazol-4-yl)-4- morpholinothieno[2,3-d]pyrimidin-6-(methylsulfonyl)ethanone

TABLE 1b Compound No. Structure Name 128

2-(1H-indol-4-yl)-6-((4- methylsulfonylpiperazin-1-yl)methyl)-4-morpholinofuro[3,2-d]pyrimidine 129

2-(1H-indazol-4-yl)-6-((4- methylsulfonylpiperazin-1-yl)methyl)-4-morpholinothieno[3,2-d]pyrimidine 130

N-((2-(1H-indazol-4-yl)-4- morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)-N-methylpiperidin-4-amine 131

(S)-1-(4-((2-(IH-indazol-4-yl)-7-methyl-4-morpholinothiena[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxypropan-1- one 132

N-((2-(1H-indazol-4-yl)-7-methyl-4- morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)-N,1-dimethylpiperidin-4-amine 133

6-((4-methylsulfonylpiperazin-1-yl)methyl)-4-morpholino-2-(1H-pyrrolo[2,3-b]pyridin-5- yl)thieno[3,2-d]pyrimidine 134

(S)-1-((S)-4-((2-(1H-indazol-4-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)-3-methylpiperazin-1-yl)-2- hydroxypropan-1-one 135

2-(1H-benzo[d]imidazol-5-yl)-6-((4- methylpiperazin-1-yl)methyl)-4-morpholinothieno[3,2-d]pyrimidine 136

2-(2-methyl-1H-benzo[d]imidazol-5-yl)-6-((4-methylsulfonylpiperazin-1-yl)methyl)-4-morpholinothieno[3,2-d]pyrimidine 137

2-(1H-indazol-5-yl)-6-((4- methylsulfonylpiperazin-1-yl)methyl)-4-morpholinothieno[3,2-d]pyrimidine 138

5-(6-((4-methylsulfonylpiperazin)1-yl)methyl)-4-morpholinothieno[3,2-d]pyrimidin-2-yl)-1H- benzo[d]imidazol-2(3H)-one139

2-(1H-benzo[d]imidazol-4-yl)-6-((4-methylsulfonylpiperazin)1-yl)methyl)-4-morpholinothieno[3,2-d]pyrimidine 140

6-((4-methylsulfonylpiperazin)1-yl)methyl)-4-morpholino-2-(1H-pyrrolo[2,3-b]pyridin)5- yl)thieno[2,3-d]pyrimidine 141

2-(1H-indazol-4-yl)-6-((4- methylsulfonylpiperazin-1-yl)methyl)-4-morpholinofuro[2,3-d]pyrimidine 142

6-((4-methylsulfonylpiperazin)1-yl)methyl)-4-morpholino-2-(1H-pyrrolo[2,3-b]pyridin)5- yl)furo[3,2-d]pyrimidine 143

N-((2-(1H-indazol-4-yl)-4- morpbolinothieno[3,2-d]pyrimidin-6-yl)methyl)-1-isopropyl-N-methylpiperidin-4- amine 144

6-(6-((4-methylsulfonylpiperazin)1-yl)methyl)-4-morphoiinothieno[3,2-d]pyrimidin-2-yl)-3H- imidazo[4,5-b]pyridine 145

6-((4-isopropylsulfonylpiperazin-1-yl)methyl)-4-morpholino-2-(1H-pyrrolo[2,3-b]pyridin-5- yl)thieno[2,3-d]pyrimidine146

6-((4-(2-thiophen)sulfonylpiperazin-1-yl)methyl)-4-morpholino-2-(1H-pyrrolo[2,3-b]pyridin-5-yl)thieno[2,3-d]pyrimidine 147

6-(6-((4-methylsulfonylpiperazin)1-yl)methyl)-4-morpholinothieno[2,3-d]pyrimidin-2-yl)-3H- imidazo[4,5-b]pyridine 148

(S)-2-hydroxy-1-(4-((7-methyl-4-morpholino-2-(1H-pyrrolo[2,3-b]pyridin-5-yl)thieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)propan- 1-one 149

(S)-2-hydroxy-1-(4-((4-morpholino-2-(1H-pyrrolo[2,3-b]pyridin-5-yl)thieno[2,3-d]pyrimidin-6-yl)methyl)piperazin-1-yl)propan- 1-one 150

(S)-2-hydroxy-1-(4-((7-methyl-4-morpholino-2-(quinolin-3-yl)thieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)propan-1-one 151

(S)-2-hydroxy-1-(4-((4-morpholino-2-(quinolin-3-yl)thieno[2,3-d]pyrimidin-6- yl)methyl)piperazin-1-yl)propan-1-one 152

2-methyl-6-(6-((4-methylsulfonylpiperazin-1-yl)methyl)-4-morpholinothieno[2,3-d]pyrimidin-2-yl)-3H-imidazo[4,5-b]pyridine 153

(S)-2-hydroxy-1-(4-((2-(2-methyl-3H- imidazo[4,5-b]pyridin-6-yl)-4-morpholinothieno[2,3-d]pyrimidin-6-yl)methyl)piperazin-1-yl)propan-1-one 154

6-(6-((4-methylsulfonylpiperazin-1-yl)methyl)-4-morpholinothieno[2,3-d]pyrimidin-2- yl)imidazo[1,2-a]pyrimidine 155

2-(1H-Indazol-4-yl)-6-(4-methanesulfonyl-[1,4]diazepan-1-ylmethyl)-4-morpholin-4-yl- thieno[2,3-d]pyrimidine 156

2-(1H-Indazol-4-yl)-6-(4-methanesulfonyl-[1,4]diazepan-1-ylmethyl)-4-morpholin-4-yl- thieno[3,2-d]pyrimidine 157

6-(4-Methanesulfonyl-piperazin-1-ylmethyl)-2-(2-methyl-1H-benzoimidazol-5-yl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine 158

2-(1H-Indazol-5-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl- thieno[3,2-d]pyrimidine 159

2-(1H-benzo[d]imidazol-5-yl)-6-((4-(methylsulfonyl)piperazin-1-yl)methyl)-4-morpholinothieno[2,3-d]pyrimidine 160

2-(2-methyl-1H-benzo[d]imidazol-5-yl)-6-((4-(methylsulfonyl)piperazin-1-yl)methyl)-4-morpholinothieno[2,3-d]pyrimidine 161

4-(6-((4-(methylsulfonyl)piperazin-1- yl)methyl)-4-morpholinothieno[2,3-djpyrimidin-2-yl)benzene-1,2-diamine 162

4-(6-((4-(metbyisulfonyl)piperazin-1-yl)methyl)-2-(pyrido[2,3-b]pyrazin-7-yl)thieno[2,3-d]pyrimidin-4-yl)morpholine 163

5-(6-((4-(methyisulfonyl)piperazin-1- yl)methyl)-4-morpholinothieno[3,2-d]pyrimidin-2-yl)-1H-indazol-3-amine 164

6-(6-((4-(methylsulfonyl)piperazin-1- yl)methyl)-4-morpholinothieno[3,2-d]pyrimidin-2-yl)-1H-indazol-3-amine 165

4-(6-((4-(methylsulfonyl)piperazin-1-yl)methyl)-2-(1H-pyrazolo[3,4-b]pyridin-5-yl)thieno[2,3-d]pyrimidin-4-yl)morpholine 166

4-(6-((4-(methylsulfonyl)piperazin-1-yl)methyl)-2-(1H-pyrazolo[3,4-c]pyridin-4-yl)thieno[2,3-d]pyrimidin-4-yl)morpholine 167

4-(6-((4-(methylsulfonyl)piperazin-1-yl)methyl)-2-(5,6,7,8-tetrahydroquinolin-3-yl)thieno[2,3-d]pyrimidin-4-yl)morpholine 168

N,1-dimethyl-N-((4-morpholino-2-(quinolin-3-yl)thieno[2,3-d]pyrimidin-6- yl)methyl)piperidin-4-amine 169

(S)-2-hydroxy-1-(4-((7-methyl-2-(2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-4- morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)propan-1-oneand the pharmaceutically acceptable salts thereof.

The Formula Ia and Ib compounds of the invention may contain asymmetricor chiral centers, and therefore exist in different stereoisomericforms. It is intended that all stereoisomeric forms of the compounds ofthe invention, including but not limited to, diastereomers, enantiomersand atropisomers, as well as mixtures thereof such as racemic mixtures,form part of the present invention.

In addition, the present invention embraces all geometric andpositional-isomers. For example, if a Formula Ia and Ib compoundincorporates a double bond or a fused ring, the cis- and trans-forms, aswell as mixtures thereof, are embraced within the scope of theinvention. Both the single positional isomers and mixture of positionalisomers are also within the scope of the present invention.

In the structures shown herein, where the stereochemistry of anyparticular chiral atom is not specified, then all stereoisomers arecontemplated and included as the compounds of the invention. Wherestereochemistry is specified by a solid wedge or dashed linerepresenting a particular configuration, then that stereoisomer is sospecified and defined. The compounds of the present invention may existin unsolvated as well as solvated forms with pharmaceutically acceptablesolvents such as water, ethanol, and the like, and it is intended thatthe invention embrace both solvated and unsolvated forms.

The compounds of the present invention may also exist in differenttautomeric forms, and all such forms are embraced within the scope ofthe invention. The term “tautomer” or “tautomeric form” refers tostructural isomers of different energies which are interconvertible viaa low energy barrier. For example, proton tautomers (also known asprototropic tautomers) include interconversions via migration of aproton, such as keto-enol and imine-enamine isomerizations. Valencetautomers include interconversions by reorganization of some of thebonding electrons.

The present invention also embraces isotopically-labeled compounds ofthe present invention which are identical to those recited herein, butfor the fact that one or more atoms are replaced by an atom having anatomic mass or mass number different from the atomic mass or mass numberusually found in nature. All isotopes of any particular atom or elementas specified are contemplated within the scope of the compounds of theinvention, and their uses. Exemplary isotopes that can be incorporatedinto compounds of the invention include isotopes of hydrogen, carbon,nitrogen, oxygen, phosphorus, sulfur, fluorine, chlorine and iodine,such as ²H, ³H, ¹¹C, ¹³C, ¹⁴C, ¹³N, ¹⁵N, ¹⁵O, ¹⁷O, ¹⁸O, ³²P, ³³P, ³⁵S,¹⁸F, ³⁶Cl, ¹²³I and ¹²⁵I. Certain isotopically-labeled compounds of thepresent invention (e.g., those labeled with ³H and ¹⁴C) are useful incompound and/or substrate tissue distribution assays. Tritiated (³H) andcarbon-14 (¹⁴C) isotopes are useful for their ease of preparation anddetectability. Further, substitution with heavier isotopes such asdeuterium (i.e., ²H) may afford certain therapeutic advantages resultingfrom greater metabolic stability (e.g., increased in vivo half-life orreduced dosage requirements) and hence may be preferred in somecircumstances. Positron emitting isotopes such as ¹⁵O, ¹³N, ¹¹C and ¹⁸Fare useful for positron emission tomography (PET) studies to examinesubstrate receptor occupancy. Isotopically labeled compounds of thepresent invention can generally be prepared by following proceduresanalogous to those disclosed in the Schemes and/or in the Examplesherein below, by substituting an isotopically labeled reagent for anon-isotopically labeled reagent.

The compounds of the invention may exist in the form of geometricalisomers or tautomers depending on the kinds of substituent groups, andthese isomers in separated forms or mixtures thereof may be used in thepresent invention. Where the compounds have asymmetric carbon atoms,optical isomer forms may exist based on such carbon atoms. All of themixtures and the isolated forms of these optical isomers may be used inthe present invention.

A suitable synthetic strategy for producing compounds of the inventionas defined above employs the precursor carboxaldehyde of formula (IIa)or (IIb):

wherein X and R² are as defined above. Starting from this precursor thesynthesis comprises performing, in either order, a palladium-mediated(Suzuki-type) cross-coupling reaction and a reductive amination. Theprocess comprises:

(a) treating a compound of formula (IIa) or (IIb):

wherein X and R² are as defined above, with a boronic acid or esterthereof of formula R³B(OR¹⁵)₂, in which R³ is as defined above and eachR¹⁵ is H or C₁-C₆ alkyl or the two groups OR¹⁵ form, together with theboron atom to which they are attached, a pinacolato boronate estergroup, in the presence of a Pd catalyst; and treating the resultingcompound of formula (IIIa) or (IIIb):

wherein X, R² and R³ are as defined above, with an amine of formulaNHR⁴R⁵ in which R⁴ and R⁵ are as defined above, in the presence of asuitable reducing agent; or

(b) treating a compound of formula (IIa) or (IIb) as defined above withan amine of formula NHR⁴R⁵ wherein R⁴ and R⁵ are as defined above, inthe presence of a suitable reducing agent; and treating the resultingcompound of formula (IVa) or (IVb):

wherein X, R², R⁴ and R⁵ are as defined above, with a boronic acid orester thereof of formula R³B(OR¹⁵)₂, in which R³ is as defined above andeach R¹⁵ is H or C₁-C₆ alkyl or the two groups OR¹⁵ form, together withthe boron atom to which they are attached, a pinacolato boronate estergroup, in the presence of a Pd catalyst.

Accordingly, the present invention provides a process for producing acompound of the invention as defined above, which process comprisestreating a compound of formula (IIIa) or (IIIb):

wherein X, R² and R³ are as defined above, with an amine of formulaNHR⁴R⁵ in which R⁴ and R⁵ are as defined above, in the presence of asuitable reducing agent.

The process may further comprise producing the compound of formula(IIIa) or (IIIb) by treating a compound of formula (IIa) or (IIb):

wherein X and R² are as defined above, with a boronic acid or esterthereof of formula R³B(OR¹⁵)₂, in which R³ is as defined above and eachR¹⁵ is H or C₁-C₆ alkyl or the two groups OR¹⁵ form, together with theboron atom to which they are attached, a pinacolato boronate estergroup, in the presence of a Pd catalyst.

The invention further provides a process for producing a compound of theinvention as defined above, which process comprises treating a compoundof formula (IVa) or (IVb):

wherein X, R², R⁴ and R⁵ are as defined above, with a boronic acid orester thereof of formula R³B(OR¹⁵)₂ in which R³ is as defined above andeach R¹⁵ is H or C₁-C₆ alkyl or the two groups OR¹⁵ form, together withthe boron atom to which they are attached, a pinacolato boronate estergroup, in the presence of a Pd catalyst.

The process may further comprise producing the compound of formula (IVa)or (IVb) by treating a compound of formula (IIa) or (IIb):

wherein X and R² are as defined above, with an amine of formula NHR⁴R⁵in which R⁴ and R⁵ are as defined above, in the presence of a suitablereducing agent.

Both the amination step and the Pd-mediated cross-coupling step takeplace under conventional conditions. The palladium catalyst may be anythat is typically used for Suzuki-type cross-couplings, such asPdCl₂(PPh₃)₂. The reducing agent is typically a borohydride, forinstance NaBH(OAc)₃, NaBH₄ or NaCNBH₄, in particular NaBH(OAc)₃.

Compounds of formula (Ia) or (Ib) in which R³ is a 3- or 4-hydroxyphenylgroup may be produced by a process which comprises:

(a) treating a compound of formula (Va) or (Vb):

wherein OR′ is bonded at position 3 or 4 of the phenyl ring to which itis attached, R′ is a hydroxy protecting group and X and R² are asdefined above, with an amine of formula NHR⁴R⁵ wherein R⁴ and R⁵ are asdefined above, in the presence of a suitable reducing agent; and

(b) removing the hydroxy protecting group.

The reducing agent is typically a borohydride, for instance as specifiedabove.

Examples of hydroxy protecting groups are known in the art, for instanceas described in “Protective Groups for Organic Chemistry”, ThirdEdition, T. W. Greene and P. G. M. Wuts, John Wiley & Sons, 1999. Forinstance, a hydroxy group can be protected as an acetal, a substitutedacetal, an ester, a xanthate, an ether or a silyl ether. The acetal ispreferably tetrahydropyran. The silyl ether is preferably trimethylsilylether, t-butyl dimethylsilyl ether, triiso-propylsilyl ether ort-butyldiphenyl-silyl ether. These protecting groups are removed byconventional techniques.

A compound of formula (Va) or (Vb) as defined above may be produced by aprocess which comprises treating a compound of formula (VIa) or (VIb):

wherein X, R² and R′ are as defined above, with a lithiating agentfollowed by N,N′-dimethylformamide (DMF). The reaction is typicallyconducted by adding a solution of the lithiating agent in a non-polarorganic solvent, for instance a hydrocarbon solvent such as hexane, to asuspension of the compound of formula (VI) in an organic solvent such astetrahydrofuran (THF). If THF is used the addition takes place at a lowtemperature, of about −78° C. The lithiating agent is typically analkyllithium, for instance n-butyllithium.

A compound of formula (VIa) or (VIb) as defined above may be produced bya process which comprises treating a compound of formula (VIIa) or(VIIb):

wherein X and R² are as defined above, with a boronic acid of formula(VIII):

wherein R′ and R¹⁵ are as defined above, in the presence of a palladiumcatalyst. The reaction is conducted under conventional conditions for aSuzuki-type cross-coupling reaction, for instance as described above.

A fused pyrimidine of the invention may be converted into apharmaceutically acceptable salt, and a salt may be converted into thefree compound, by conventional methods. The phrase “pharmaceuticallyacceptable salt” as used herein, refers to pharmaceutically acceptableorganic or inorganic salts of a compound of the invention.

Examples of pharmaceutically acceptable salts include salts withinorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodicacid, sulphuric acid, nitric acid and phosphoric acid; and organic acidssuch as methanesulfonic acid, benzenesulphonic acid, formic acid, aceticacid, trifluoroacetic acid, propionic acid, oxalic acid, malonic acid,succinic acid, fumaric acid, maleic acid, lactic acid, malic acid,tartaric acid, citric acid, ethanesulfonic acid, aspartic acid andglutamic acid.

Exemplary salts include, but are not limited, to sulfate, citrate,acetate, oxalate, chloride, bromide, iodide, nitrate, bisulfate,phosphate, acid phosphate, isonicotinate, lactate, salicylate, acidcitrate, tartrate, oleate, tannate, pantothenate, bitartrate, ascorbate,succinate, maleate, gentisinate, fumarate, gluconate, glucuronate,saccharate, formate, benzoate, glutamate, methanesulfonate “mesylate”,ethanesulfonate, benzenesulfonate, p-toluenesulfonate, and pamoate(i.e., 1,1′-methylene-bis-(2-hydroxy-3-naphthoate)) salts. Apharmaceutically acceptable salt may involve the inclusion of anothermolecule such as an acetate ion, a succinate ion or other counter ion.The counter ion may be any organic or inorganic moiety that stabilizesthe charge on the parent compound. Furthermore, a pharmaceuticallyacceptable salt may have more than one charged atom in its structure.Instances where multiple charged atoms are part of the pharmaceuticallyacceptable salt can have multiple counter ions. Hence, apharmaceutically acceptable salt can have one or more charged atomsand/or one or more counter ion.

If the compound of the invention is a base, the desired pharmaceuticallyacceptable salt may be prepared by any suitable method available in theart, for example, treatment of the free base with an inorganic acid,such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid,methanesulfonic acid, phosphoric acid and the like, or with an organicacid, such as acetic acid, maleic acid, succinic acid, mandelic acid,fumaric acid, malonic acid, pyruvic acid, oxalic acid, glycolic acid,salicylic acid, a pyranosidyl acid, such as glucuronic acid orgalacturonic acid, an alpha hydroxy acid, such as citric acid ortartaric acid, an amino acid, such as aspartic acid or glutamic acid, anaromatic acid, such as benzoic acid or cinnamic acid, a sulfonic acid,such as p-toluenesulfonic acid or ethanesulfonic acid, or the like.

If the compound of the invention is an acid, the desiredpharmaceutically acceptable salt may be prepared by any suitable method,for example, treatment of the free acid with an inorganic or organicbase, such as an amine (primary, secondary or tertiary), an alkali metalhydroxide or alkaline earth metal hydroxide, or the like. Illustrativeexamples of suitable salts include, but are not limited to, organicsalts derived from amino acids, such as glycine and arginine, ammonia,primary, secondary, and tertiary amines, and cyclic amines, such aspiperidine, morpholine and piperazine, and inorganic salts derived fromsodium, calcium, potassium, magnesium, manganese, iron, copper, zinc,aluminum and lithium.

Typically the salt is a mesylate, a hydrochloride, a phosphate, abenzenesulphonate or a sulphate. Most typically the salt is a mesylateor a hydrochloride.

The salts, for instance salts with any of the inorganic or organic acidsmentioned above, may be mono-salts or bis-salts. Thus, for example, themesylate salt may be the mono-mesylate or the bis-mesylate.

A fused pyrimidine of the invention and its salts may exist as a solvateor a hydrate. A “solvate” refers to an association or complex of one ormore solvent molecules and a compound of the invention. Examples ofsolvents that form solvates include, but are not limited to, water,isopropanol, ethanol, methanol, DMSO, ethyl acetate, acetic acid, andethanolamine. The term “hydrate” refers to the complex where the solventmolecule is water.

Biological Activity

Compounds of the present invention have been found in biological-teststo be inhibitors of PI3 kinase. Determination of the activity of PI3kinase activity of a compound of the present invention is possible by anumber of direct and indirect detection methods. Certain exemplarycompounds described herein were prepared, characterized, and assayed fortheir PI3K binding activity (Example 7). Certain exemplary compounds ofthe invention had PI3K binding activity IC₅₀ values less than 50 uM.

The compounds of the present invention may inhibit p110 catalyticsubunit isoforms including alpha, beta, gamma, and delta as paninhibitors. Certain compounds of the invention may be p110 isoformselective inhibitors by selectively inhibiting one of one of the p110isoforms; alpha, beta, gamma, or delta. A p110 selective inhibitor maymitigate the risk of toxicity due to potential toxicities associatedwith inhibiting the other p110 isoforms. Certain compounds of theinvention may be p110 isoform pan inhibitors by possessing significantbinding to two or more of the p110 isoforms.

Binding of compounds of the invention from above Tables 1a and 1b topurified preparations of p110 isoforms alpha, beta, delta, and gamma wasmeasured by a Scintillation Proximity Assay (SPA) to determine bindingactivity (IC₅₀ μMol) and selectivity of binding of beta, delta, andgamma isoforms relative to alpha (Example 8). These values are expressedin Table 2.

A compound of the present invention may be used as an inhibitor of PI3kinase, in particular of a class Ia PI3 kinase. The compounds aretypically selective for class Ia kinases over class Ib and typicallyexhibit a 20-fold selectivity for class Ia over class Ib PI3 kinases. Inparticular the compounds are selective for the p110alpha isoform.

Accordingly, a compound of the present invention can be used to treat adisease or disorder arising from abnormal cell growth, function orbehaviour. Such abnormal cell growth, function or behaviour is typicallyassociated with PI3 kinase. Examples of such diseases and disorders arediscussed by Drees et al in Expert Opin. Ther. Patents (2004)14(5):703-732. These include cancer, immune disorders, cardiovasculardisease, viral infection, inflammation, metabolism/endocrine disordersand neurological disorders. Examples of metabolism/endocrine disordersinclude diabetes and obesity.

Examples of cancers which the present compounds can be used to treatinclude leukaemia, brain tumours, renal cancer, gastric cancer andcancer of the skin, bladder, breast, uterus, lung, colon, prostate,ovary and pancreas. A human or animal patient suffering from an immunedisorder, cancer, cardiovascular disease, viral infection, inflammation,a metabolism/endocrine disorder or a neurological disorders may thus betreated by a method comprising the administration thereto of a compoundof the present invention as defined above. The condition of the patientmay thereby be improved or ameliorated.

Diseases and conditions treatable according to the methods of thisinvention include, but are not limited to, cancer, stroke, diabetes,hepatomegaly, cardiovascular disease, Alzheimer's disease, cysticfibrosis, viral disease, autoimmune diseases, atherosclerosis,restenosis, psoriasis, allergic disorders, inflammation, neurologicaldisorders, a hormone-related disease, conditions associated with organtransplantation, immunodeficiency disorders, destructive bone disorders,proliferative disorders, infectious diseases, conditions associated withcell death, thrombin-induced platelet aggregation, chronic myelogenousleukemia (CML), liver disease, pathologic immune conditions involving Tcell activation, and CNS disorders in a patient. In one embodiment, ahuman patient is treated with a compound of Formula Ia or Ib and apharmaceutically acceptable carrier, adjuvant, or vehicle, wherein saidcompound of Formula Ia or Ib is present in an amount to detectablyinhibit PI3 kinase activity.

Cancers which can be treated according to the methods of this inventioninclude, but are not limited to, breast, ovary, cervix, prostate,testis, genitourinary tract, esophagus, larynx, glioblastoma,neuroblastoma, stomach, skin, keratoacanthoma, lung, epidermoidcarcinoma, large cell carcinoma, non-small cell lung carcinoma (NSCLC),small cell carcinoma, lung adenocarcinoma, bone, colon, adenoma,pancreas, adenocarcinoma, thyroid, follicular carcinoma,undifferentiated carcinoma, papillary carcinoma, seminoma, melanoma,sarcoma, bladder carcinoma, liver carcinoma and biliary passages, kidneycarcinoma, myeloid disorders, lymphoid disorders, hairy cells, buccalcavity and pharynx (oral), lip, tongue, mouth, pharynx, small intestine,colon-rectum, large intestine, rectum, brain and central nervous system,Hodgkin's and leukemia.

Cardiovascular diseases which can be treated according to the methods ofthis invention include, but are not limited to, restenosis,cardiomegaly, atherosclerosis, myocardial infarction, and congestiveheart failure.

Neurodegenerative disease which can be treated according to the methodsof this invention include, but are not limited to, Alzheimer's disease,Parkinson's disease, amyotrophic lateral sclerosis, Huntington'sdisease, and cerebral ischemia, and neurodegenerative disease caused bytraumatic injury, glutamate neurotoxicity and hypoxia.

Inflammatory diseases which can be treated according to the methods ofthis invention include, but are not limited to, rheumatoid arthritis,psoriasis, contact dermatitis, and delayed hypersensitivity reactions.

In addition to possessing biochemical potency a compound of theinvention exhibits physicochemical and pharmacokinetic properties whichmakes it particularly well adapted for drug use. This is shown forinstance in the results of the biological assays described in Example 5which follows. In particular the compound possesses high aqueoussolubility at physiological pH; the solubility is greater than 100 μM.High solubility at physiological pH is desirable since it promotesbioavailability.

The compound also possesses high metabolic stability, as shown inparticular by the hepatocyte clearance assay described in Example 2 inwhich the compound was shown to have low hepatocyte clearance. Lowhepatocyte clearance correlates with a low rate of liver metabolism. Itcan therefore be seen that the compound of the present invention possessimproved physicochemical and pharmacokinetic properties whilst retainingbiochemical potency as an inhibitor of PI3 kinase.

A compound of the present invention can be administered in a variety ofdosage forms, for example orally such as in the form of tablets,capsules, sugar- or film-coated tablets, liquid solutions or suspensionsor parenterally, for example intramuscularly, intravenously orsubcutaneously. The compound may therefore be given by injection orinfusion.

The dosage depends on a variety of factors including the age, weight andcondition of the patient and the route of administration. Daily dosagescan vary within wide limits and will be adjusted to the individualrequirements in each particular case. Typically, however, the dosageadopted for each route of administration when a compound is administeredalone to adult humans is 0.0001 to 50 mg/kg, most commonly in the rangeof 0.001 to 10 mg/kg, body weight, for instance 0.01 to 1 mg/kg. Such adosage may be given, for example, from 1 to 5 times daily. Forintravenous injection a suitable daily dose is from 0.0001 to 1 mg/kgbody weight, preferably from 0.0001 to 0.1 mg/kg body weight. A dailydosage can be administered as a single dosage or according to a divideddose schedule.

Typically a dose to treat human patients may range from about 10 mg toabout 1000 mg of a compound of the invention. A typical dose may beabout 100 mg to about 300 mg of the compound. A dose may be administeredonce a day (QID), twice per day (BID), or more frequently, depending onthe pharmacokinetic and pharmacodynamic properties, includingabsorption, distribution, metabolism, and excretion of the particularcompound. In addition, toxicity factors may influence the dosage andadministration regimen. When administered orally, the pill, capsule, ortablet may be ingested daily or less frequently for a specified periodof time. The regimen may be repeated for a number of cycles of therapy.

A compound is formulated for use as a pharmaceutical or veterinarycomposition also comprising a pharmaceutically or veterinarilyacceptable carrier or diluent. The compositions are typically preparedfollowing conventional methods and are administered in apharmaceutically or veterinarily suitable form. The compound may beadministered in any conventional form, for instance as follows:

A) Orally, for example, as tablets, coated tablets, dragees, troches,lozenges, aqueous or oily suspensions, liquid solutions, dispersiblepowders or granules, emulsions, hard or soft capsules, or syrups orelixirs. Compositions intended for oral use may be prepared according toany method known in the art for the manufacture of pharmaceuticalcompositions and such compositions may contain one or more agentsselected from the group consisting of sweetening agents, flavouringagents, colouring agents and preserving agents in order to providepharmaceutically elegant and palatable preparations.

Tablets contain the active ingredient in admixture with non-toxicpharmaceutically acceptable excipients which are suitable for themanufacture of tablets. These excipients may be for example, inertdiluents, such as calcium carbonate, sodium carbonate, lactose,dextrose, saccharose, cellulose, corn starch, potato starch, calciumphosphate or sodium phosphate; granulating and disintegrating agents,for example, maize starch, alginic acid, alginates or sodium starchglycolate; binding agents, for example starch, gelatin or acacia;lubricating agents, for example silica, magnesium or calcium stearate,stearic acid or talc; effervescing mixtures; dyestuffs, sweeteners,wetting agents such as lecithin, polysorbates or lauryl sulphate. Thetablets may be uncoated or they may be coated by known techniques todelay disintegration and adsorption in the gastrointestinal tract andthereby provide a sustained action over a longer period. For example, atime delay material such as glyceryl monostearate or glyceryl distearatemay be employed. Such preparations may be manufactured in a knownmanner, for example by means of mixing, granulating, tableting, sugarcoating or film coating processes.

Formulations for oral use may also be presented as hard gelatin capsuleswherein the active ingredient is mixed with an inert solid diluent, forexample, calcium carbonate, calcium phosphate or kaolin, or as softgelatin capsules wherein the active ingredient is present as such, ormixed with water or an oil medium, for example, peanut oil, liquidparaffin, or olive oil.

Aqueous suspensions contain the active materials in admixture withexcipients suitable for the manufacture of aqueous suspensions. Suchexcipients are suspending agents, for example, sodiumcarboxymethylcellulose, methylcellulose, hydroxypropylmethyl-cellulose,sodium alginate, polyvinylpyrrolidone gum tragacanth and gum acacia;dispersing or wetting agents may be naturally-occurring phosphatides,for example lecithin, or condensation products of an alkylene oxide withfatty acids, for example polyoxyethylene stearate, or condensationproducts of ethylene oxide with long chain aliphatic alcohols, forexample heptadecaethyleneoxycetanol, or condensation products ofethylene oxide with partial esters derived from fatty acids and ahexitol such as polyoxyethylene sorbitol monooleate, or condensationproducts of ethylene oxide with partial esters derived from fatty acidsand hexitol anhydrides for example polyoxyethylene sorbitan monooleate.

The said aqueous suspensions may also contain one or more preservatives,for example, ethyl or n-propyl p-hydroxybenzoate, one or more colouringagents, such as sucrose or saccharin.

Oily suspension may be formulated by suspending the active ingredient ina vegetable oil, for example arachis oil, olive oil, sesame oil orcoconut oil, or in a mineral oil such as liquid paraffin. The oilysuspensions may contain a thickening agent, for example beeswax, hardparaffin or cetyl alcohol.

Sweetening agents, such as those set forth above, and flavouring agentsmay be added to provide a palatable oral preparation. These compositionsmay be preserved by this addition of an antioxidant such as ascorbicacid. Dispersible powders and granules suitable for preparation of anaqueous suspension by the addition of water provide the activeingredient in admixture with a dispersing or wetting agent, a suspendingagent and one or more preservatives. Suitable dispersing or wettingagents and suspending agents are exemplified by those already mentionedabove. Additional excipients, for example sweetening, flavouring andcolouring agents, may also be present.

The pharmaceutical compositions of the invention may also be in the formof oil-in-water emulsions. The oily phase may be a vegetable oil, forexample olive oil or arachis oils, or a mineral oil, for example liquidparaffin or mixtures of these. Suitable emulsifying agents may benaturally-occurring gums, for example gum acacia or gum tragacanth,naturally occurring phosphatides, for example soy bean lecithin, andesters or partial esters derived from fatty acids an hexitol anhydrides,for example sorbitan mono-oleate, and condensation products of the saidpartial esters with ethylene oxide, for example polyoxyethylene sorbitanmonooleate. The emulsion may also contain sweetening and flavouringagents. Syrups and elixirs may be formulated with sweetening agents, forexample glycerol, sorbitol or sucrose. In particular a syrup fordiabetic patients can contain as carriers only products, for examplesorbitol, which do not metabolise to glucose or which only metabolise avery small amount to glucose.

Such formulations may also contain a demulcent, a preservative andflavouring and coloring agents;

B) Parenterally, either subcutaneously, or intravenously, orintramuscularly, or intrasternally, or by infusion techniques, in theform of sterile injectable aqueous or oleaginous suspensions. Thissuspension may be formulated according to the known art using thosesuitable dispersing of wetting agents and suspending agents which havebeen mentioned above. The sterile injectable preparation may also be asterile injectable solution or suspension in a non-toxicpaternally-acceptable diluent or solvent, for example as a solution in1,3-butane diol.

Among the acceptable vehicles and solvents that may be employed arewater, Ringer's solution and isotonic sodium chloride solution. Inaddition, sterile, fixed oils are conventionally employed as a solventor suspending medium. For this purpose any bland fixed oil may beemployed including synthetic mono- or diglycerides. In addition fattyacids such as oleic acid find use in the preparation of injectables;

C) By inhalation, in the form of aerosols or solutions for nebulizers;

D) Rectally, in the form of suppositories prepared by mixing the drugwith a suitable non-irritating excipient which is solid at ordinarytemperature but liquid at the rectal temperature and will therefore meltin the rectum to release the drug. Such materials are cocoa butter andpoly-ethylene glycols;

E) Topically, in the form of creams, ointments, jellies, collyriums,solutions or suspensions.

F) Vaginally, in the form of pessaries, tampons, creams, gels, pastes,foams or spray formulations containing in addition to the activeingredient such carriers as are known in the art to be appropriate.

Sustained-release preparations of a compound of the invention may beprepared. Suitable examples of sustained-release preparations includesemipermeable matrices of solid hydrophobic polymers containing acompound of Formula Ia or Ib, which matrices are in the form of shapedarticles, e.g., films, or microcapsules. Examples of sustained-releasematrices include polyesters, hydrogels (for example,poly(2-hydroxyethyl-methacrylate), or poly(vinyl alcohol)), polylactides(U.S. Pat. No. 3,773,919), copolymers of L-glutamic acid andgamma-ethyl-L-glutamate, non-degradable ethylene-vinyl acetate,degradable lactic acid-glycolic acid copolymers such as the LUPRONDEPOT™ (injectable microspheres composed of lactic acid-glycolic acidcopolymer and leuprolide acetate) and poly-D-(−)-3-hydroxybutyric acid.

A compound of the invention may be employed alone or in combination withother therapeutic agents for the treatment of a disease or disorderdescribed herein, such as a hyperproliferative disorder (e.g., cancer).In certain embodiments, a compound of the invention is combined in apharmaceutical combination formulation, or dosing regimen as combinationtherapy, with a second compound that has anti-hyperproliferativeproperties or that is useful for treating a hyperproliferative disorder(e.g., cancer). The second compound of the pharmaceutical combinationformulation or dosing regimen preferably has complementary activities tothe compound of the invention such that they do not adversely affecteach other. Such compounds are suitably present in combination inamounts that are effective for the purpose intended. In one embodiment,a composition of this invention comprises a compound of the invention,in combination with a chemotherapeutic agent such as described herein.

The combination therapy may be administered as a simultaneous orsequential regimen. When administered sequentially, the combination maybe administered in two or more administrations. The combinedadministration includes coadministration, using separate formulations ora single pharmaceutical formulation, and consecutive administration ineither order, wherein preferably there is a time period while both (orall) active agents simultaneously exert their biological activities.

Suitable dosages for any of the above coadministered agents are thosepresently used and may be lowered due to the combined action (synergy)of the newly identified agent and other chemotherapeutic agents ortreatments.

The invention will be further described in the Examples which follow:

EXAMPLE 1A General Synthetic Procedures

The following general procedures A, B and C are referred to in thesubsequent Examples and Reference Examples:

A) Suzuki Coupling

Substituted 2-chloro-4-morpholinothieno[3,2-d]pyrimidine or2-chloro-4-morpholinothieno[2,3-d]pyrimidine was combined with 1.5equivalents of4-(4,4,5,5-tertamethyl-1,3,2-dioxaborolan-2-yl)1H-indazole(alternatively, a variety of boronic acids or boronic esters can be usedin place of the indazole boronic ester indicated) and dissolved in 3.0equivalents of sodium carbonate as a 1 molar solution in water and anequal volume of acetonitrile. In some cases potassium acetate was usedin place of sodium carbonate to adjust the pH of the aqueous layer. Thereaction was then heated to between 140-150° C. under pressure in aBiotage Optimizer microwave reactor (Biotage, Inc.) for 10 to 30minutes. The contents were extracted with ethyl acetate. Afterevaporation of the organic layer the product was purified on silica orby reverse phase HPLC.

B) Amide Coupling

2-Chloro-4-morpholino-6-((piperazin-1-yl)methyl)thieno[3,2-d]pyrimidineor2-chloro-4-morpholino-6-((piperazin-1-yl)methyl)thieno[2,3-d]pyrimidineis treated with 1.5 eq HATU, 3 eq of amine and 3 eq of DIPEA in DMF toapproximately 0.1 M concentration. The reaction is stirred untilcomplete and extracted in Ethyl Acetate with Saturated BicarbonateSolution one time. The organic layer is dried, filtered and concentratedto yield the crude intermediate.

C) Reductive Amination

2-Chloro-4-morpholinothieno[3,2-d]pyrimidine-6-carbaldehyde or2-chloro-4-morpholinothieno[2,3-d]pyrimidine-6-carbaldehyde wasdissolved to a 0.2 M concentration in dichloroethane. To this solutionwas added 1.5 to 2.0 equivalents of an amine, 10 equivalents oftrimethylorthoformate, and 1 equivalent of acetic acid. The mixture wasallowed to stir for 2-6 hours prior to adding 1.5 equivalents of sodiumtriacetoxyborohydride. Following 12 to 16 hours of stirring the reactionwas poured into saturated sodium bicarbonate and extracted several timeswith ethyl acetate. This intermediate was either purified on silica gelor used crude in the next reaction.

EXAMPLE 1B Further General Synthetic Procedures D) Removal oft-butoxylcarbonyl (BOC) Group

Ten or more equivalents of 4N HCl in Dioxane, with or withoutdichloromethane as a co-solvent, are added to the starting material(general scheme shown above but similar scaffolds also used). Heating upto 40° C. for several hours is occasionally required to remove the bocgroup. The reaction is concentrated to dryness and used crude insubsequent reaction.

E) Suzuki Coupling Reactions

Generally, substituted 2-chloro-4-morpholinofuro[3,2-d]pyrimidine 14 (1eq), 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-amine(1.7 eq) (or other boronic acid/ester) andbis(triphenylphosphine)palladium(II) dichloride (0.1 eq) in 1M KOAcaqueous solution (3 eq) and an equal volume of acetonitrile (3 eq) washeated to 100° C. in a sealed microwave reactor for 10-15 min. Uponcompletion, the contents are extracted with ethyl acetate, or anotherorganic solvent. After evaporation of the organic layer the product 15,may be purified on silica or by reverse phase HPLC.

REFERENCE EXAMPLE 1 2,4-Dichloro-thieno[3,2-d]pyrimidine

A mixture of methyl 3-amino-2-thiophenecarboxylate (13.48 g, 85.85 mmol)and urea (29.75 g, 5 eq.) was heated at 190° C. for 2 hours. The hotreaction mixture was then poured onto sodium hydroxide solution and anyinsoluble material removed by filtration. The mixture was then acidified(HCl, 2N) to yield 1H-thieno[3,2-d]pyrimidine-2,4-dione) as a whiteprecipitate, which was collected by filtration and air dried (9.49 g,66%).

¹H NMR (400 MHz, d₆-DMSO) 6.90 (1H, d, J=5.2 Hz), 8.10 (1H, d, J=5.2Hz), 11.60-11.10 (2H, br, s).

A mixture of 1H-thieno[3,2-d]pyrimidine-2,4-dione (9.49 g, 56.49 mmol)and phosphorous oxychloride (150 mL) was heated at reflux for 6 hours.The reaction mixture was then cooled and poured onto ice/water withvigorous stirring yielding a precipitate. The mixture was then filteredto yield 2,4-dichloro-thieno[3,2-d]pyrimidine as a white solid (8.68 g,75%).

¹H NMR (400 MHz, CDCl₃) 7.56 (1H, d, J=5.5 Hz). 8.13 (1H, d, J=5.5 Hz).

REFERENCE EXAMPLE 2 2-Chloro-4-morpholin-4-yl-thieno[3,2-d]pyrimidine

A mixture of 2,4-dichloro-thieno[3,2-d]pyrimidine (8.68 g, 42.34 mmol),morpholine (8.11 mL, 2.2 eq.) and methanol (150 mL) was stirred at roomtemperature for 1 hour. The reaction mixture was then filtered, washedwith water and methanol, to yield the title compound as a white solid(11.04 g, 100%).

¹H NMR (400 MHz, d₆-DMSO) 3.74 (4H, t, J=4.9 Hz), 3.90 (4H, t, J=4.9Hz), 7.40 (1H, d, J=5.6 Hz), 8.30 (1H, d, J=5.6 Hz).

REFERENCE EXAMPLE 32-Chloro-4-morpholin-4-yl-thieno[3,2-d]pyrimidine-6-carbaldehyde

To a suspension of 2-chloro-4-morpholin-4-yl-thieno[3,2-d]pyrimidine(65) (1.75 g, 6.85 mmol) in dry THF (40 mL) at −78° C. was added a 2.5Msolution of nBuLi in hexane (3.3 mL, 1.2 eq.). After stirring for 1hour, dry N,N-dimethylformamide (796 μL, 1.5 eq.) was added. Thereaction mixture was stirred for 1 hour at −78° C. and then warmedslowly to room temperature. After a further 2 hours at room temperaturethe reaction mixture poured onto ice/water yielding a yellowprecipitate. This was collected by filtration and air-dried to yield thetitle compound (1.50 g, 77%).

¹H NMR (400 MHz, d₆-DMSO) 3.76 (4H, t, J=4.9 Hz), 3.95 (4H, t, J=4.9Hz), 8.28 (1H, s), 10.20 (1H, s).

2-Chloro-4-morpholin-4-yl-thieno[2,3-d]pyrimidine-6-carbaldehyde wasprepared in an analogous manner by commencing withmethyl-2-aminothiophen-3-carboxylate.

2-Chloro-7-methyl-4-morpholin-4-yl-thieno[3,2-d]pyrimidine-6-carbaldehydewas also prepared in analogous manner by commencing with3-amino-4-methyl-thiophene-2-carboxylic acid ethyl ester.

REFERENCE EXAMPLE 44-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)-1H-indazole Process 1

To a solution of 2-methyl-3-nitroaniline (2.27 g, 14.91 mmol) in aceticacid (60 mL) was added a solution of sodium nitrite (1.13 g, 1.1 eq.) inwater (5 mL). After 2 hours, the deep red solution was poured ontoice/water and the precipitate collected by filtration to yield4-nitro-1H-indazole (1.98 g, 81%).

A mixture of 4-nitro-1H-indazole (760 mg, 4.68 mmol), palladium oncharcoal (10%, cat.) and ethanol (30 mL) was stirred under a balloon ofhydrogen for 4 hours. The reaction mixture was then filtered throughcelite, and the solvent removed in vacuo to yield 1H-indazol-4-ylamine(631 mg, 100%).

An aqueous solution of sodium nitrite (337 mg, 4.89 mmol) in water (2mL) was added dropwise to a suspension of 1H-indazol-4-ylamine (631 mg,4.74 mmol) in 6M hydrochloric acid (7.2 mL) at below 0° C. Afterstirring for 30 minutes sodium tetrafluoroborate (724 mg) was added. Thereaction mixture became very thick and was filtered and washed brieflywith water to yield 1H-indazole-4-diazonium, tetrafluoroborate salt (218mg, 20%) as a deep red solid.

Dry methanol (4 mL) was purged with argon for 5 minutes. To this wasadded 1H-indazole-4-diazonium, tetrafluoroborate salt (218 mg, 0.94mmol), bis-pinacolato diboron (239 mg, 1.0 eq.) and[1,1′-bis(diphenylphosphino)ferrocene]palladium (II) chloride (20 mg).The reaction mixture was stirred for 5 hours and then filtered throughcelite. The residue was purified using flash chromatography to yield thedesired title compound (117 mg).

Process 2

To a solution of 3-bromo-2-methyl aniline (5.0 g, 26.9 mmol) inchloroform (50 mL) was added potassium acetate (1.05 eq., 28.2 mmol,2.77 g). Acetic anhydride (2.0 eq., 53.7 mmol, 5.07 mL) was added withconcurrent cooling in ice-water. The mixture was then stirred at roomtemperature for 10 minutes after which time a white gelatinous solidformed. 18-Crown-6 (0.2 eq., 5.37 mmol, 1.42 g) was then added followedby iso-amyl nitrite (2.2 eq., 59.1 mmol, 7.94 mL) and the mixture washeated under reflux for 18 h. The reaction mixture was allowed to cool,and was partitioned between chloroform (3×100 mL) and saturated aqueoussodium hydrogen carbonate (100 mL). The combined organic extracts werewashed with brine (100 mL), separated and dried (MgSO₄).

The crude product was evaporated onto silica and purified bychromatography eluting with 20%→40% EtOAc-petrol to give1-(4-bromo-indazol-1-yl)-ethanone (A) (3.14 g, 49%) as an orange solid,and 4-bromo-1H-indazole (B) (2.13 g, 40%) as a pale orange solid.

A ¹H NMR (400 MHz, CDCl₃) 2.80 (3H, s), 7.41 (1H, t, J=7.8 Hz), 7.50(1H, d, J=7.8 Hz), 8.15 (1H, s), 8.40 (1H, d, J=7.8 Hz).

B: ¹H NMR (400 MHz, CDCl₃) 7.25 (1H, t, J=7.3 Hz), 7.33 (1H, d, J=7.3Hz), 7.46 (1H, d, J=7.3 Hz), 8.11 (1H, s), 10.20 (1H, br s),

To a solution of the 1-(4-bromo-indazol-1-yl)-ethanone (3.09 g, 12.9mmol) in MeOH (50 mL) was added 6N aqueous HCl (30 mL) and the mixturewas stirred at room temperature for 7 h. The MeOH was evaporated and themixture partitioned between EtOAc (2×50 mL) and water (50 mL). Thecombined organic layers were washed with brine (50 mL), separated anddried (MgSO₄). The solvent was removed by evaporation under reducedpressure to give 4-bromo-1H-indazole (2.36 g, 93%).

To a solution of the 4-bromo-1H-indazole (500 mg, 2.54 mmol) andbis(pinacolato)diboron (1.5 eq., 3.81 mmol) in DMSO (20 mL) was addedpotassium acetate (3.0 eq., 7.61 mmol, 747 mg; dried in drying pistol)and PdCl₂(dppf)₂ (3 mol %, 0.076 mmol, 62 mg). The mixture was degassedwith argon and heated at 80° C. for 40 h. The reaction mixture wasallowed to cool and partitioned between water (50 mL) and ether (3×50mL). The combined organic layers were washed with brine (50 mL),separated and dried (MgSO₄). The crude material was purified bychromatography eluting with 30%→40% EtOAc-petrol to give an inseparable3:1 mixture of the4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1H-indazole (369 mg,60%) and indazole (60 mg, 20%); this was isolated as a yellow gum whichsolidified upon standing to furnish as an off-white solid.

¹H NMR (400 MHz, d₆-DMSO) 1.41 (12H, s), 7.40 (1H, dd, J=8.4 Hz, 6.9Hz), 7.59 (1H, d, J=8.4 Hz), 7.67 (1H, d, J=6.9 Hz), 10.00 (1H, br s),8.45 (1H, s), and indazole: 7.40 (1H, t), 7.18 (1H, t, J=7.9 Hz), 7.50(1H, d, J=9.1 Hz), 7.77 (1H, d, J=7.9 Hz), 8.09 (1H, s). Impurity at1.25.

REFERENCE EXAMPLE 52-(1H-Indazol-4-yl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine-6-carbaldehyde

A mixture of2-chloro-4-morpholin-4-yl-thieno[3,2-d]pyrimidine-6-carbaldehyde (100mg, 0.35 mmol),4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1H-indazole (95 mg,0.39 mmol) and sodium carbonate (112 mg) were suspended in toluene (2.5mL), ethanol (1.5 mL) and water (0.7 mL). To this was addedbis(triphenylphosphine)palladium(II) chloride (13.5 mg) and the reactionvessel was flushed with argon. The reaction mixture was microwaved at120° C. for 1 hour and then partitioned between dichloromethane andwater, the organic layer was washed with brine, dried over magnesiumsulfate, filtered and evaporated in vacuo. The resulting residue waspurified using flash chromatography to yield the title compound (97 mg).

REFERENCE EXAMPLE 6 Preparation of2-(1H-Indazol-4-yl)-6-(4-methyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine

To a mixture of2-(1H-Indazol-4-yl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine-6-carbaldehyde(91 mg, 0.26 mmol), 1-methylpiperazine (34 mg, 0.36 mmol) and aceticacid (15 uL) in 1,2-dichloroethane (2 mL) was added sodiumtriacetoxyborohydride (60 mg, 0.28 mmol). The reaction mixture wasstirred at room temperature overnight and then basified (NaHCO₃,saturated), diluted with dichloromethane, washed with brine. Organiclayer was separated, dried (MgSO₄), filtered and evaporated in vacuo.The residue was purified using flash chromatography to give the titlecompound (33 mg).

REFERENCE EXAMPLE 7 2-chloro-6-(4-methyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine

To a mixture of2-chloro-4-morpholin-4-yl-thieno[3,2-d]pyrimidine-6-carbaldehyde (66)(147 mg, 0.52 mmol), 1-methyl-piperazine (1.5 eq., 87 μL) and aceticacid (1.05 eq., 32 μL) in 1,2-dichloroethane (3 mL) was added sodiumtriacetoxyborohydride (1.1 eq., 121 mg) and then stirred at roomtemperature overnight. The reaction mixture was diluted withdichloromethane, washed with a saturated solution of sodium hydrogencarbonate, brine, separated and dried (MgSO₄). The crude product wasevaporated in vacuo and purified by chromatography to give the titlecompound 72 as an off-white crystalline solid (51 mg, 45%).

REFERENCE EXAMPLE 8(2-chloro-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methanol

A solution of2-chloro-4-morpholinothieno[3,2-d]pyrimidine-6-carbaldehyde (1.0 g, 3.5mmol) in MeOH (30 mL) at 0° C. was treated with NaBH₄ (0.1 g, 3.5 mmol).The solution was allowed to warm to room temperature and stirred 15 min.The reaction mixture was quenched with a mixture of a saturated solutionof sodium bicarbonate and water (1:1, v/v). The aqueous solution wasextracted with EtOAc. The combined organic layers were dried over Na₂SO₄and concentrated in vacuo. The crude material required no furtherpurification (0.9 g, 90%). MS (Q1) 286 (M)+

REFERENCE EXAMPLE 96-(bromomethyl)-2-chloro-4-morpholinothieno[3,2-d]pyrimidine

To a solution of(2-chloro-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methanol (100 mg, 0.4mmol) in benzene (3.0 mL) at 0° C. was added PBr₃ (30 μL, 0.4 mmol). Thereaction was heated at reflux for 1 hour. After cooling to roomtemperature the reaction was quenched by the addition of water. Theaqueous layer was extracted with EtOAc. The combined organics were driedover Na₂SO₄ and concentrated in vacuo. The crude material did notrequire further purification (115 mg, 94%). MS (Q1) 350 (M)+

REFERENCE EXAMPLE 101-(2-Chloro-4-morpholin-4-yl-thieno[3,2-d]pyrimidin-6-ylmethyl)-4-methanesulfonyl-piperazin-2-one

To a solution of 4-BOC-piperazinone (0.3 g, 1.6 mmol) in DMF (3 mL) at0° C. was added NaH (60% in mineral oil, 1.9 mmol). Next,6-(bromomethyl)-2-chloro-4-morpholinothieno[3,2-d]pyrimidine (0.6 g, 2mmol) was added and the reaction stirred for 15 min. The reaction wasquenched with saturated NH₄Cl and the aqueous layer was extracted withEtOAc. The combined organics were dried over Na₂SO₄ and concentrated invacuo. This intermediate was dissolved in CH₂Cl₂ (40 mL) and MeOH (40mL) and Et₂O (10 mL) and cooled to 0° C. To this solution was added 4 MHCl in dioxane (20 mL). The reaction was warmed to room temperature,stirred 18 h, then was concentrated in vacuo. To the residue was addedCH₂Cl₂ (50 mL), Et₃N (1.5 mL, 11 mmol), and MeSO₂Cl (0.6 mL, 8 mmol).The reaction mixture stirred 42 h at room temperature. The reaction wasquenched with water and extracted with EtOAc. The combined organics weredried over Na₂SO₄ and concentrated in vacuo (0.25 g, 28% over 3 steps).MS (Q1) 446 (M)+

REFERENCE EXAMPLE 112-Chloro-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine

Reaction between N—BOC-piperazine and methane sulfonyl chloride indichloromethane and triethylamine yielded4-methanesulfonyl-piperazine-1-carboxylic acid tert-butyl ester.Cleavage of the BOC protecting group using HCl (2M) in dichloromethaneyielded 1-methanesulfonyl-piperazine. HCl salt.

Reaction between 1-methanesulfonyl-piperazine. HCl salt and2-chloro-4-morpholin-4-yl-thieno[3,2-d]pyrimidine-6-carbaldehyde usingprocedure C yielded the title compound.

REFERENCE EXAMPLE 122-Chloro-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[2,3-d]pyrimidine

Reaction between 1-methanesulfonyl-piperazine. HCL salt and2-chloro-4-morpholin-4-yl-thieno[2,3-d]pyrimidine-6-carbaldehyde usingprocedure C yielded the title compound

REFERENCE EXAMPLE 13 Tert-butyl furan-3-ylcarbamate

3-Furoic acid (5.60 g, 1.0 eq) was dissolved in tert-butanol (200 ml)and treated with triethylamine (10 ml, 1.4 eq) and diphenyl phosphorylazide (12 ml, 1.1 eq). Mixture was heated at reflux for 18 h. Reactionmixture was cooled to room temperature, then concentrated to 50 ml andpoured into saturated aq. NaHCO₃. Mixture was stirred at 0° C. for 2 h.Solid was collected by filtration and dried under high vacuum. The crudereaction mixture was purified by flash chromatography to yieldtert-butyl furan-3-ylcarbamate (6.95 g, 76%): ¹H NMR (CDCl₃, 400 MHz) δ7.71 (bs, 1H), 7.27 (m, 1H), 6.27 (bs, 1H), 6.20 (bs, 1H), 1.50 (s, 9H);MS (Q1) 184 (M)⁺.

REFERENCE EXAMPLE 14 Tert-butyl 2-(methoxycarbonyl)furan-3-ylcarbamate

To a solution of tert-butyl furan-3-ylcarbamate (1.7 g, 1.0 eq) in THF(50 ml) at −30° C. was added TMEDA (1.75 ml, 1.3 eq) followed by 1.6Msolution of n-butyllithium (8.4 ml, 2.25 eq, 1.6M in hexanes). Reactionmixture was allowed to warm up to 0° C. and stirred for 1 h, beforebeing cooled back to −30° C. Dimethyl carbonate (2.4 ml, 3.0 eq) wasquickly added, before the reaction mixture was allowed to warm up toroom temperature for 1 hr. Reaction mixture was quenched with 2M HCl,followed by addition of saturated aq. NaCl. Mixture was extracted withethyl acetate. The combined organic extracts were dried with Na₂SO₄ andconcentrated. The crude reaction mixture was purified by flashchromatography to yield tert-butyl2-(methoxycarbonyl)furan-3-ylcarbamate (1.14 g, 51%): MS (Q1) 242 (M)⁺.

REFERENCE EXAMPLE 15 Methyl 3-aminofuran-2-carboxylate

Tert-butyl 2-(methoxycarbonyl)furan-3-ylcarbamate (1.14 g, 1.0 eq) wasdissolved in dichloromethane (8 ml) and treated with trifluoroaceticacid (5 ml). Reaction mixture was stirred at room temperature for 3 h,and was then concentrated. Residue was dissolved in dichloromethane andwashed with saturated aq. NaHCO₃. The organic layer was dried (Na₂SO₄)and concentrated Mixture was extracted with ethyl acetate. The combinedorganic extracts were dried with Na₂SO₄ and concentrated. The crudereaction mixture was purified by flash chromatography to yield methyl3-aminofuran-2-carboxylate (574 mg, 86%): MS (Q1) 142 (M)⁺.

REFERENCE EXAMPLE 16 Ethyl 3-ureidofuran-2-carboxylate

To a solution of methyl 3-aminofuran-2-carboxylate (100 mg, 1.0 eq) indichloromethane (3 ml) at −78° C. was added chlorosulfonyl isocyanate(0.09 ml, 1.4 eq) dropwise. The reaction was slowly warmed to roomtemperature and stirred for 40 minutes. Reaction was concentrated. Tothe residue was added 6N HCl (3.5 ml) and mixture was heated to 100° C.for 20 minutes. Reaction mixture was allowed to cool down to roomtemperature, and was neutralized with saturated aq. NaHCO₃. Solid wascollected by filtration to yield ethyl 3-ureidofuran-2-carboxylate (120mg, 92%) as a beige solid which was used in the next reaction withoutfurther purification.

REFERENCE EXAMPLE 17 Furo[3,2-d]pyrimidine-2,4-diol

Ethyl 3-ureidofuran-2-carboxylate (120 mg, 1.0 eq) was suspended inmethanol (6 ml) and treated with 1.5 M NaOH (1.5 ml). Reaction mixturewas heated to reflux for 90 minutes. Reaction mixture was allowed tocool down to room temperature, and was acidified with 6N HCl up to pH 3.Mixture was concentrated. Methanol was added to residue and solid wasfiltered and dried at 95° C. under high vacuum for 24 h to yieldfuro[3,2-d]pyrimidine-2,4-diol (90 mg, 91%) which was used in the nextreaction without further purification.

REFERENCE EXAMPLE 18 2,4-Dichlorofuro[3,2-d]pyrimidine

Furo[3,2-d]pyrimidine-2,4-diol (39 mg, 1.0 eq) was dissolved in POCl₃(1.8 ml). Mixture was cooled to −40° C. and N,N-diisopropylethylamine(0.45 ml) wad slowly added. Reaction mixture was then heated to refluxfor 48 h, then cooled to room temperature Reaction mixture was pouredinto ice/water. Mixture was extracted with ethyl acetate. The combinedorganic layers were washed with saturated aq. NaHCO₃, dried (Na₂SO₄) andconcentrated to yield 2,4-dichlorofuro[3,2-d]pyrimidine (23 mg, 48%)which was used in the next reaction without further purification.

REFERENCE EXAMPLE 19 2-Chloro-4-morpholinofuro[3,2-d]pyrimidine

2,4-Dichlorofuro[3,2-d]pyrimidine (23 mg, 1.0 eq) was suspended inmethanol (1.7 ml) and treated with morpholine (0.09 ml, 4.0 eq).Reaction mixture was stirred at room temperature for 2 h, before beingquenched with saturated aq. NaHCO₃. Mixture was extracted withdichloromethane. The combined organic layers were dried (Na₂SO₄) andconcentrated to yield 2-chloro-4-morpholinofuro[3,2-d]pyrimidine (14 mg,48%) which was used in the next reaction without further purification.

REFERENCE EXAMPLE 202-Chloro-4-morpholinofuro[3,2-d]pyrimidine-6-carbaldehyde

To a solution of 2-chloro-4-morpholinofuro[3,2-d]pyrimidine (40 mg, 1.0eq) dissolved in THF (1.7 ml) at −78° C. was added 1.6M solution ofn-butyllithium (0.14 ml, 1.3 eq, 1.6M in hexanes). Reaction mixture wasstirred at −78° C. for 30 minutes. DMF (0.05 ml, 4.0 eq) was added andreaction mixture was allowed to slowly warm up to room temperature andstirred for 90 minutes. Reaction mixture was quenched with water, andextracted with dichloromethane. The combined organic layers were dried(Na₂SO₄) and concentrated. The crude reaction mixture was purified byflash chromatography to yield2-chloro-4-morpholinofuro[3,2-d]pyrimidine-6-carbaldehyde (22 mg, 50%):¹H NMR (CDCl₃, 400 MHz) δ 9.92 (s, 1H), 7.48 (s, 1H), 4.12 (m, 4H), 3.86(dd, 4H); MS (Q1) 268 (M)⁺.

REFERENCE EXAMPLE 212-Chloro-6-((4-(methylsulfonyl)piperazin-1-yl)methyl)-4-morpholinofuro[3,2-d]pyrimidine

2-Chloro-4-morpholinofuro[3,2-d]pyrimidine-6-carbaldehyde (65 mg, 1.0eq) was dissolved in 1,2-dichloroethane (9.7 ml) and treated withhydrochloride salt of 1-methanesulfonylpiperazine (69 mg, 1.4 eq),sodium acetate (28 mg, 1.4 eq) and trimethyl orthoformate (0.27 ml, 10eq). Reaction mixture was stirred at room temperature for 12 h. Sodiumtriacetoxyborohydride (62 mg, 1.2 eq) was added and reaction mixture wasstirred at room temperature for 8 h. Reaction mixture was quenched withsaturated aq. NaHCO₃ and extracted with dichloromethane. The combinedorganic layers were dried (Na₂SO₄) and concentrated. The crude reactionmixture was purified by flash chromatography to yield2-chloro-6-((4-(methylsulfonyl)piperazin-1-yl)methyl)-4-morpholinofuro[3,2-d]pyrimidine(70 mg, 68%): MS (Q1) 416 (M)⁺.

EXAMPLE 2 Compounds of the Invention—Series A

The following compounds of the invention were prepared. The compoundnumbering corresponds to that used in Table 1A above.

14:1-(2-Chloro-4-morpholin-4-yl-thieno[3,2-d]pyrimidin-6-ylmethyl)-4-methanesulfonyl-piperazin-2-one(100 mg, 0.2 mmol) was converted to 14 using General Procedure A (10 mg,10%). MS (Q1) 528 (M)+

68: To 1 g of2-chloro-4-morpholinothieno[3,2-d]pyrimidine-6-carbaldehyde was added855 mg 1-BOC-piperazine via Procedure C to give 1.59 g of2-chloro-4-morpholino-6-((Boc-piperazin-1-yl)methyl)thieno[3,2-d]pyrimidine.The crude HCl salt of2-chloro-4-morpholino-6-((piperazin-1-yl)methyl)thieno[3,2-d]pyrimidinewas then formed by treatment with 5 eq 4N HCl in dioxane in a solutionof DCM and subsequent evaporation to dryness.

100 mg of crude HCl salt of2-chloro-4-morpholino-6-((piperazin-1-yl)methyl)thieno[3,2-d]pyrimidinewas treated with 135 mg of Boc-Glycine via Procedure B. This crudeintermediate was then subjected to Procedure A to give 31.5 mg of 68. MS(Q1) 493.2 (M)+.

67: 25 mg of crude HCl salt of2-chloro-4-morpholino-6-((piperazin-1-yl)methyl)thieno[3,2-d]pyrimidinewas treated with 135 mg of N,N-Dimethylglycine via Procedure B. Thiscrude intermediate was then subjected to Procedure A to give 7.4 mg of67. MS (Q1) 521.2 (M)+.66: 400 mg of crude HCl salt of2-chloro-4-morpholino-6-((piperazin-1-yl)methyl)thieno[3,2-d]pyrimidinewas treated with 175 mg of L-Lactic Acid via Procedure B. This crudeintermediate was then subjected to Procedure A to give 212 mg of 66. MS(Q1) 508.2 (M)+.56: The crude HCl salt of2-chloro-4-morpholino-6-((piperazin-1-yl)methyl)thieno[3,2-d]pyrimidine(50 mg) was treated with 5 eq methyl chloroformate and 6 eq DIPEA in 1mL of DMF. The reaction mixture was concentrated and extracted intoEthyl Acetate with Saturated Ammonium Chloride. The aqueous layer wasback-extracted once with DCM. The organics were combined andconcentrated to dryness. This crude intermediate was then subjected toProcedure A to give 3.7 mg of 56. MS (Q1) 494.2 (M)+.55: The crude HCl salt of2-chloro-4-morpholino-6-((piperazin-1-yl)methyl)thieno[3,2-d]pyrimidine(50 mg) was treated with 5 eq ethyl chloroformate and 6 eq DIPEA in 1 mLof DMF. The reaction mixture was concentrated and extracted into EthylAcetate with Saturated Ammonium Chloride. The aqueous layer wasback-extracted once with DCM. The organics were combined andconcentrated to dryness. This crude intermediate was then subjected toProcedure A to give 35.4 mg of 55. MS (Q1) 508.2 (M)+.54: The crude HCl salt of2-chloro-4-morpholino-6-((piperazin-1-yl)methyl)thieno[3,2-d]pyrimidine(50 mg) was treated with 3 eq Acetic Anhydride and 5 eq DIPEA in 1 mL ofDCM. The reaction mixture was concentrated and extracted into EthylAcetate with Saturated Ammonium Chloride. The aqueous layer wasback-extracted once with DCM. The organics were combined andconcentrated to dryness. This crude intermediate was then subjected toProcedure A to give 20.2 mg of 54. MS (Q1) 478.2 (M)+.53: The crude HCl salt of2-chloro-4-morpholino-6-((piperazin-1-yl)methyl)thieno[3,2-d]pyrimidine(50 mg) was treated with 5 eq of Formic Acid, 5 eq EDC and 5 eq DIPEA in1 mL of DMF. This crude intermediate was then subjected to Procedure Ato give 5.1 mg of 53. MS (Q1) 464.2 (M)+.52: The crude HCl salt of2-chloro-4-morpholino-6-((piperazin-1-yl)methyl)thieno[3,2-d]pyrimidine(50 mg) was treated with 2.5 eq of pivaloyl chloride and 3 eq DIPEA in 1mL of DCM. This crude intermediate was then subjected to Procedure A togive 36.7 mg of 52. MS (Q1) 520.3 (M)+.48: The crude HCl salt of2-chloro-4-morpholino-6-((piperazin-1-yl)methyl)thieno[3,2-d]pyrimidine(50 mg) was treated with 2.5 eq of cyclopropanecarbonyl chloride and 3eq DIPEA in 1 mL of DCM. This crude intermediate was then subjected toProcedure A to give 27.2 mg of 48. MS (Q1) 504.2 (M)+.107: The crude HCl salt of2-chloro-4-morpholino-6-((piperazin-1-yl)methyl)thieno[3,2-d]pyrimidine(100 mg) was treated with 70 mg of D-Lactic Acid via Procedure B. Thiscrude intermediate was then subjected to Procedure A to give(R)-1-(4-((2-(1H-indazol-4-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxypropan-1-one.MS (Q1) 508.2 (M)+.108: The crude HCl salt of2-chloro-4-morpholino-6-((piperazin-1-yl)methyl)thieno[3,2-d]pyrimidine(100 mg) was treated with 75 mg of 2-Hydroxyisobutyric Acid viaProcedure B. This crude intermediate was then subjected to Procedure Ato give1-(4-((2-(1H-indazol-4-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxy-2-methylpropan-1-one.MS (Q1) 522.2 (M)+.109: The crude HCl salt of2-chloro-4-morpholino-6-((piperazin-1-yl)methyl)thieno[3,2-d]pyrimidine(100 mg) was treated with 55 mg of Glycolic Acid via Procedure B. Thiscrude intermediate was then subjected to Procedure A to give1-(4-((2-(1H-indazol-4-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxyethanone.MS (Q1) 494.4 (M)+.110: The crude HCl salt of2-chloro-4-morpholino-6-((piperazin-1-yl)methyl)thieno[3,2-d]pyrimidine(100 mg) was treated with 55 μL of Methoxyacetic Acid via Procedure B.This crude intermediate was then subjected to Procedure A to give1-(4-((2-(1H-indazol-4-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-methoxyethanone.MS (Q1) 508 (M)+.111: The crude HCl salt of2-chloro-4-morpholino-6-((piperazin-1-yl)methyl)thieno[3,2-d]pyrimidine(100 mg) was treated with 70 μL of tetrahydro-2-furoic acid viaProcedure B. This crude intermediate was then subjected to Procedure Ato give(4-((2-(1H-indazol-4-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)(tetrahydrofuran-2-yl)methanone.MS (Q1) 534.3 (M)+.112: The crude HCl salt of2-chloro-4-morpholino-6-((piperazin-1-yl)methyl)thieno[3,2-d]pyrimidine(100 mg) was treated with 100 mg of Boc-amino-cyclopropanecarboxylicacid via Procedure B. This crude intermediate was then subjected toProcedure A to give(4-((2-(1H-indazol-4-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)(1-aminocyclopropyl)methanone.MS (Q1) 519.3 (M)+.113: The crude HCl salt of2-chloro-4-morpholino-6-((piperazin-1-yl)methyl)thieno[3,2-d]pyrimidine(100 mg) was treated with 140 mg of Boc-Alanine via Procedure B. Thiscrude intermediate was then subjected to Procedure A to give(S)-1-(4-((2-(1H-indazol-4-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-aminopropan-1-one.MS (Q1) 507.3 (M)+.114: The crude HCl salt of2-chloro-4-morpholino-6-((piperazin-1-yl)methyl)thieno[3,2-d]pyrimidine(100 mg) was treated with 140 mg of Boc-D-Alanine via Procedure B. Thiscrude intermediate was then subjected to Procedure A to give(R)-1-(4-((2-(1H-indazol-4-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-aminopropan-1-one.MS (Q1) 507.3 (M)+.115: The crude HCl salt of2-chloro-4-morpholino-6-((piperazin-1-yl)methyl)thieno[3,2-d]pyrimidine(100 mg) was treated with 100 mg of methanesulphonylacetic acid viaProcedure B. This crude intermediate was then subjected to Procedure Ato give1-(4-((2-(1H-indazol-4-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-(methylsulfonyl)ethanone.MS (Q1) 556.3 (M)+.116: To 700 mg of2-chloro-4-morpholinothieno[2,3-d]pyrimidine-6-carbaldehyde was added645 mg 1-BOC-piperazine via Procedure C to give 1.12 g of2-chloro-4-morpholino-6-((Boc-piperazin-1-yl)methyl)thieno[2,3-d]pyrimidine.The crude HCl salt of2-chloro-4-morpholino-6-((piperazin-1-yl)methyl)thieno[2,3-d]pyrimidinewas then formed by treatment with 5 eq 4N HCl in dioxane in a solutionof DCM and subsequent evaporation to dryness.

The crude HCl salt of2-chloro-4-morpholino-6-((piperazin-1-yl)methyl)thieno[2,3-d]pyrimidine(100 mg) was treated with 65 mg of L-Lactic Acid via Procedure B. Thiscrude intermediate was then subjected to Procedure A to give(S)-1-(4-((2-(1H-indazol-4-yl)-4-morpholinothieno[2,3-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxypropan-1-one.MS (Q1) 508.2 (M)+.

117: The crude HCl salt of2-chloro-4-morpholino-6-((piperazin-1-yl)methyl)thieno[2,3-d]pyrimidine(75 mg) was treated with 51 mg of D-Lactic Acid via Procedure B. Thiscrude intermediate was then subjected to Procedure A to give(R)-1-(4-((2-(1H-indazol-4-yl)-4-morpholinothieno[2,3-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxypropan-1-one.MS (Q1) 508.2 (M)+.118: The crude HCl salt of2-chloro-4-morpholino-6-((piperazin-1-yl)methyl)thieno[2,3-d]pyrimidine(75 mg) was treated with 55 mg of 2-Hydroxyisobutyric Acid via ProcedureB. This crude intermediate was then subjected to Procedure A to give1-(4-((2-(1H-indazol-4-yl)-4-morpholinothieno[2,3-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxy-2-methylpropan-1-one.MS (Q1) 522.2 (M)+.119: The crude HCl salt of2-chloro-4-morpholino-6-((piperazin-1-yl)methyl)thieno[2,3-d]pyrimidine(75 mg) was treated with 40 mg of Glycolic Acid via Procedure B. Thiscrude intermediate was then subjected to Procedure A to give1-(4-((2-(1H-indazol-4-yl)-4-morpholinothieno[2,3-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxyethanone.MS (Q1) 494.4 (M)+.120: The crude HCl salt of2-chloro-4-morpholino-6-((piperazin-1-yl)methyl)thieno[2,3-d]pyrimidine(75 mg) was treated with 41 μL of methoxylacetic acid via Procedure B.This crude intermediate was then subjected to Procedure A to give1-(4-((2-(1H-indazol-4-yl)-4-morpholinothieno[2,3-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-methoxyethanone.MS (Q1) 508 (M)+.121: The crude HCl salt of2-chloro-4-morpholino-6-((piperazin-1-yl)methyl)thieno[2,3-d]pyrimidine(75 mg) was treated with 50 μL of Tetrahydro-2-furoic Acid via ProcedureB. This crude intermediate was then subjected to Procedure A to give(4-((2-(1H-indazol-4-yl)-4-morpholinothieno[2,3-d]pyrimidin-6-yl)methyl)piperazin-1-yl)(tetrahydrofuran-2-yl)methanone.MS (Q1) 534.3 (M)+.122: The crude HCl salt of2-chloro-4-morpholino-6-((piperazin-1-yl)methyl)thieno[2,3-d]pyrimidine(75 mg) was treated with 100 mg of Boc-2-Aminoisobutyric Acid viaProcedure B. This crude intermediate was then subjected to Procedure Ato give1-(4-((2-(1H-indazol-4-yl)-4-morpholinothieno[2,3-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-amino-2-methylpropan-1-one.MS (Q1) 521.5 (M)+.123: The crude HCl salt of2-chloro-4-morpholino-6-((piperazin-1-yl)methyl)thieno[2,3-d]pyrimidine(75 mg) was treated with 100 mg of Boc-amino-cyclopropanecarboxylic acidvia Procedure B. This crude intermediate was then subjected to ProcedureA to give(4-((2-(H-indazol-4-yl)-4-morpholinothieno[2,3-d]pyrimidin-6-yl)methyl)piperazin-1-yl)(1-aminocyclopropyl)methanone.MS (Q1) 519.3 (M)+.124: The crude HCl salt of2-chloro-4-morpholino-6-((piperazin-1-yl)methyl)thieno[2,3-d]pyrimidine(75 mg) was treated with 93 mg of Boc-Glycine Acid via Procedure B. Thiscrude intermediate was then subjected to Procedure A to give1-(4-((2-(1H-indazol-4-yl)-4-morpholinothieno[2,3-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-aminoethanone.MS (Q1) 493.3 (M)+.125: The crude HCl salt of2-chloro-4-morpholino-6-((piperazin-1-yl)methyl)thieno[2,3-d]pyrimidine(75 mg) was treated with 100 mg of Boc-Alanine Acid via Procedure B.This crude intermediate was then subjected to Procedure A to give(S)-1-(4-((2-(1H-indazol-4-yl)-4-morpholinothieno[2,3-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-aminopropan-1-one.MS (Q1) 507.3 (M)+.126: The crude HCl salt of2-chloro-4-morpholino-6-((piperazin-1-yl)methyl)thieno[2,3-d]pyrimidine(75 mg) was treated with 100 mg of N-Boc-D-alanine via Procedure B. Thiscrude intermediate was then subjected to Procedure A to give(R)-1-(4-((2-(1H-indazol-4-yl)-4-morpholinothieno[2,3-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-aminopropan-1-one.MS (Q1) 507.3 (M)+.127: The crude HCl salt of2-chloro-4-morpholino-6-((piperazin-1-yl)methyl)thieno[2,3-d]pyrimidine(75 mg) was treated with 100 mg of methanesulphonylacetic acid viaProcedure B. This crude intermediate was then subjected to Procedure Ato give1-(4-((2-(1H-indazol-4-yl)-4-morpholinothieno[2,3-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-(methylsulfonyl)ethanone.MS (Q1) 556.3 (M)+.63: 2-Chloro-4-morpholinothieno[3,2-d]pyrimidine-6-carbaldehyde (50 mg)was reacted with 4-hydroxypiperidine following the protocol in generalprocedure C. The crude material was then used in general procedure A togive 3 mg of 63 following reversed phase HPLC purification. MS (Q1) 451(M)+64: 2-Chloro-4-morpholinothieno[3,2-d]pyrimidine-6-carbaldehyde (50 mg)was reacted with 3-hydroxypyrrolidine following the protocol in generalprocedure C. The crude material was then used following generalprocedure A to give 7 mg of 64 following reversed phase HPLCpurification. MS (Q1) 437 (M)+65: 2-Chloro-4-morpholinothieno[3,2-d]pyrimidine-6-carbaldehyde (50 mg)was dissolved in 2 mL dimethylformamide. To this solution was added 2.6equivalents of 3-hydroxypiperidine, 3 equivalents of magnesium sulfate,and 0.04 mL of acetic acid. The mixture was allowed to stir for 6 hoursprior to adding 2.5 equivalents of sodium triacetoxyborohydride.Following 12 to 16 hours of stirring the reaction was poured intosaturated sodium bicarbonate and extracted several times withethylacetate. This chloro intermediate used crude following the protocolfor general procedure A to give 6 mg of 65 after reversed phase HPLCpurification. MS (Q1) 451 (M)+49: 2-Chloro-4-morpholinothieno[3,2-d]pyrimidine-6-carbaldehyde (175 mg)was reacted with 3-(methanesulfonyl)pyrrolidine following the protocolin general procedure C. The crude material was then used in generalprocedure A to give 177 mg of G-34670 following purification on silica(0 to 15% MeOH gradient in dichloromethane over 40 min, 40 g column). MS(Q1) 499.2 (M)+50: 2-Chloro-4-morpholinothieno[3,2-d]pyrimidine-6-carbaldehyde (200 mg)was reacted according to procedure C with(S)-4-N-trityl-2-methyl-piperazine. The crude material was thendissolved in 10 mL of methanol and treated with 0.5 mL of concentratedHCl for several hours before basifying with NaOH and extracting intoEtOAc. After evaporation the crude reaction mixture containing2-chloro-6-(((S)-2-methylpiperazin-1-yl)methyl-4-morpholinothieno[3,2-d]pyrimidinewas dissolved in 10 mL of dichloromethane and treated with 0.3 mL ofdiisopropylethylamine and 54 μL of methanesulfonyl chloride. Afterovernight stirring an additional 20 μL of methanesulfonyl chloride wasadded to convert remaining starting material to product. Upon completionthe reaction was extracted with dichloromethane and water and thenpurified on silica gel using a MeOH gradient in dichloromethane to give186 mg of2-chloro-6-(((S)-4-N-sulfonyl-2-methylpiperazin-1-yl)methyl-4-morpholinothieno[3,2-d]pyrimidine.160 mg of this material was used following general procedure SUZUKI andpurified with reversed phase HPLC to give compound 50. MS (Q1) 528 (M)+1: 2-Chloro-4-morpholinothieno[3,2-d]pyrimidine-6-carbaldehyde (100 mg)was reacted according to procedure C with(1S,4S)—N-Boc-2,5-diaza-bicyclo[2.2.1]heptane to give 140 mg of the Bocprotected piperazine following silica gel purification (25% to 100%EtOAc gradient in hexanes, 12 g column). The Boc group was removed bytreating the compound with 1.5 mmol of HCl in dioxane. After evaporationthe free amine was sulfonylated in 3 mL of dichloromethane using 100 μLof triethylamine as a base and 35 μL of methanesulfonylchloride. Aftertwo hours the reaction was complete and extracted with dichloromethaneand saturated NaCl. The crude material from this reaction was usedfollowing general procedure SUZUKI and purified with reversed phase HPLCto give 61 mg of compound 1. MS (Q1) 526 (M)+75: N-Butyllithium (9.4 mL, 22.48 mmol, 2.5 M in hexane solution) wasadded to a mixture of 2-chloro-4-morpholinothieno[3,2-d]pyrimidine (3.0g, 11.74 mmol) in 60 mL of THF at −78° C. The reaction mixture wasallowed to warm to −40° C. and stirred for 30 min. A solution of iodine(6.0 g, 23.48 mmol) in 10 mL of THF was added dropwise. After theaddition was completed. The reaction mixture was brought to roomtemperature and stirred for 2 h. The mixture was quenched by dilutingwith dichloromethane (300 mL) and extracting with H₂O (2×100 mL). Theorganic layer was washed with Na₂S₂O₃ (2×100 mL), H₂O (2×100 mL), driedover MgSO₄, filtered and evaporated to afford2-chloro-6-iodo-4-morpholinothieno[3,2-d]pyrimidine (3.4 g, 75%).

2-Chloro-6-iodo-4-morpholinothieno[3,2-d]pyrimidine (150 mg),2-oxazolidinone (103 mg), potassium phosphate tribasic (250 mg), copperiodide (7 mg), 4 μL of N,N-dimethylethylenediamine in 2 mL of1,4-dioxane was heated to 100° C. for 15 hr. The reaction mixture wasevaporated and the residue was diluted with ethyl acetate (50 mL),washed with brine (30 mL), dried over MgSO₄, filtered and evaporated.The crude product was purified on reverse phase HPLC to give 46 mg of3-(2-chloro-4-morpholinothieno[3,2-d]pyrimidin-6-yl) oxazolidin-2-one.

3-(2-Chloro-4-morpholinothieno[3,2-d]pyrimidin-6-yl) oxazolidin-2-one(46 mg) was coupled to4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazole viaProcedure A. The product was purified by reverse phase HPLC to yield 8.6mg of 3-(2-(1H-indazol-4-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)oxazolidin-2-one. MS (Q1) 423 (M)⁺

73: 2-Chloro-6-iodo-4-morpholinothieno[3,2-d]pyrimidine (150 mg), 90 μLof 2-pyrrolidinone, potassium phosphate tribasic (250 mg), copper iodide(7 mg), 4 μL of N,N-dimethylethylenediamine in 2 mL of 1,4-dioxane washeated to 100° C. for 16 h. The reaction mixture was evaporated and theresidue was diluted with ethyl acetate (60 mL), washed with brine (30mL), dried over MgSO₄, filtered and evaporated. The crude product waspurified on reverse phase HPLC to give 53 mg of1-(2-chloro-4-morpholinothieno[3,2-d]pyrimidin-6-yl)pyrrolidin-2-one.

1-(2-Chloro-4-morpholinothieno[3,2-d]pyrimidin-6-yl)pyrrolidin-2-one (35mg) was coupled to4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazole viaProcedure A. The product was purified by reverse phase HPLC to yield19.5 mg of1-(1H-indazol-4-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)pyrrolidin-2-one.MS (Q1) 421 (M)⁺

81:2-Chloro-6-(4-methylsulfonyl-piperazin-1-yl-methyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidinewas reacted with 2-fluoropyridine-5-boronic acid in General Procedure Aon a 18.5 mmol scale to give 34.2 mg. of the desired product afterRP-HPLC purification. MS (Q1) 493.1 (M)+.80:2-Chloro-6-(4-methylsulfonyl-piperazin-1-yl-methyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidinewas reacted with 3-fluorophenyl boronic acid in General Procedure A on a18.5 mmol scale to give 20.8 mg. of the desired product after RP-HPLCpurification. MS (Q1) 492.3 (M)+.79:2-Chloro-6-(4-methylsulfonyl-piperazin-1-yl-methyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidinewas reacted with 3-(N-methylaminocarbonyl)phenyl boronic acid in GeneralProcedure A on a 18.5 mmol scale to give 7.4 mg. of the desired productafter RP-HPLC purification. MS (Q1) 531.3 (M)+.78:2-Chloro-6-(4-methylsulfonyl-piperazin-1-yl-methyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidinewas reacted with 2-fluoropyridine-3-boronic acid in General Procedure Aon a 18.5 mmol scale to give 23.5 mg. of the desired product afterRP-HPLC purification. MS (Q1) 493.4 (M)+.77:2-Chloro-6-(4-methylsulfonyl-piperazin-1-yl-methyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidinewas reacted with pyrimidine-5-boronic acid in General Procedure A on a18.5 mmol scale to give 8.1 mg. of the desired product after RP-HPLCpurification. MS (Q1) 476.3 (M)+.76:2-Chloro-6-(4-methylsulfonyl-piperazin-1-yl-methyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidinewas reacted with 3-methylsulfonylaminophenyl boronic acid in GeneralProcedure A on a 18.5 mmol scale to give 76 mg. of the desired productafter RP-HPLC purification. MS (Q1) 567.2 (M)+.2:2-Chloro-6-((4-(methylsulfonyl)piperazin-1-yl)methyl)-4-morpholinofuro[3,2-d]pyrimidine(40 mg, 1.0 eq) was dissolved in toluene/ethanol/water (4:2:1, 1.6 ml)and treated with4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazole (59 mg, 2.5eq), PdCl₂(PPh₃)₂ (6.8 mg, 0.10 eq) and sodium carbonate (36 mg, 3.5eq). The vial was sealed and heated with stirring in the microwave to150° C. for 15 minutes. The crude reaction mixture was concentrated andpurified by reverse phase HPLC to afford2-(1H-indazol-4-yl)-6-((4-(methylsulfonyl)piperazin-1-yl)methyl)-4-morpholinofuro[3,2-d]pyrimidine:MS (Q1) 498 (M)⁺.

EXAMPLE 3 Further Compounds of the Invention—Series B

The following compounds of the invention were prepared. The compoundnumbering corresponds to that used in Table 1A above.

5:2-Chloro-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[2,3-d]pyrimidinewas reacted with pyrimidine-5-boronic acid in General Procedure A.Purification on silica yielded the desired compound.

MS (Q1) 476.3 (M)+.

NMR (400 MHz CDCl3): 2.67 (4H, t (J 4.79), CH2), 2.81 (3H, s, CH3), 3.29(4H, m, CH2), 3.83 (2H, s, CH2), 3.89-4.01 (8H, m, CH2), 7.18 (1H, s,ar), 9.28 (1H, s, ar), 9.67 (2H, s, ar)

11:2-Chloro-6-(4-methylsulfonyl-piperazin-1-yl-methyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidinewas reacted with benzenesulfonamide-3-boronic acid pinacol ester inGeneral Procedure A. Purification on silica yielded the desiredcompound.

NMR: (CDCl3): 2.68-2.72 (4H, m), 2.82 (3H, s), 3.29-3.33 (4H, m), 3.90(2H, s), 3.90-3.94 (4H, m), 4.05-4.10 (4H, m), 4.81 (2H, br. s), 7.33(1H, s), 7.62-7.66 (1H, m), 8.00 (1H, d, J=8.0), 8.68 (1H, d, J=8.0),9.02 (1H, s)

(ESI+): MH+ 553.18

12:2-Chloro-6-(4-methylsulfonyl-piperazin-1-yl-methyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidinewas reacted with 4-(hydroxymethyl)phenyl-boronic acid in GeneralProcedure A. Purification on silica yielded the desired compound

NMR: (DMSO-d6): 2.58-2.62 (4H, m), 2.89 (3H, s), 3.13-3.18 (4H, m),3.78-3.81 (4H, m), 3.92 (2H, s), 3.95-4.00 (4H, m), 4.56 (2H, d, J=5.7),5.23 (1H, t, J=5.7), 7.40 (1H, s), 7.44 (2H, d, J=8.2), 8.38 (2H, d,J=8.2)

(ESI+): MH+ 504.18

13:2-Chloro-6-(4-methylsulfonyl-piperazin-1-yl-methyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidinewas reacted with 3-carbamoylphenyl boronic acid in General Procedure A.Purification on silica yielded the desired compound

(DMSO-d6): 2.58-2.62 (4H, m), 2.89 (3H, s), 3.13-3.18 (4H, m), 3.78-3.81(4H, m), 3.92 (2H, s), 3.95-4.00 (4H, m), 7.40 (1H, br), 7.42 (1H, s),7.53-7.58 (1H, m), 7.94 (1H, d, J=7.7), 8.09 (1H, br), 8.51 (1H, d,J=7.7), 8.38 (1H, s)

(ESI+): MH+ 517.24

84:2-Chloro-6-(4-methylsulfonyl-piperazin-1-yl-methyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidinewas reacted with pyridine-3-boronic acid in General Procedure A.Purification on silica yielded the desired compound.

NMR: (CDCl3): 2.68-2.72 (4H, m), 2.82 (3H, s), 3.29-3.33 (4H, m), 3.90(2H, s), 3.90-3.94 (4H, m), 4.05-4.10 (4H, m), 7.33 (1H, s), 7.34-7.38(1H, m), 8.68 (2H, d, J=5.6), 9.64 (1H, s)

(ESI+): MH+ 475.11

47:2-Chloro-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[2,3-d]pyrimidinewas reacted with 3-formylphenylboronic acid in General Procedure A toyield3-[6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[2,3-d]pyrimidin-2-yl]-benzaldehyde.Treatment of this aldehyde with sodium borohydride (2.5 equivalents) inethanol yielded the desired compound.

¹H NMR CDCL3

NMR: 1.67 (t, H, OH, J=6.08 Hz), 2.64-2.67 (m, 4H, 2×Ch2), 2.80 (s, 3H,Ch3), 3.27-3.29 (m, 4H, 2×CH2), 3.89-3.90 (m, 4H, 2×CH2), 3.96-3.98 (m,4H, 2×Ch2), 4.80 (d, 2H, CH2, J=6.06 Hz), 7.14 (s, H, ArH), 7.46 (m, 2H,2×ArH), 8.38 (m, H, ArH), 8.43 (s, H, ArH).

MH+=504.15

85:2-Chloro-6-(4-methylsulfonyl-piperazine-1-yl-methyl)-4-morpholin-4-yl-thieno[3,2-d}pyrimidinewas reacted withN-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenylmethanesulfonamidein General Procedure A. Purification on silica yielded the desiredcompound.

NMR: (CDCl3): 2.68-2.72 (4H, m), 2.82 (3H, s), 3.06 (3H, s), 3.29-3.33(4H, m), 3.90 (2H, s), 3.90-3.94 (4H, m), 4.05-4.10 (4H, m), 6.45 (1H,br. s), 7.27 (2H, d, J=8.8), 7.32 (1H, s), 8.44 (2H, d, J=8.8)

MS: (ESI+): MH+ 567.20

86:2-Chloro-6-(4-methylsulfonyl-piperazine-1-yl-methyl)-4-morpholin-4-yl-thieno[3,2-d}pyrimidinewas reacted with 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)anilinein General Procedure A. Purification on silica yielded4-[6-(4-Methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidin-2-yl]-aniline.This was then reacted with acetic anhydride in dichloromethane andtriethylamine to give the desired compound.

NMR: (CDCl3): 2.20 (3H, s), 2.68-2.72 (4H, m), 2.82 (3H, s), 3.29-3.33(4H, m), 3.90 (2H, s), 3.90-3.94 (4H, m), 4.05-4.10 (4H, m), 7.22 (1H,br. s), 7.32 (1H, s), 7.62 (2H, d, J=8.5), 8.42 (2H, d, J=8.5)

NMR: (ESI+): MH+ 531.19

89:2-Chloro-6-(4-methylsulfonyl-piperazine-1-yl-methyl)-4-morpholin-4-yl-thieno[3,2-d}pyrimidinewas reacted with3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinoline in GeneralProcedure A. Purification on silica yielded the desired compound.

NMR: (CDCl3): 2.68-2.72 (4H, m), 2.82 (3H, s), 3.29-3.33 (4H, m), 3.90(2H, s), 3.90-3.94 (4H, m), 4.05-4.10 (4H, m), 7.49 (1H, s), 7.58 (1H,t, J=7.0), 7.75 (1H, t, J=7.0), 7.97 (1H, d, J=7.6), 8.29 (1H, d,J=8.4), 9.17 (1H, d, J=1.9), 9.96 (1H, d, J=2.1)

MS: (ESI+): MH+ 525.24

90:2-Chloro-6-(4-methylsulfonyl-piperazine-1-yl-methyl)-4-morpholin-4-yl-thieno[3,2-d}pyrimidinewas reacted with4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoquinoline in GeneralProcedure A. Purification on silica yielded the desired compound.

NMR: (CDCl3): 2.68-2.72 (4H, m), 2.82 (3H, s), 3.29-3.33 (4H, m),3.90-3.94 (4H, m), 3.96 (2H, s), 4.05-4.10 (4H, m), 7.42 (1H, s), 7.64(1H, t, J=7.0), 7.75 (1H, t, J=7.0), 8.06 (1H, d, J=8.0), 8.83 (1H, d,J=8.6), 9.13 (1H, s), 9.32 (1H, s)

MS: (ESI+): MH+ 525.23

87:2-chloro-6-(4-methanesulfonyl-piperidin-1-ylmethyl)-4-morpholin-4-yl-thieno[2,3-d]pyrimidinewas reacted with pyridine-3-boronic acid in General Procedure A.Purification on silica yielded the desired compound.

NMR: (CDCl₃): 2.65-2.67 (m, 4H, 2×CH2), 2.87 (s, 3H, CH3), 3.27-3.30 (m,4H, 2×CH2), 3.82 (s, 2H, CH2), 3.88-3.90 (m, 4H, 2×CH2), 3.97-3.99 (m,4H, 2×CH2), 7.16 (s, H, ArH), 7.36-7.39 (m, H, ArH), 8.66-8.69 (m, 2H,2×ArH), 9.62 (d, H, ArH, J=1.28 Hz).

MS: (ESI+): MH+=475.18

91:2-chloro-6-(4-methanesulfonyl-piperidin-1-ylmethyl)-4-morpholin-4-yl-thieno[2,3-d]pyrimidinewas reacted 3-acetylphenylboronic acid in General Procedure A.Purification on silica yielded the desired compound.

NMR: (CDCl₃): 2.65-2.67 (m, 4H, 2×CH2), 2.70 (s, 3H, CH3), 2.80 (s, 3H,CH3), 3.27-3.30 (m, 4H, 2×CH2), 3.82 (s, 2H, CH2), 3.89-3.92 (m, 4H,2×CH2), 3.98-4.00 (m, 4H, 2×CH2), 7.16 (s, H, ArH), 7.55 (t, H, ArH,J=7.75 Hz), 8.03 (d, H, ArH, J=7.73 Hz), 8.64 (d, H, ArH, J=7.78 Hz),9.01 (s, H, ArH).

MS: (ESI+): MH+=516.19

93:1-{3-[6-(4-Methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[2,3-d]pyrimidin-2-yl]-phenyl}-ethanonewas treated with sodium borohydride (2.8 eq.) in ethanol. Purificationon silica yielded the desired compound.

NMR: (CDCl₃): 1.57 (d, 3H, CH3), 1.85 (d, H, OH), 2.64-2.67 (m, 4H,2×CH2), 2.80 (s, 3H, CH3), 3.27-3.28 (m, 4H, 2×CH2), 3.81 (s, 2H, CH2),3.88-3.91 (m, 4H, 2×CH2) 3.96-3.98 (m, 4H, 2×CH2), 5.00-5.03 (m, H, CH),7.14 (s, H, ArH), 7.42-7.49 (m, 2H, 2×ArH), 8.35 (d, H, ArH, J=7.27 Hz),8.43 (s, H, ArH).

MS: (ESI+): MH+=518.27

94:2-chloro-6-(4-methanesulfonyl-piperidin-1-ylmethyl)-4-morpholin-4-yl-thieno[2,3-d]pyrimidinewas reacted with4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoquinoline in GeneralProcedure A. Purification on silica yielded the desired compound.

NMR: (CDCl₃): 2.67-2.69 (m, 4H, 2×CH2), 2.80 (s, 3H, CH3), 3.29-3.31 (m,4H, 2×CH2), 3.85 (s, 2H, CH2), 3.88-3.90 (m, 4H, 2×CH2), 3.99-4.01 (m,4H, 2×CH2), 7.22 (s, H, ArH), 7.63 (t, ArH, J=7.53 Hz), 7.75 (t, H, ArH,J=8.31 Hz), 8.03 (d, H, ArH, J=8.1 Hz), 8.88 (d, H, ArH, J=8.61 Hz),9.16 (s, H, ArH), 9.30 (s, H, ArH).

MS: (ESI+): MH+=525.23

95:2-chloro-6-(4-methanesulfonyl-piperidin-1-ylmethyl)-4-morpholin-4-yl-thieno[2,3-d]pyrimidinewas reacted with3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinoline in GeneralProcedure A. Purification on silica yielded the desired compound.

NMR: (CDCl₃): 2.66-2.69 (m, 4H, 2×CH2), 2.80 (s, 3H, CH3), 3.28-3.31 (m,4H, 2×CH2), 3.83 (s, 2H, CH2), 3.91-3.91 (m, 4H, 2×CH2), 4.01-4.04 (m,4H, 2×CH2), 7.18 (s, H, ArH), 7.57 (t, H, ArH, J=7.27 Hz), 7.74 (t, H,ArH, J=7.14 Hz), 7.96 (d, H, ArH, J=8.47 Hz), 9.15 (d, H, ArH, J=2.0Hz), 9.94 (d, H, ArH, J=2.0 Hz).

MS: (ESI+): MH+=525.28

37: To a solution of 4-methoxybenzyl alcohol (1.73 g) in DMSO (10 mL) atroom temperature was added sodium hydride (500 mg). The reaction mixturewas stirred for 75 min and then a solution of 3,5-dibromopyridine (3.0g) in DMSO (15 mL) was added. The reaction mixture was then heated at90° C. for 2.5 h and then allowed to cool to room temperature, quenchedwith water (60 mL) and extracted into diethyl ether (3×60 mL). Thecombined organics were washed with brine (100 mL), dried (MgSO₄),reduced in vacuo and purified by column chromatography to give3-bromo-5-(4-methoxy-benzyloxy)-pyridine as a white solid (1.76 g).

To a solution of 3-bromo-5-(4-methoxy-benzyloxy)-pyridine (300 mg) inTHF (10 mL) was added triisopropyl borate (0.28 mL) and the mixturecooled to −78° C. Then n-butyllithium (0.49 mL of a 2.5 M solution inhexanes) was added maintaining the temperature below −65° C. Thereaction mixture was then allowed to warm to −20° C. over 1 h and thenquenched with 2 M aqueous hydrochloric acid (2 mL). The mixture wasallowed to warm to room temperature over 1 h and then diluted with water(25 mL), the pH was adjusted to 7 and then extracted into ethyl acetate(3×25 mL). The combined organics were washed with brine (20 mL), dried(MgSO₄) and reduced in vacuo. A mixture of the crude product and pinacol(236 mg) in toluene (15 mL) was then heated at reflux for 4 h. Themixture was then reduced in vacuo, dissolved in ethyl acetate (30 mL)and washed with water (2×30 mL) and brine (30 mL). The combined organicswere dried (MgSO₄) and reduced in vacuo to give3-(4-methoxy-benzyloxy)-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-pyridineas an off-white solid (162 mg).

2-Chloro-6-(4-methyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidinewas reacted with3-(4-methoxy-benzyloxy)-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-pyridinein General Procedure A. Purification on silica yielded2-[5-(4-methoxy-benzyloxy)-pyridin-3-yl]-6-(4-methyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine.This was then reacted with trifluoroacetic acid in dichloromethane togive the desired compound.

NMR: (CDCl3): 2.31 (3H, s, Me), 2.46-2.68 (8H, m, CH2), 3.73 (2H, s,CH2), 3.74-3.82 (4H, m, CH2), 3.94-3.99 (4H, m, CH2), 7.20 (1H, s, Ar),8.12 (1H, s, Ar), 8.22 (1H, s, Ar) and 9.07 (1H, s, Ar).

MS: (ESI+): MH+ 427.15

39:2-Chloro-6-(4-methyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidinewas reacted with4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-pyrazole-1-carboxylicacid tert-butyl ester in General Procedure A. The BOC group was cleavedunder the conditions of the Suzuki reaction. Purification on silicayielded the desired compound.

NMR: (DMSO): 13.05 (bs, 1H); 8.31 (bs, 2H); 7.26 (s, 1H); 3.92 (m, 4H),3.85 (s, 2H); 3.77 (m, 4H); 2.41 (m, 8H); 2.15 (s, 3H).

MS: (ESI+): MH+ 400.21

40:2-Chloro-6-(4-methyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidinewas reacted with 3-formyl phenyl boronic acid in General Procedure A.Purification on silica yielded3-[6-(4-methyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidin-2-yl]-benzaldehyde.This was then treated with methylmagnesium bromide in THF to give thedesired compound.

NMR: (CDCl3): 1.49 (d, J=6.5, 3H), 2.10 (d, J=1.7, 1H), 2.25 (s, 3H),2.46 (s, br, 4H), 2.54 (s, br, 4H), 3.74 (s, 2H), 3.82 (t, J=4.8, 4H),3.98 (t, J=4.8, 4H), 4.94 (q, J=6.4, 1H), 7.23 (s, 1H), 7.35-7.42 (m,2H), 8.27 (m, 1H), 8.35 (s, 1H).

MS: (ESI+): MH+ 454.27

41:2-Chloro-6-(4-methyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidinewas reacted with 3-formyl phenyl boronic acid in General Procedure A.Purification on silica yielded3-[6-(4-methyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidin-2-yl]-benzaldehyde.This was then treated with sodium borohydride in methanol to give thedesired compound.

NMR: (CDCl3): 2.25 (s, 3H), 2.47 (s, 4H), 2.54 (s, 4H), 3.75 (s, 2H),3.80 (t, J=4.8, 4H), 3.98 (t, J=4.8, 4H), 4.71 (s, 2H), 7.23 (m, 1H),7.38 (m, 2H), 8.28 (m, 1H), 8.34 (s, 1H).

MS: (ESI+): MH+ 440.23

35: A solution of 4-methoxybenzylalcohol (10 g) in ether (300 ml) wasshaken with hydrobromic acid, 48%, (150 ml). The organic phase waswashed with saturated sodium bromide, dried (K₂CO₃) and the solventsremoved in vacuo to give 4-methoxybenzylbromide (13.17 g).

To a solution of 3-bromo-4-fluorophenol (0.59 g) in tetrahydrofuran (7ml) under nitrogen was added sodium hydride, 60% dispersion in mineraloil (0.13 g). The solution was stirred at room temperature. After 30minutes a solution of 4-methoxybenzylbromide (0.62 g) was added intetrahydrofuran (5 ml). The reaction mixture was stirred at 50° C.overnight. The reaction mixture was partitioned between dichloromethaneand brine, then dried (MgSO₄), the solvents were removed in vacuo togive a crude residue. This crude residue was purified using flashchromatography to give 2-bromo-1fluoro-4-(4-methoxy-benzyloxy)-benzene(0.71 g). To a solution of2-bromo-1fluoro-4-(4-methoxy-benzyloxy)-benzene (0.33 g) intetrahydrofuran (10 ml) under nitrogen was added triisopropylborate(0.29 ml). The mixture was cooled to −78° C. and 2.5M n-butyllithiumsolution in hexanes was added. The reaction mixture was stirred at −40°C. for 1 hour, then warmed to 20° C. and quenched with 2M hydrochloricacid (aq) (2 ml). The reaction mixture was warmed to room temperatureand stirred for 1 hour. The reaction mixture was adjusted to pH 7 usingsaturated sodium bicarbonate solution, then partitioned between ethylacetate and water, dried (MgSO₄) and the solvents removed in vacuo toyield a crude residue (0.31 g). A mixture of this crude residue andpinacol (0.25 g) in toluene (10 ml) were stirred under reflux overnightin a Dean-Stark apparatus. The solvents were removed in vacuo, theresidue was then partitioned between ethyl acetate and water, thecombined organics were washed with water then brine and dried (MgSO₄),the solvents were removed in vacuo to yield2-[2-fluoro-5-(4-methoxy-benzyloxy-phenyl]-4,4,5,5-tetramethyl-[1,3,2]dioxyborolane(0.28 g)

2-Chloro-6-(4-methyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidinewas reacted with2-[2-fluoro-5-(4-methoxy-benzyloxy-phenyl]-4,4,5,5-tetramethyl-[1,3,2]dioxyborolanein general procedure A. Purification on silica yielded2-[2-fluoro-5-(4-methoxy-benzyloxy)-phenyl]-6-(4-methyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine.This was then reacted with trifluoroacetic acid in dichloromethane toyield the desired compound.

NMR: 400 MHz; CDCl3: 2.34 (3H, s); 2.58 (8H, m); 3.84 (2H, s); 3.90 (4H,t, J=4.8 Hz); 4.04 (4H, t, J=4.8 Hz); 6.84 (1H, m); 7.02 (1H, t, J=9.6Hz); 7.30 (1H, s); 7.57 (1H, m).

MS: (ESI+): MH+ 444

36: A solution of 4-methoxybenzylalcohol (10 g) in ether (300 ml) wasshaken with hydrobromic acid, 48%, (150 ml). The organic phase waswashed with saturated sodium bromide, dried (K₂CO₃) and the solventsremoved in vacuo to give 4-methoxybenzylbromide (113.17 g).

To a solution of 5-bromo-2,3-difluorophenol (1.0 g) in tetrahydrofuran(10 ml) under nitrogen was added sodium hydride, 60% dispersion inmineral oil (0.20 g). The solution was stirred at room temperature.After 30 minutes a solution of 4-methoxybenzylbromide (0.96 g) was addedin tetrahydrofuran (7 ml). The reaction mixture was stirred at 50° C.overnight. The reaction mixture was partitioned between dichloromethaneand brine, then dried (MgSO₄), the solvents were removed in vacuo togive a crude residue. This crude residue was purified using flashchromatography to give5-bromo-1,2-difluoro-3-(4-methoxy-benzyloxy)-benzene (0.76 g).

To a solution of 5-bromo-1,2-difluoro-3-(4-methoxy-benzyloxy)-benzene(0.35 g) in tetrahydrofuran (10 ml) under nitrogen was addedtriisopropylborate (0.29 ml). The mixture was cooled to −78° C. and 2.5Mn-butyllithium solution in hexanes was added. The reaction mixture wasstirred at −40° C. for 1 hour, then warmed to 20° C. and quenched with2M hydrochloric acid (aq) (2 ml). The reaction mixture was warmed toroom temperature and stirred for 1 hour. The reaction mixture wasadjusted to pH 7 using saturated sodium bicarbonate solution, thenpartitioned between ethyl acetate and water, dried (MgSO₄) and thesolvents removed in vacuo to yield a crude residue (0.31 g). A mixtureof this crude residue and pinacol (0.25 g) in toluene (10 ml) werestirred under reflux overnight in a Dean-Stark apparatus. The solventswere removed in vacuo, the residue was then partitioned between ethylacetate and water, the combined organics were washed with water thenbrine and dried (MgSO₄), the solvents were removed in vacuo to yield2-[3,4-difluoro-5-(4-methoxy-benzyloxy)-phenyl]-4,4,5,5-tetramethyl-[1,3,2]dioxaborolane(0.28 g)

2-Chloro-6-(4-methyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidinewas reacted with yield2-[3,4-difluoro-5-(4-methoxy-benzyloxy)-phenyl]-4,4,5,5-tetramethyl-[1,3,2]dioxaborolanein general procedure A. Purification on silica yielded2-[3,4-difluoro-5-(4-methoxy-benzyloxy)-phenyl]-6-(4-methyl-piperazin-1-ylmethyl)-4-morpholin-yl-thieno[3,2-d]pyrimidine.This was then reacted with trifluoroacetic acid in dichloromethane toyield the desired compound.

NMR: 400 MHz; CDCl3: 2.36 (3H, s); 2.67 (8H, m); 3.84 (2H, s); 3.90 (4H,t, J=4.7 Hz); 4.00 (4H, t, J=4.7 Hz); 7.24 (1H, s); 7.80 (1H, m); 7.90(1H, d, J=7.6 Hz).

MS: (ESI+): MH+ 462

33: A solution of 4-methoxybenzylalcohol (10 g) in ether (300 ml) wasshaken with hydrobromic acid, 48%, (150 ml). The organic phase waswashed with saturated sodium bromide, dried (K₂CO₃) and the solventsremoved in vacuo to give 4-methoxybenzylbromide (13.17 g).

To a solution of 5-bromo-2-chlorophenol (1.0 g) in tetrahydrofuran (10ml) under nitrogen was added sodium hydride, 60% dispersion in mineraloil (0.20 g). The solution was stirred at room temperature. After 30minutes a solution of 4-methoxybenzylbromide (0.97 g) was added intetrahydrofuran (7 ml). The reaction mixture was stirred at 50° C.overnight. The reaction mixture was partitioned between dichloromethaneand brine, then dried (MgSO₄), the solvents were removed in vacuo togive a crude residue. This crude residue was purified using flashchromatography to give 4-bromo-1-chloro-2-(4-methoxy-benzyloxy)-benzene(0.96 g).

To a solution of 4-bromo-1-chloro-2-(4-methoxy-benzyloxy)-benzene (0.35g) in tetrahydrofuran (10 ml) under nitrogen was addedtriisopropylborate (0.29 ml). The mixture was cooled to −78° C. and 2.5Mn-butyllithium solution in hexanes was added. The reaction mixture wasstirred at −40° C. for 1 hour, then warmed to 20° C. and quenched with2M hydrochloric acid (aq) (2 ml). The reaction mixture was warmed toroom temperature and stirred for 1 hour. The reaction mixture wasadjusted to pH 7 using saturated sodium bicarbonate solution, thenpartitioned between ethyl acetate and water, dried (MgSO₄) and thesolvents removed in vacuo to yield a crude residue (0.31 g). A mixtureof this crude residue and pinacol (0.25 g) in toluene (10 ml) werestirred under reflux overnight in a Dean-Stark apparatus. The solventswere removed in vacuo, the residue was then partitioned between ethylacetate and water, the combined organics were washed with water thenbrine and dried (MgSO₄), the solvents were removed in vacuo to yield2-[4-chloro-3-(4-methoxy-benzyloxy)-phenyl]-4,4,5,5-tetramethyl-[1,3,2]dioxaborolane(0.28 g).

2-Chloro-6-(4-methyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidinewas reacted with2-[4-chloro-3-(4-methoxy-benzyloxy)-phenyl]-4,4,5,5-tetramethyl-[1,3,2]dioxaborolanein general procedure A. Purification on silica yielded2-[4-chloro-3-(4-methoxy-benzyloxy)-phenyl]-6-(4-methyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine.This was then reacted with trifluoroacetic acid in dichloromethane toyield the desired compound.

NMR: 400 MHz; CDCl3: 2.25 (3H, s); 2.50 (8H, m); 3.77 (2H, s); 3.82 (4H,t, J=4.9 Hz); 3.98 (4H, t, J=5.0 Hz); 7.23 (1H, s); 7.32 (1H, d, J=8.4Hz); 7.93 (1H, d, J=8.4 Hz); 8.04 (1H, s).

MS: (ESI+): MH+ 460

16: To 2-methylbenzimidazole (75 mg) in N,N-dimethylformamide (3 mL) wasadded sodium hydride (60% dispersion, 23 mg). After stirring for 30mins,2-chloro-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[2,3-d]pyrimidine(242 mg) was added and the reaction mixture was heated to 90° C. After16 hours the reaction mixture was cooled, diluted with ethyl acetate andwashed with brine. The organic fraction was concentrated in vacuo andpurified using flash chromatography to yield the title compound [M+H]+528.21

(400 MHz CDCl3): 2.68 (4H, t (J 4.80), CH2), 2.81 (3H, s, CH3), 2.94(3H, s, CH3), 3.30 (4H, t (J 4.61), CH2), 3.83 (2H, s, CH2), 3.88-4.00(8H, m, CH2), 7.19 (1H, s, ar), 7.31 (1H, m, ar), 7.70-7.73 (1H, m, ar),8.10-8.12 (1H, m, ar)

88:6-(4-Methanesulfonyl-piperazin-1-ylmethyl)-2-(2-methyl-imidazol-1-yl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidinewas made in a similar manner to the compound above using2-methylimidazole and2-chloro-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine.

(CDCl3): 2.68-2.72 (4H, m), 2.82 (3H, s), 2.85 (3H, s), 3.29-3.33 (4H,m), 3.90 (2H, s), 3.90-3.94 (4H, m), 4.05-4.10 (4H, m), 6.93 (1H, d,J=1.6), 7.25 (1H, s), 7.82 (1H, d, J=1.6)

(ESI+): MH+ 478.17

101:6-(4-Methanesulfonyl-piperazin-1-ylmethyl)-2-(2-methyl-benzoimidazol-1-yl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidinewas made in a similar manner to the compound above using2-methylbenzimidazole and2-chloro-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine.

(ESI+): MH+

(CDCl3): 2.68-2.72 (4H, m), 2.82 (3H, s), 2.92 (3H, s), 3.29-3.33 (4H,m), 3.90 (2H, s), 3.90-3.94 (4H, m), 4.05-4.10 (4H, m), 7.27-7.30 (2H,m), 7.32 (1H, s), 7.71-7.75 (1H, m), 8.09-8.12 (1H, m)

EXAMPLE 4 Compounds of the Invention—Series C

The following compounds of the invention were prepared. The compoundnumbering corresponds to that used in Table IA above.

3: To 1-Boc-4-piperidone (10 g) in ethanol stirring at 0° C. was addedsodium borohydride (9.45 g) portionwise. The reaction mixture wasstirred at 0° C. for 1 hour. The reaction mixture was then quenched withwater and extracted with chloroform. The combined organic were washedwith brine and dried (MgSO₄). The solvent was removed in vacuo to yield9.2 g of 4-hydroxy-piperidine-1-carboxylic acid tert-butyl ester.

To 4-hydroxy-piperidine-1-carboxylic acid tert-butyl ester (9.2 g) indichloromethane (170 ml), stirring at 0° C. was added methane sulphonylchloride (5.33 ml) and triethylamine (10.24 ml). The reaction mixturewas slowly warmed to room temperature and stirred overnight. Thereaction mixture was partitioned between chloroform and water. Thecombined organics were washed with brine and dried (MgSO₄). The solventwas removed in vacuo to yield 14 g of4-methanesulfonyl-piperidine-carboxylic acid tert-butyl ester. A mixtureof 4-methanesulfonyl-piperidine-carboxylic acid tert-butyl ester (2.82g) thioacetate (2.31 g) and DMF (40 ml) was stirred at 60° C. After 4hours the reaction mixture was cooled and partitioned between ethylacetate and brine. The combined organics were dried (MgSO₄) and thesolvents removed in vacuo. The resulting crude mixture was purified byflash chromatography to yield 4-acetylsulfanyl-piperidine-1-carboxylicacid tert-butyl ester (1.8 g). 4-acetylsulfanyl-piperidine-1-carboxylicacid tert-butyl ester (400 mg) was stirred in acetic acid (3 ml) andwater (3 ml) at 0° C. Chlorine gas was bubbled through the reactionmixture. The reaction mixture was stirred for 1.5 hours. The reactionmixture was then diluted with water to yield a precipitate which wascollected by filtration to yield4-chlorosulfonyl-piperidine-1-carboxylic acid tert-butyl ester (295 mg).

To a solution of 4-chlorosulfonyl-piperidine-1-carboxylic acidtert-butyl ester (295 mg) in dichloromethane stirring at 0° C. was addedtriethylamine (96 μL) and morpholine (55 μL). The reaction mixture wasstirred overnight then quenched with water and extracted intodichloromethane. The combined organics were washed with brine and dried(MgSO4). The solvent was removed in vacuo to yield4-(morpholine-4-sulfonyl)-piperidine-1-carboxylic acid tert-butyl ester(120 mg).

To a solution of 4-(morpholine-4-sulfonyl)-piperidine-1-carboxylic acidtert-butyl ester in dichloromethane (10 ml) and methanol (10 ml) wasadded 2M hydrogen chloride in ether (2 μL). The reaction mixture wasstirred overnight. The solvents were removed in vacuo to yield4-(piperidine-4-sulfonyl)-morpholine hydrochloride salt.

Reaction with2-chloro-4-morpholin-4-yl-thieno[3,2-d]pyrimidine-6-carbaldehyde usingprocedure C yielded1-(2-chloro-4-morpholin-4-yl-thieno[3,2-d]pyrimidin-6-ylmethyl)-piperidine-4-sulfonicacid dimethylamide. This compound was subjected to procedure A to yieldthe desired final compound which was purified using flashchromatography.

(M+H)+ 542.28

(400 MHz CDCl3): 1.95-2.04 (4H, m, CH2), 2.14 (2H, td (J 11.36, 2.99),CH2), 2.94 (6H, s, CH3), 2.99 (1H, m, CH), 3.13 (2H, d (J 11.59), CH2),3.85 (2H, s, CH2), 3.92-3.95 (4H, m, CH2), 4.08-4.15 (4H, m, CH2), 7.36(1H, s, ar), 7.50 (1H, t (J 7.73), ar), 7.58 (1H, d (J 8.34), ar), 8.27(1H, d (J 7.52), 9.02 (1H, s, ar), 10.25 (1H, b, NH)

The following compounds were prepared in an analogous manner using theappropriate amine.

27:1-[2-(1H-Indazol-4-yl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidin-6-ylmethyl]-piperidine-4-sulfonicacid dimethylamide was prepared as above using piperidine-4-sulfonicacid dimethyl amide hydrochloride salt.

(M+H)+ 542.28

(400 MHz CDCl3): 1.95-2.04 (4H, m, CH2), 2.14 (2H, td (J 11.36, 2.99),CH2), 2.94 (6H, s, CH3), 2.99 (1H, m, CH), 3.13 (2H, d (J 11.59), CH2),3.85 (2H, s, CH2), 3.92-3.95 (4H, m, CH2), 4.08-4.15 (4H, m, CH2), 7.36(1H, s, ar), 7.50 (1H, t (J 7.73), ar), 7.58 (1H, d (J 8.34), ar), 8.27(1H, d (J 7.52), 9.02 (1H, s, ar), 10.25 (1H, b, NH)

22:1-[2-(1H-Indazol-4-yl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidin-6-ylmethyl]-piperidine-4-sulfonicacid methylamide was prepared as above using piperidine-4-sulfonic acidmethylamine hydrochloride salt.

MH+=528.24

400 MHz ¹H NMR CDCl3

1.60-1.70 (m, 2H, CH2), 1.90-2.0 (m, 2H, CH2), 2.1-2.2 (m, 2H, CH2),2.58 (d, 3H, CH3, J=4.76 Hz), 2.95-3.05 (m, 2H, CH2), 3.80-3.85 (m, 4H,2×CH2), 3.88 (s, 2H, CH2), 3.95-4.05 (m, 4H, 2×CH2), 6.90 (m, H, ArH),7.45 (m, H, ArH), 7.64 (d, H, ArH, J=8.21 Hz), 8.2 (d, H, ArH, J=7.2Hz), 8.86 (s, H, ArH), 13.15 (sbr, H, NH).

24:2-(1H-Indazol-4-yl)-6-[4-(4-methyl-piperazine-1-sulfonyl)-piperidin-1-ylmethyl]-4-morpholin-4-yl-thieno[3,2-d]pyrimidinewas prepared as above using1-methyl-4-(piperidine-4-sulphonyl)-piperazine hydrochloride salt.

400 MHz ¹H NMR CDCl3

1.90-2.0 (m, 2H, CH2), 2.05-2.15 (m, 2H, CH2), 2.32 (s, 3H, CH3),2.45-2.55 (m, 4H, 2×CH2), 2.90-3.09 (m, H, CH), 3.05-3.15 (m, 2H, CH2),3.38-3.43 (m, 4H, 2×CH2), 7.35 (s, H, ArH), 7.49 (t, H, ArH, J=7.6 Hz),7.58 (d, H, ArH, J=8.33 Hz), 8.27 (d, H, ArH, J=7.53 Hz), 9.00 (s, H,ArH), 10.15 (sbr, H, NH).

MH+=597.25

18:1-[2-(1H-Indazol-4-yl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidin-6-ylmethyl]-piperidine-4-sulfonicacid (2-methoxy-ethyl)-methyl-amide was prepared as above usingpiperidine-4-sulfonic acid (2-methoxy-ethyl)-methyl-amide hydrochloridesalt.

(CDCl3): 1.98-2.10 (4H, m), 2.11-2.19 (2H, m), 2.99 (3H, s), 3.00-3.10(1H, m), 3.12-3.18 (2H, m), 3.37 (3H, s), 3.41-3.45 (2H, m), 3.53-3.58(2H, m), 3.84 (2H, s), 3.90-3.94 (4H, m), 4.10-4.14 (4H, m), 7.38 (1H,s), 7.48-7.52 (1H, m), 7.58 (1H, d, J=8.3), 8.38 (1H, d, J=7.6), 9.20(1H, s), 10.10 (1H, br)

(ESI+): MH+ 586

19:1-[2-(1H-Indazol-4-yl)-4-morpholin-4-yl-thieno[2,3-d]pyrimidin-6-ylmethyl]-piperidine-4-sulfonicacid dimethylamide was prepared as above using piperidine-4-sulfonicacid dimethyl amide hydrochloride salt.

NMR: 1.9-2.0 (m, 2H, CH2), 2.0-2.2 (m, 4h, 2×CH2), 2.94 (s, 6H, 2×CH3),2.95-3.0 (m, H, CH), 3.05-3.10 (m, 2H, CH2), 3.79 (s, 2H, CH2),3.92-3.94 (m, 4H, 2×CH2), 7.15 (s, H, ArH), 7.50 (t, H, ArH, J=7.79 Hz),7.59 (d, H, ArH, J=8.23 Hz), 8.32 (d, H, ArH, J=7.34 Hz), 9.02 (s, H,ArH), 10.1 (sbr, H, NH).

MH+=542.19

20:1-[2-(1H-Indazol-4-yl)-7-methyl-4-morpholin-4-yl-thieno[3,2-d]pyrimidin-6-ylmethyl]-piperidine-4-sulfonicacid dimethylamide was prepared as above using piperidine-4-sulfonicacid dimethyl amide hydrochloride salt.

NMR: 1.98-2.08 (4H, m), 2.12-2.18 (2H, m), 2.54 (3H, s), 2.94 (6H, s),2.98-3.06 (1H, m), 3.12-3.18 (2H, m), 3.84 (2H, s), 3.90-3.94 (4H, m),4.10-4.14 (4H, m), 7.48-7.52 (1H, m), 7.58 (1H, d, J=8.3), 8.38 (1H, d,J=7.6), 9.20 (1H, s), 10.10 (1H, br)

(ESI+): MH+ 556

21: A mixture of 4-methanesulfonyloxy-piperidine-1-carboxylic acidtert-butyl ester (1.015 g) and sodium thiomethoxide (635 mg) was heatedto 80° C. in dimethylformamide (10 mL). After 4 h, the reaction mixturewas diluted with water, extracted with ethyl acetate, dried (MgSO₄),filtered and concentrated in vacuo and then purified by flashchromatography to give 4-methylsulfanyl-piperidine-1-carboxylic acidtert-butyl ester (600 mg). To a solution of4-methylsulfanyl-piperidine-1-carboxylic acid tert-butyl ester (600 mg)in chloroform (15 mL) was added mCPBA (1.46 g). After stirring for 2days, the reaction mixture was diluted with dichloromethane, washed withsodium bicarbonate solution, dried (MgSO₄) and the solvent removed invacuo to yield 4-methanesulfonyl-piperidine-1-carboxylic acid tert-butylester (505 mg) as a white solid.

Treatment of this compound with HCl in dichloromethane/methanol yielded4-methanesulfonyl-piperidine, which was isolated as the hydrochloridesalt.

Reaction with2-chloro-4-morpholin-4-yl-thieno[2,3-d]pyrimidine-6-carbaldehyde usingprocedure C yielded2-chloro-6-(4-methanesulfonyl-piperidin-1-ylmethyl)-4-morpholin-4-yl-thieno[2,3-d]pyrimidine.This compound was subjected to procedure A to yield the desired finalcompound which was purified using flash chromatography.

1H NMR CDCL3

1.9-2.0 (m, 2H, Ch2), 2.1-2.2 (m, 4H, 2×CH2), 2.84 (m, 4H, 2×CH2),3.15-3.20 (m, 2H, CH2), 3.90-3.95 (m, 4H, 2×CH2), 4.0-4.05 (m, 4H,2×CH2), 7.15 (s, H, ArH), 7.50 (t, H, ArH, J=7.78), 7.59 (d, H, ArH,J=8.32 Hz), 8.32 (d, H, ArH, J=7.21 Hz), 9.02 (s, H, ArH), 10.1 (sbr, H,NH).

MH+=513.19

The following compound was prepared in an analogous manner:

23: (ESI+): MH+ 527

(CDCl3): 1.94-2.03 (2H, m), 2.12-2.24 (4H, m), 2.55 (3H, s), 2.88 (3H,s), 2.88-2.95 (1H, m), 3.21-3.25 (2H, m), 3.84 (2H, s), 3.90-3.94 (4H,m), 4.10-4.14 (4H, m), 7.48-7.52 (1H, m), 7.58 (1H, d, J=8.3), 8.38 (1H,d, J=7.6), 9.20 (1H, s), 10.10 (1H, br)

45: Reaction between2-chloro-4-morpholin-4-yl-thieno[3,2-d]pyrimidine-6-carbaldehyde and1-methyl-4-(methylamino)piperidine using procedure C yielded(2-chloro-4-morpholin-4-yl-thieno[3,2-d]pyrimidin-6-ylmethyl)-methyl-(1-methyl-piperidin-4-yl)-amine.This compound was subjected to procedure A to yield the desired finalcompound which was purified using flash chromatography.

1H NMR 400 MHz DMSO

13.2 (bs, 1H); 8.87 (s, 1H); 8.21 (d, 1H); 7.65 (d, 1H, J=7.3 Hz); 7.46(t, 2H, J=7.7 Hz); 3.90 (m, CH2×4); 3.93 (s, 2H); 2.79 (d, 2H, J=11.2);2.40 (m, 1H); 2.25 (s, 3H); 2.12 (s, 3H); 1.68 (m, CH2×3).

M/S (m+1)=478.3; LC>95% purity

9: To a solution of piperazine (1 g) and triethylamine (1.78 mL) indichloromethane (20 mL) at 0° C. was added dropwisetrifluoromethanesulfonyl chloride (1.24 mL). The reaction mixture wasstirred at room temperature for 16 h and then quenched with water (20mL) and extracted into dichloromethane (2×40 mL). The combined organiclayers were washed with saturated aqueous brine solution (2×40 mL),dried (MgSO₄) and concentrated to afford1-trifluoromethanesulfonyl-piperazine as a pale yellow solid (1.92 g,76%).

Reaction between2-chloro-4-morpholin-4-yl-thieno[3,2-d]pyrimidine-6-carbaldehyde and1-trifluoromethanesulfonyl-piperazine using procedure C yielded2-chloro-4-morpholin-4-yl-6-(4-trifluoromethanesulfonyl-piperazin-1-ylmethyl)-thieno[3,2-d]pyrimidine.This compound was subjected to procedure A to yield the desired finalcompound which was purified using flash chromatography

[M+H]+ 568.23

NMR: (400 MHz, CDCl3): 2.67-2.72 (4H, m, CH2), 3.53-3.64 (4H, m, CH2),3.90-3.98 (6H, m, CH2), 4.08-4.14 (4H, m, CH2), 7.40 (1H, s, Ar), 7.48(1H, t, J 8.23, Ar), 7.53 (1H, d, J 8.28, Ar), 8.27 (1H, d, J 7.33, Ar),9.02 (1H, s, Ar) and 10.11 (1H, s, NH).

4: To a solution of (S)-methylpiperazine (400 mg) in dichloromethane (20mL) at 0° C. was added di-tert-butyl dicarbonate (871 mg). The reactionwas stirred at room temperature for 4 h and then quenched with water (20mL) and extracted into dichloromethane (2×40 mL). The combined organicswere washed with saturated aqueous brine solution (40 mL), dried (MgSO₄)and concentrated to give (S)-3-methyl-piperazine-1-carboxylic acidtert-butyl ester as a white solid (669 mg, 84%).

To a solution of (S)-3-methyl-piperazine-1-carboxylic acid (669 mg) andtriethylamine (0.56 mL) in dichloromethane (10 mL) at 0° C. was addeddropwise methanesulfonyl chloride (0.28 mL). The reaction mixture wasstirred at room temperature for 16 h and then quenched with water (10mL) and extracted into dichloromethane (2×20 mL). The combined organiclayers were washed with saturated aqueous brine solution (2×20 mL),dried (MgSO₄) and concentrated to give(S)-4-methanesulfonyl-3-methyl-piperazine-1-carboxylic acid tert-butylester as a pale yellow solid (924 mg, 99%).

To a solution of (S)-4-methanesulfonyl-3-methyl-piperazine-1-carboxylicacid tert-butyl ester (924 mg) in dichloromethane (20 mL) at 0° C. wasadded dropwise HCl (6.65 mL of a 2 M solution in diethyl ether). Thereaction mixture was stirred at room temperature for 2 h. Theprecipitate formed was then collected by filtration and dried to afford(S)-1-methanesulfonyl-2-methyl-piperazine hydrochloride salt as a whitesolid (583 mg, 82%).

Reaction between2-chloro-4-morpholin-4-yl-thieno[3,2-d]pyrimidine-6-carbaldehyde and(S)-1-methanesulfonyl-2-methyl-piperazine hydrochloride salt usingprocedure C yielded2-chloro-6-((S)-4-methanesulfonyl-3-methyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine.This compound was subjected to procedure A to yield the desired finalcompound which was purified using flash chromatography.

NMR: (400 MHz, CDCl3): 1.42 (3H, d, J 6.75, Me), 2.33 (1H, td, J 11.42and 3.45), 2.43 (1H, dd, J 3.62 and 11.23), 2.76 (1H, d, J 11.17), 2.88(3H, s, Me), 2.91 (1H, d, J 11.54), 3.34 (1H, td, J 12.01 and 3.04),3.59 (1H, d, J 12.81), 3.72-3.94 (6H, m, CH2), 4.08-4.12 (6H, m, CH2),7.39 (1H, s, Ar), 7.51 (1H, t, J 8.19, Ar), 7.60 (1H, t, J 8.29, Ar),8.25 (1H, d, J 6.96, Ar), 9.01 (1H, s, Ar) and 10.12 (1H, s, NH).

[M+H]+ 528.26

The following compound was prepared in an analogous manner using2-chloro-4-morpholin-4-yl-thieno[2,3-d]pyrimidine-6-carbaldehyde.

96: (400 MHz, CDCl3): 1.34 (3H, d (J 6.77), CH3), 2.25-2.35 (2H, m,CH2), 2.70 (1H, d, CH), 2.80 (3H, s, CH3), 2.90 (1H, d, CH), 3.25-3.30(1H, m, CH), 3.42 (1H, d, CH), 3.55 (1H, m, CH), 3.67 (1H, d, CH), 3.76(1H, d, CH), 3.86-3.93 (8H, m, CH2), 7.09 (1H, s, ar), 7.44-7.46 (1H, m,ar), 7.52 (1H, d, ar), 8.25 (1H, d (J 7.56) ar), 8.96 (1H, s, ar), 10.00(1H, b, NH)

(M+H)+ 528.24

10: This compound was prepared in an analogous manner to the compoundabove using (R)-methylpiperazine as the starting material.

NMR: (400 MHz, CDCl3): 1.42 (3H, d, J 6.75, Me), 2.33 (1H, td, J 11.42and 3.45), 2.43 (1H, dd, J 3.62 and 11.23), 2.76 (1H, d, J 11.17), 2.88(3H, s, Me), 2.91 (1H, d, J 11.54), 3.34 (1H, td, J 12.01 and 3.04),3.59 (1H, d, J 12.81), 3.72-3.94 (6H, m, CH2), 4.08-4.12 (6H, m, CH2),7.40 (1H, s, Ar), 7.51 (1H, t, J 8.22, Ar), 7.60 (1H, t, J 8.31, Ar),8.27 (1H, d, J 6.79, Ar), 9.01 (1H, s, Ar) and 10.20 (1H, s, NH).

[M+H]+ 528.27

The following compound was prepared in an analogous manner using2-chloro-4-morpholin-4-yl-thieno[2,3-d]pyrimidine-6-carbaldehyde.

98: (M+H)+ 528.23

NMR: (400 MHz CDCl3): 1.25-1.28 (1H, m, CH), 1.42 (3H, d (J 6.71), CH3),1.54 (1H, s, CH), 2.29-2.40 (2H, m, CH), 2.77 (1H, d (J 11.1), CH), 2.87(3H, s, CH3), 2.95 (1H, d (J 11.25), CH), 3.30-3.36 (1H, m, CH), 3.60(1H, d, (J 12.75), CH), 3.72 (1H, d (J 14.18), CH), 3.85 (2H, d (J14.13), CH2), 3.92-4.01 (8H, m, CH2), 4.12-4.13 (1H, m, CH), 7.16 (1H,s, ar), 7.51 (1H, t (J 7.75, ar), 7.60 (1H, d (J 8.29), ar), 8.32 (1H, d(J 7.29), ar), 9.04 (1H, s, ar), 10.10 (1H, b, NH)

8: To a solution of piperazine (1 g) and triethylamine (1.78 mL) indichloromethane (20 mL) at 0° C. was added dropwise 2-propanesulfonylchloride (1.30 mL). The reaction mixture was stirred at room temperaturefor 16 h and then quenched with water (20 mL) and extracted intodichloromethane (2×40 mL). The combined organic layers were washed withsaturated aqueous brine solution (2×40 mL), dried (MgSO₄) andconcentrated to afford 1-(propane-2-sulfonyl)-piperazine as a whitesolid (1.87 g, 84%).

Reaction between2-chloro-4-morpholin-4-yl-thieno[3,2-d]pyrimidine-6-carbaldehyde and1-(propane-2-sulfonyl)-piperazine using procedure C yielded2-chloro-4-morpholin-4-yl-6-[4-(propane-2-sulfonyl)-piperazin-1-ylmethyl]-thieno[3,2-d]pyrimidine.This compound was subjected to procedure A to yield the desired finalcompound which was purified using flash chromatography.

[M+H]+ 542.22

NMR: (400 MHz, CDCl3): 1.28 (6H, d, J 6.84, Me), 2.51-2.61 (4H, m, CH2),3.13 (1H, septet, J 6.93, CH), 3.35-3.60 (4H, m, CH2), 3.81 (2H, s,CH2), 3.83-3.90 (4H, m, CH2), 3.96-4.04 (4H, m, CH2), 7.32 (1H, s, Ar),7.40 (1H, t, J 8.20, Ar), 7.48 (1H, d, J 8.22, Ar), 8.20 (1H, d, J 7.32,Ar), 8.92 (1H, s, Ar) and 10.26 (1H, s, Ar).

The following compound was prepared in an analogous manner using2-chloro-4-morpholin-4-yl-thieno[2,3-d]pyrimidine-6-carbaldehyde.

97: NMR: (400 MHz, CDCl3): 1.24 (1H, m, CH), 1.36 (6H, d (J 6.84), CH3),2.62 (4H, m, CH2), 3.44-3.49 (4H, m, CH2), 3.82 (2H, s, CH2), 3.93-4.00(8H, m, CH2), 7.17 (1H, s, ar), 7.51-7.53 (1H, m, ar), 7.59 (1H, m, ar),8.32 (1H, d (J 6.69), ar), 9.04 (1H, s, ar), 10.05 (1H, b, NH)

(M+H)+ 542.24

7: To a solution of cis-2,6-dimethyl-piperazine (600 mg) andtriethylamine (0.80 mL) in dichloromethane (10 mL) at 0° C. was addeddropwise methanesulfonyl chloride (0.43 mL). The reaction mixture wasstirred at room temperature for 16 h and then quenched with water (10mL) and extracted into dichloromethane (2×20 mL). The combined organiclayers were washed with saturated aqueous brine solution (2×20 mL),dried (MgSO₄) and concentrated to afford(3S,5R)-1-methanesulfonyl-3,5-dimethyl-piperazine as a white solid (817mg, 81%).

Reaction between6-(bromomethyl)-2-chloro-4-morpholinothieno[3,2-d]pyrimidine and(3S,5R)-1-methanesulfonyl-3,5-dimethyl-piperazine using potassiumcarbonate and acetonitrile yielded2-chloro-6-((2S,6R)-4-methanesulfonyl-2,6-dimethyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine.This compound was subjected to procedure A to yield the desired finalcompound which was purified using flash chromatography.

[M+H]+ 542.24

NMR: (400 MHz, CDCl3): 1.18 (6H, d, J 6.90, Me), 2.48-2.52 (2H, m, CH2),2.72 (3H, s, SO2Me), 2.78-2.88 (2H, m, CH2), 3.51-3.56 (2H, m, CH2),3.81-3.88 (4H, m, CH2), 3.96-4.02 (4H, m, CH2), 4.12 (2H, s, CH2), 7.28(1H, s, Ar), 7.42 (1H, t, J 8.22, Ar), 7.49 (1H, d, J 8.31, Ar), 8.20(1H, d, J 7.26, Ar) 8.94 (1H, s, Ar) and 10.08 (1H, s, NH).

The following compound was prepared in an analogous manner using2-chloro-4-morpholin-4-yl-thieno[2,3-d]pyrimidine-6-carbaldehyde.

102: NMR: (400 Mhz, CDCl3): 1.19-1.24 (6H, m, CH3), 2.61 (2H, t (J10.72), CH2), 2.80 (3H, s, CH3), 2.88-2.90 (2H, m, CH2), 3.59 (2H, d (J10.46), CH2), 3.93-4.00 (8H, m, CH2) 4.14 (2H, s, CH2), 7.12 (1H, s,ar), 7.51 (1H, t (J 7.80), ar), 7.60 (1H, d (J 8.29), ar), 8.32 (1H, d(J 6.73), ar), 9.04 (1H, s, ar), 10.10 (1H, b, NH)6: Reaction between2-chloro-4-morpholin-4-yl-thieno[3,2-d]pyrimidine-6-carbaldehyde andcis-2,6-dimethyl-piperazine using procedure C yielded2-chloro-6-((3R,5S)-3,5-dimethyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine.This compound treated with methane sulphonyl chloride using standardconditions to yield2-chloro-6-((3R,5S)-4-methanesulfonyl-3,5-dimethyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine.This compound was subjected to procedure A to yield the desired finalcompound which was purified using flash chromatography.

[M+H]+ 542.25

(400 MHz, CDCl3): 1.52 (6H, d, J 6.93, Me), 2.33 (2H, dd, J 11.37 and4.34, CH2), 2.81 (2H, d, J 11.15, CH2), 2.89 (3H, s, SO2Me), 3.86 (2H,s, CH2), 3.88-3.94 (4H, m, CH2), 4.05-4.13 (6H, m, CH2), 7.40 (1H, s,Ar), 7.51 (1H, t, J 8.20, Ar), 7.58 (1H, d, J 8.29, Ar), 8.27 (1H, d, J7.32, Ar), 9.02 (1H, s, Ar) and 10.14 (1H, s, Ar).

92: To 1-BOC-homopiperazine (0.8 ml) was added methane sulphonylchloride (0.34 ml) and triethylamine (0.68 ml). The reaction mixture wasstirred at room temperature for 4 hours. The reaction mixture was thenpartitioned between dichloromethane and water. The combined organicextracts were then washed with brine and dried (MgSO₄). The solvent wasremoved in vacuo to yield 1.23 g crude4-methanesulfonyl-[1,4]diazepane-1-carboxylic acid tert-butyl ester.

Crude 4-Methanesulfonyl-[1,4]diazepane-1-carboxylic acid tert-butylester (1.23 g) was stirred in anhydrous methanol (10 ml). 2M hydrogenchloride in ether (22 ml) was added. The reaction mixture was stirred atroom temperature. After 5 minutes a precipitate formed, addition ofanhydrous methanol (5 ml) caused this to dissolve. The reaction mixturewas stirred overnight at room temperature. The solvents were removed invacuo to yield 1.06 g of 1-methanesulfonyl-[1,4]diazepane hydrochloridesalt.

Reaction between2-chloro-4-morpholin-4-yl-thieno[3,2-d]pyrimidine-6-carbaldehyde and1-methanesulfonyl-[1,4]diazepane hydrochloride salt using procedure Cyielded2-chloro-6-(4-methanesulfonyl-[1,4]diazepan-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine.This compound was subjected to procedure A to yield the desired finalcompound which was purified using flash chromatography.

NMR: (400 MHz, CDCl3): 1.26 (3H, s, CH3), 1.96 (2H, m, CH2), 2.86-2.88(4H, m, CH2), 3.49-3.52 (4H, m, CH2), 3.92-3.94 (4H, m, CH2), 4.03 (2H,s, CH2), 4.08-4.11 (4H, m, CH2), 7.38 (1H, s, ar), 7.51-7.53 (1H, m,ar), 7.58 (1H, d, ar), 8.28 (1H, d, J (7.41), ar), 9.02 (1H, s, ar),10.05 (1H, b, NH)

(M+H)+ 528.23

94: To a mixture of isobutylaldehyde (9.5 mL) and dioxane (0.38 mL) indiethyl ether (40 mL) at room temperature was added bromine (0.11 mL).The reaction mixture was cooled to 0° C. and bromine (5.1 mL) was addeddropwise. The reaction mixture was stirred for 10 min and then pouredinto ice water (250 mL). Sodium carbonate (6 g) was added gradually tothe mixture with vigorous stirring. Then, the organic phase wasseparated, dried (MgSO₄) and distilled using Kugelrohr apparatus to give2-bromo-2-methyl-propionaldehyde as a colourless oil (3.794 g).

To a solution of ethylene diamine (8.40 mL) in toluene (20 mL) at 0° C.was added 2-bromo-2-methyl-propionaldehyde (3.794 g). The reactionmixture was stirred vigorously at room temperature for 1 h and then atreflux for 30 min. After cooling to room temperature the two phases wereseparated and the lower phase was extracted with toluene (2×30 mL). Thetoluene phase was then concentrated and distilled using Kugelrhorapparatus to give 6,6-dimethyl-1,2,3,6-tetrahydro-pyrazine (1.56 g).

To a solution of 6,6-dimethyl-1,2,3,6-tetrahydro-pyrazine (1.56 g) inethanol (100 mL) was added Pd/C (300 mg). The reaction mixture wasstirred for 16 h with a hydrogen balloon. The mixture was then filteredthrough Celite and the filtrate concentrated and distilled usingkugelrohr apparatus to afford 2,2-dimethyl-piperazine as a colourlessoil which solidified on standing (1.23 g).

To a solution of 2,2-dimethylpiperazine (400 mg) and triethylamine (0.59mL) in dichloromethane (10 mL) at 0° C. was added dropwisemethanesulfonyl chloride (0.30 mL). The reaction mixture was stirred atroom temperature for 16 h and then quenched with water (10 mL) andextracted into dichloromethane (2×20 mL). The combined organic layerswere washed with saturated aqueous brine solution (2×20 mL), dried(MgSO₄) and concentrated to afford1-methanesulfonyl-3,3-dimethyl-piperazine as a white solid (412 mg,61%).

Reaction between2-chloro-4-morpholin-4-yl-thieno[3,2-d]pyrimidine-6-carbaldehyde and1-methanesulfonyl-3,3-dimethyl-piperazine using procedure C yielded2-chloro-6-(4-methanesulfonyl-2,2-dimethyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine.This compound was subjected to procedure A to yield the desired finalcompound which was purified using flash chromatography.

(400 MHz, CDCl3): 1.15 (6H, s, Me), 2.62-2.68 (2H, m, CH2), 2.72 (3H, s,Me), 2.95 (2H, s, CH2), 3.12-3.18 (2H, m, CH2), 3.81-3.90 (6H, m, CH2),3.98-4.04 (4H, m, CH2), 7.32 (1H, s, Ar), 7.42 (1H, t, J 8.22, Ar), 7.50(1H, d, J 8.23, Ar), 8.20 (1H, d, J 7.18, Ar), 8.92 (1H, s, Ar) and 9.98(1H, s, NH).

[M+H]+ 542.25

100: To a solution of 2,2-dimethylpiperazine (400 mg) in dichloromethane(20 mL) at 0° C. was added di-tert-butyl dicarbonate (766 mg). Thereaction was stirred at room temperature for 4 h and then quenched withwater (20 mL) and extracted into dichloromethane (2×40 mL). The combinedorganics were washed with saturated aqueous brine solution (40 mL),dried (MgSO₄) and concentrated to give3,3-diemethyl-piperazine-1-carboxylic acid tert-butyl ester as a whitesolid (720 mg, 96%).

To a solution of 3,3-diemethyl-piperazine-1-carboxylic acid tert-butylester (720 mg) and triethylamine (0.59 mL) in dichloromethane (10 mL) at0° C. was added dropwise methanesulfonyl chloride (0.30 mL). Thereaction mixture was stirred at room temperature for 16 h and thenquenched with water (10 mL) and extracted into dichloromethane (2×20mL). The combined organic layers were washed with saturated aqueousbrine solution (2×20 mL), dried (MgSO₄) and concentrated to give4-methanesulfonyl-3,3-dimethyl-piperazine-1-carboxylic acid tert-butylester as a white solid (914 mg, 93%).

To a solution of 4-methanesulfonyl-3,3-dimethyl-piperazine-1-carboxylicacid tert-butyl ester (914 mg) in dichloromethane (20 mL) at 0° C. wasadded dropwise HCl (6.65 mL of a 2 M solution in diethyl ether). Thereaction mixture was stirred at room temperature for 2 h. Theprecipitate formed was then collected by filtration and dried to afford1-methanesulfonyl-2,2-dimethyl-piperazine hydrochloride salt as a whitesolid (540 mg, 75%).

Reaction between2-chloro-4-morpholin-4-yl-thieno[3,2-d]pyrimidine-6-carbaldehyde and1-methanesulfonyl-2,2-dimethyl-piperazine hydrochloride salt usingprocedure C yielded2-chloro-6-(4-methanesulfonyl-3,3-dimethyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine.This compound was subjected to procedure A to yield the desired finalcompound which was purified using flash chromatography.

(400 MHz, CDCl3): 1.49 (6H, s, Me), 2.28 (2H, s, CH2), 2.55-2.58 (2H, m,CH2), 2.88 (3H, s, Me), 3.44-3.48 (2H, m, CH2), 3.76 (2H, s, CH2),3.82-3.89 (4H, m, CH2), 4.01-4.08 (4H, m, CH2), 7.29 (1H, s, Ar), 7.41(1H, t, J 8.22, Ar), 7.52 (1H, d, J 8.24, Ar), 8.20 (1H, d, J 7.21, Ar),8.96 (1H, s, Ar) and 10.02 (1H, s, NH).

[M+H]+ 542.27

29: Reaction between N—BOC-piperazine and methane sulfonyl chloride indichloromethane and triethylamine yielded4-methanesulfonyl-piperazine-1-carboxylic acid tert-butyl ester.Cleavage of the BOC protecting group using HCl (2M) in dichloromethaneyielded 1-methanesulfonyl-piperazine. HCl salt.

Reaction between 1-methanesulfonyl-piperazine. HCL salt and2-chloro-7-methyl-4-morpholin-4-yl-thieno[3,2-d]pyrimidine-6-carbaldehydeusing procedure C yielded2-chloro-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-7-methyl-4-morpholin-4-yl-thieno[3,2-d]pyrimidine.This compound was subjected to procedure A to yield the desired finalcompound which was purified using flash chromatography.

NMR: (CDCl3): 2.55 (3H, s), 2.71-2.75 (4H, m), 2.82 (3H, s), 3.30-3.33(4H, m), 3.89 (2H, s), 3.90-3.93 (4H, m), 4.06-4.10 (4H, m), 7.51-7.54(1H, m), 7.60 (1H, d, J=8.3), 8.37 (1H, d, J=6.8), 9.18 (1H, s), 10.05(1H, br)

(ESI+): MH+ 528 (100%)

31: Reaction between 1-methylpiperazine and2-chloro-4-morpholin-4-yl-thieno[2,3-d]pyrimidine-6-carbaldehyde usingProcedure C yielded2-chloro-6-(4-methyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[2,3-d]pyrimidine.This compound was subjected to procedure A to yield the desired finalcompound which was purified using flash chromatography.

400 MHz ¹H NMR CDCl3

2.31 (s, 3H, CH3), 2.50 (m, 4H, 2×CH2), 2.60 (m, 4H, 2×CH2), 3.78 (s,2H, CH2), 3.91-3.94 (m, 4H, 2×CH2), 3.98-4.00 (m, 4H, 2×CH2), 7.16 (s,H, ArH), 7.50 (t, H, ArH, J=7.39 Hz), 7.58 (d, H, ArH, J=8.29 Hz), 8.32(d, H, ArH, J=7.37 Hz), 9.03 (s, H, ArH), 10.15 (sbr, H, NH).

MH+=450.18

57:2-Chloro-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[2,3-d]pyrimidine(see intermediates) was subjected to procedure A. The final compound waspurified using flash chromatography.

400 MHz ¹H NMR CDCl3

2.67 (m, 4H, 2×CH2), 2.81 (s, 3H, CH3), 3.30 (m, 4H, 2×CH2), 3.83 (s,2H, CH2), 3.92-3.94 (m, 4H, 2×CH2), 3.98-4.00 (m, 4H, 2×CH2), 7.17 (s,H, ArH), 7.50 (t, H, ArH, J=7.81 Hz), 7.59 (d, H, ArH, J=8.31 Hz), 8.31(d, H, ArH, J=6.98 Hz), 10.12 (sbr, H, NH). MH+=514.10

43: To a solution of N—BOC-piperazine (1.06 g) in CH₂Cl₂/MeOH (20 mL) at0° C. was added 2M HCl in ether (3.14 mL). After 1 h the solvent wasremoved in vacuo to give a white solid. This was dissolved in water andNaCN was added (280 mg). To this mixture was added a solution of acetone(420 μL) in water (2 mL). The resultant was stirred at room temperaturefor 72 h then diluted with water and extracted with ethyl acetate.Combined extracts were dried (Na₂SO₄), filtered and concentrated to give4-(cyano-dimethyl-methyl)-piperazine-1-carboxylic acid tert-butyl ester(77%).

To a solution of 4-(cyano-dimethyl-methyl)-piperazine-1-carboxylic acidtert-butyl ester (1 g) and K₂CO₃ (100 mg) in dry DMSO (20 mL) at 0° C.was added a 27.5% hydrogen peroxide (2 mL) dropwise. The resultingmixture was heated at 40° C. overnight then diluted with water give asolid. This was collected, washed and dried to give4-(1-carbamoyl-1-methyl-ethyl)-piperazine-1-carboxylic acid tert-butylester (806 mg). Subsequent treatment with 2M HCl in ether gave2-piperazin-1-yl-isobutyramide dihydrochloride (100%).

Reductive amination of2-chloro-4-morpholin-4-yl-thieno[3,2-d]pyrimidine-6-carbaldehyde with2-piperazin-1-yl-isobutyramide dihydrochloride according GeneralProcedure C gave2-[4-(2-chloro-4-morpholin-4-yl-thieno[3,2-d]pyrimidin-6-ylmethyl)-piperazin-1-yl]-isobutyramideafter purification on silica.

2-[4-(2-Chloro-4-morpholin-4-yl-thieno[3,2-d]pyrimidin-6-ylmethyl)-piperazin-1-yl]-isobutyramidewas reacted with4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1H-indazole in GeneralProcedure A. Purification on silica yielded the desired compound.

NMR: (CDCl₃): 1.24 (s, 6H, 2×CH2), 2.55-2.65 (m, 8H, 4×CH2), 3.85 (s,2H, CH2), 3.90-3.92 (m, 4H, 2×CH2), 4.07-4.09 (m, 4H, 2×CH2), 5.35 (m,H, NH), 7.09 (m, H, NH), 7.37 (s, H, ArH), 7.48 (t. H, ArH, J=7.72 Hz),7.57 (d, H, ArH, J=8.22 Hz), 8.26 (d, H, ArH, J=7.14 Hz), 9.0 (s, H,ArH), 10.4 (sbr, H, NH).

MS: (ESI+): MH+=521.27

44: To a solution of piperidone (317 mg) and potassium carbonate (530mg) in acetonitrile at room temperature (20 mL) was added 2-bromoethylmethyl ether (0.48 mL). The reaction mixture was heated at reflux for 16h, allowed to cool to room temperature and then reduced in vacuo. Theresidue was then redissolved in dichloromethane (20 mL) and washed withwater (20 mL) and brine (20 mL), dried (MgSO₄) and reduced in vacuo togive 1-(2-methoxy-ethyl)-piperidin-4-one as colourless oil (171 mg).

To a suspension of2-chloro-4-morpholin-4-yl-thieno[3,2-d]pyrimidine-6-carbaldehyde (1.0 g)and molecular sieves in methanol (20 mL) at room temperature was addedacetic acid (0.1 mL) and a solution of methylamine (219 mg) in methanol(1 ml). The reaction mixture was stirred at room temperature for 24 h.Then sodium borohydride (542 mg) was added portionwise and the reactionstirred at room temperature for a further 30 min. The reaction was thenquenched with saturated aqueous sodium hydrogen carbonate solution (10mL) and extracted into dichloromethane (2×10 mL). The combined organicswere washed with brine (20 mL), dried (MgSO4) and reduced in vacuo togive(2-chloro-4-morpholin-4-yl-thieno[3,2-d]pyrimidin-6-ylmethyl)-methyl-amineas a white solid (0.95 g).

(2-chloro-4-morpholin-4-yl-thieno[3,2-d]pyrimidin-6-ylmethyl)-methyl-aminewas then reacted with 1-(2-methoxy-ethyl)-piperidin-4-one in generalprocedure C. Purification on silica yielded(2-chloro-4-morpholin-4-yl-thieno[3,2-d]pyrimidin-6-ylmethyl)-[1-(2-methoxy-ethyl)-piperidin-4-yl]-methyl-amine.

(2-Chloro-4-morpholin-4-yl-thieno[3,2-d]pyrimidin-6-ylmethyl)-[1-(2-methoxy-ethyl)-piperidin-4-yl]-methyl-aminewas then reacted with 4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1H-indazole in general procedure A. Purification on silicayielded the title compound.

NMR: DMSO: 13.15 (bs, 1H); 8.86 (s, 1H); 8.21 (d, 1H, J=7.3 Hz); 7.65(d, 1H, J=8.2 Hz); 7.45 (m, 2H); 3.99 (m, 4H); 3.94 (s, 2H); 3.82 (m,4H); 3.38 (m, 2H); 3.22 (s, 3H); 2.94 (m, 2H); 2.49 (m, 2H); 2.48 (m,1H); 2.22 (s, 3H); 1.94 (m, 2H); 1.74 (m, 2H); 1.35 (m, 2H).

32: Hydrogen chloride gas (4 g) was bubbled through methanol (120 mL) at0° C. Proline (3.80 g) was then added and the mixture was stirred atroom temperature for 4.5 h and then reduced in vacuo to givepyrrolidine-2-carboxylic acid methyl ester hydrochloride salt as a whitesolid (5.5 g).

To a suspension of pyrrolidine-2-carboxylic acid methyl esterhydrochloride salt (5.5 g) in acetonitrile (90 mL) was addedtriethylamine (10.2 mL) and di-tert-butyldicarbonate (8.0 g). Thereaction mixture was stirred at room temperature for 16 h and thenreduced in vacuo. The residue was redissolved in dichloromethane (40 mL)and washed with brine (40 mL), dried (MgSO4), reduced in vacuo andpurified by column chromatography to give pyrrolidine-1,2-dicarboxylicacid 1-tert-butyl ester 2-methyl ester as a yellow oil (6.33 g).

To a solution of pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester2-methyl ester (3.5 g) in toluene (40 mL) at −78° C. was added dropwisediisobutylaluminium hydride (20 mL of a 1.5 M solution in toluene)maintaining the temperature below −65° C. The reaction mixture wasstirred at −78° C. for 2 h and then quenched with methanol (10 mL). Themixture was then diluted with diethyl ether (50 mL), potassium sodiumtartrate tetrahydrate was added and the mixture stirred vigorously for20 min at room temperature. The two phases were then separated and theaqueous layer extracted with dichloromethane (2×50 mL). The combinedorganics were then washed with brine (100 mL), dried (MgSO₄), reduced invacuo and purified by column chromatography to give2-formyl-pyrrolidine-1-carboxylic acid tert-butyl ester as a pale yellowoil (2.687 g).

To a suspension of 2-formyl-pyrrolidine-1-carboxylic acid tert-butylester (2.68 g) in methanol (30 mL) at room temperature was added asolution of methylamine (831 mg) in methanol (3 mL). The reactionmixture was stirred at room temperature for 72 h and then sodiumborohydride (760 mg) and molecular sieves were added. After stirring atroom temperature for 2 h, the reaction mixture was filtered and thefiltrate reduced in vacuo. The residue was redissolved indichloromethane (30 mL) and washed with saturated sodium bicarbonatesolution (30 mL). The combined organics were washed with brine (30 mL),dried (MgSO₄) and reduced in vacuo to give2-methylaminomethyl-pyrrolidine-1-carboxylic acid tert-butyl ester as apale yellow oil (2.56 g).

To a solution of 2-methylaminomethyl-pyrrolidine-1-carboxylic acidtert-butyl ester (500 mg) in dichloromethane (10 mL) at room temperaturewas added triethylamine (0.36 mL) and methanesulphonyl chloride (0.20mL). The reaction mixture was stirred at room temperature for 4 h andthen partitioned between dichloromethane (20 mL) and saturated aqueoussodium bicarbonate solution (30 mL). The combined organics were washedwith brine (30 mL), dried (MgSO₄), reduced in vacuo and purified bycolumn chromatography to give2-[(methanesulfonyl-methyl-amino)-methyl]-pyrrolidine-1-carboxylic acidtert-butyl ester as a white solid (0.63 g).

To a solution of2-[(methanesulfonyl-methyl-amino)-methyl]-pyrrolidine-1-carboxylic acidtert-butyl ester (0.63 g) in dichloromethane (10 mL) at room temperaturewas added hydrogen chloride (3.0 mL of a 2 M solution in diethyl ether).The reaction mixture was stirred at room temperature for 72 h and thenreduced in vacuo to giveN-methyl-N-pyrrolidin-2-ylmethyl-methanesulfonamide as a crystallinesolid (0.49 g).

To a mixture of6-bromomethyl-2-chloro-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (0.50 g)and N-methyl-N-pyrrolidin-2-ylmethyl-methanesulfonamide (390 mg) inacetonitrile (10 mL) was added potassium carbonate (490 mg). Thereaction mixture was heated at 80° C. for 16 h and then allowed to coolto room temperature. The reaction mixture was then partitioned betweendichloromethane (20 mL) and saturated aqueous sodium bicarbonatesolution (20 mL). The combined organics were washed with brine (30 mL),dried (MgSO₄), reduced in vacuo and purified by column chromatography togiveN-[1-(2-chloro-4-morpholin-4-yl-thieno[3,2-d]pyrimidin-6-ylmethyl)-pyrrolidin-2-ylmethyl]-N-methyl-methanesulfonamideas a pale yellow solid (580 mg).

N-[1-(2-Chloro-4-morpholin-4-yl-thieno[3,2-d]pyrimidin-6-ylmethyl)-pyrrolidin-2-ylmethyl]-N-methyl-methanesulfonamidewas reacted with4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1H-indazole in generalprocedure A. Purification on silica yielded the title compound.

NMR: CDCl₃: 1.80 (3H, m); 2.02 (1H, m); 2.40 (1H, m); 2.80 (3H, s); 2.97(4H, m); 3.18 (3H, m); 3.90 (4H, m); 4.10 (4H, t, J=4.7 Hz); 4.30 (1H,d, J=14.6 Hz); 7.37 (1H, s); 7.50 1H, t, J=7.7 Hz); 7.58 (1H, d, J=8.2Hz); 8.28 (1H, d, J=7.1 Hz); 9.02 (1H, s); 10.00 (1H, br s).

MS: (ESI+): MH+ 542

42: To a solution of tetrahydrothiopyran-4-one (400 mg) stirring inacetonitrile (5 ml) and Na2.EDTA (0.0004 M aq, 3 ml) was added potassiumperoxymonosulphate (Oxone, 6.34 g) and NaHCO3 (2.69 g) in severalaliquots over 30 minutes. The reaction mixture was stirred at roomtemperature for a further 2 hours, then diluted with water (40 ml),extracted into dichloromethane, and dried (MgSO4) to give1,1-dioxo-tetrahydro-thiopyran-4-one (330 mg) as a white solid. To thiscompound (75 mg) stirring in anhydrous 1,2-dichloroethane (6 ml) wasadded 2-chloro-4-morpholin-4-yl-thienopyrimidine-6-yl methyl methylamine(150 mg, as previously prepared from2-chloro-4-morpholin-4-yl-thienopyrimidine-6-carbaldehyde andmethylamine under reductive amination conditions), followed by glacialacetic acid (31 μl) and sodium triacetoxy borohydride (138 mg). Thereaction mixture was stirred for 24 hours at room temperature, and theproduct isolated by extraction into dichloromethane, followed bypurification by flash chromatography to give(2-chloro-4-morpholin-4-yl-thienopyrimidine-6-ylmethyl)-(1,1-dioxo-hexahydro-thiopyran-4-yl)-methyl-amine(115 mg) as a yellow solid, which was used in a Suzuki coupling with4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1H-indazole, to give,after flash silica purification the title compound (38 mg) as a whitesolid.

¹H NMR 400 MHz DMSO

13.18 (bs, 1H); 8.87 (s, 1H); 8.21 (d, 1H, J=7.2 Hz); 7.65 (d, 1H, J=8.2Hz)

7.45 (m, 2H); 3.98 (m, 6H) 3.82 (m, 4H); 3.26-3.06 (m, CH2×2)

2.91 (m, 1H); 2.28 (s, 3H); 2.04 (m, CH2×2)

M/S ESI (m+1)=513.1

LC>95% purity

34: To a solution of 1-methanesulphonyl-piperidine-4-one (182 mg;prepared from N—BOC-piperidone by reaction of piperidone-4-one TFA saltwith methane sulphonyl chloride), stirring in anhydrous1,2-dichloroethane (6 ml) was added 2-methoxyethylamine (90 μl) followedby glacial acetic acid (62 μl). Sodium triacetoxy borohydride (284 mg),was added in aliquots over 30 minutes and the reaction mixture stirredfor 12 hours at room temperature, then diluted with dichloromethane (40ml), washed with 50% NaHCO3 solution and dried (MgSO4). The solventswere removed in vacuo to give a residue which was purified by silicaflash chromatography to give1-methanesulphonyl-piperidin-4-yl-2-methoxy-ethylamine (148 mg), as awhite solid.

To a solution of 1-methanesulphonyl-piperidin-4-yl-2-methoxy-ethylamine(146 mg), stirring in 1,2-dichloroethane (10 ml), was added2-chloro-4-morpholin-4-yl-thieno[3,2-d]pyrimidine-6-carbaldehyde (176mg), followed by glacial acetic acid (38 μl), and sodium triacetoxyborohydride (171 mg). The reaction mixture was stirred for 12 hours atroom temperature. The product was isolated by extraction intodichloromethane, followed by purification by flash silicachromatography, to give(2-chloro-4-morpholino-4-yl-thieno[3,2-d]pyrimidin-6-ylmethyl)-(1-methanesulphonyl-piperidin-4-yl)-(2-methoxyethylamine),(103 mg) as a white solid, which was used in a Suzuki coupling with4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1H-indazole, to give,after flash silica purification the title compound (72 mg) as a whitesolid.

1H NMR 400 MHz d6 DMSO

13.15 (bs, 1H); 8.87 (s, 1H); 8.21 (d, 1H, J=8.3 Hz)

7.65 (d, 1H, J=8.3 Hz); 7.46 (t, 1H); 4.08 (s, 2H)

4.01 (m, 4H+CH2); 3.83 (m, 4H) 3.60 (m, 2H); 3.22 (s, 3H);

2.81 (s, 3H); 2.75 (m, CH2×2); 2.67 (m, CH); 1.86 (m, CH2)

LC-MS

(m+1) 586.2

Purity>95%

30: To a solution of 4-(2-aminoethyl)-morpholine (600 mg) stirring inanhydrous 1,2-dichloroethane (40 ml), was added2-chloro-4-morpholin-4-yl-thieno[3,2-d]pyrimidine-6-carbaldehyde (1.31g), followed by glacial acetic acid (277 μl) and sodium triacetoxyborohydride (1.27 g) added in several aliquots over 30 minutes. Thereaction mixture was stirred for 12 hours at room temperature, thendiluted with chloroform (50 ml), washed with 50% NaHCO3 solution anddried (MgSO4). The solvents were removed in vacuo to give a residuewhich was purified by flash silica chromatography to give(2-chloro-4-morpholin-4-yl-thieno[3,2-d]pyrimidine-6-ylmethyl)-(2-morpholin-4-yl-ethyl)-amine(398 mg), as a white solid.

To this compound (172 mg), stirring in anhydrous 1,2-dichloroethane (8ml), was added 1-methanesulphonyl-piperidine-4-one, (77 mg; preparedfrom N—BOC-piperidone by reaction of piperidone-4-one TFA salt withmethane sulphonyl chloride), followed by glacial acetic acid (26 μl),and sodium triacetoxy borohydride (129 mg). The reaction mixture wasstirred for 12 hours at room temperature and then diluted withchloroform (30 ml), washed with 50% NaHCO3 solution and dried (MgSO4).The solvents were removed in vacuo to give a residue which was purifiedby silica flash chromatography to give(2-chloro-4-morpholin-4-yl-thieno[3,2-d]pyrimidin-6-ylmethyl)-(1-methanesulphonyl-piperidine-4-yl)-(2-morpholin-4-yl-ethyl)-amine,(123 mg) as an off-white solid, which was used in a Suzuki coupling with4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1H-indazole, to give,after flash silica purification the title compound (6 mg) as a whitesolid.

1H NMR 400 MHz DMSO

13.15 (bs, H); 8.87 (s, 1H); 8.30 (s, 1H); 8.21 (d, 1H, J=6.9 Hz);

7.65 (d, 1H, J=8.2 Hz); 7.46 (m, 1H); 4.02 (m, 4H+CH2), 3.83 (m, 4H);

3.61 (m, CH2×2); 3.53 (m, CH2×2); 2.81 (s, 3H); 2.68 (m, CH2×2);

2.40 (m, CH+CH2×2); 1.86 (m, CH2); 1.56 (m, CH2).

71: To a solution of 1-methyl-piperidone (1.00 g) in 1,2-dichloroethane(20 ml) was added 2-methoxyethylamine (0.77 ml), followed by sodiumtriacetoxyborohydride (2.62 g) and acetic acid (0.53 g). The reactionmixture was stirred at room temperature overnight.Dichloromethane/aqueous sodium hydrogen carbonate extraction andpurification on silica gave(2-methoxy-ethyl)-(1-methyl-piperidin-4-yl)-amine (1.52 g).

2-Chloro-4-morpholin-4-yl-thieno[3,2-d]pyrimidine-6-carbaldehyde (150mg) and (2-methoxy-ethyl)-(1-methyl-piperidin-4-yl)-amine (128 mg) werestirred together in 1,2-dichloroethane (8 ml) and acetic acid (32 mg)with sodium triacetoxyborohydride (146 mg) at room temperatureovernight. Dichloromethane/aqueous sodium hydrogen carbonate extractionand purification on silica yielded(2-chloro-4-morpholin-4-yl-thieno[3,2-d]pyrimidin-6-ylmethyl)-(2-methoxy-ethyl)-(1-methyl-piperidin-4-yl)-amine(97 mg).

(96 mg), 4-indazole-boronate ester (107 mg), sodium carbonate (70 mg)and PdCl₂(PPh₃)₂ (8 mg) in toluene (2 ml), ethanol (1 ml) and water (0.5ml) were heated in a microwave at 120° C. for 60 min.Dichloromethane/water extraction and purification on silica gave thetitle compound (64 mg).

NMR: (DMSO) 13.15 (bs, 1H); 8.86 (s, 1H); 8.21 (d, 1H, J=7.0 Hz); 7.65(d, 1H, J=8.0 Hz); 7.45 (t, 2H, J=7.7 Hz); 4.05 (s, 2H); 3.99 (m,CH2×2); 3.82 (m, CH2×2); 3.39 (m, 2H); 3.21 (s, 3H); 2.79 (m, 2H); 2.73(m, 2H); 2.49 (m, 1H); 2.12 (s, 3H); 1.89-1.49 (m, CH2×3)

MS: MH+=522.31

59: Hydrogen chloride gas (4 g) was bubbled through methanol (120 mL) at0° C. Proline (3.80 g) was then added and the mixture was stirred atroom temperature for 4.5 h and then reduced in vacuo to givepyrrolidine-2-carboxylic acid methyl ester hydrochloride salt as a whitesolid (5.5 g).

To a suspension of pyrrolidine-2-carboxylic acid methyl esterhydrochloride salt (5.5 g) in acetonitrile (90 mL) was addedtriethylamine (10.2 mL) and di-tert-butyldicarbonate (8.0 g). Thereaction mixture was stirred at room temperature for 16 h and thenreduced in vacuo. The residue was redissolved in dichloromethane (40 mL)and washed with brine (40 mL), dried (MgSO₄), reduced in vacuo andpurified by column chromatography to give pyrrolidine-1,2-dicarboxylicacid 1-tert-butyl ester 2-methyl ester as a yellow oil (6.33 g).

To a solution of pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester2-methyl ester (3.5 g) in toluene (40 mL) at −78° C. was added dropwisediisobutylaluminium hydride (20 mL of a 1.5 M solution in toluene)maintaining the temperature below −65° C. The reaction mixture wasstirred at −78° C. for 2 h and then quenched with methanol (10 mL). Themixture was then diluted with diethyl ether (50 mL), potassium sodiumtartrate tetrahydrate was added and the mixture stirred vigorously for20 min at room temperature. The two phases were then separated and theaqueous layer extracted with dichloromethane (2×50 mL). The combinedorganics were then washed with brine (100 mL), dried (MgSO₄), reduced invacuo and purified by column chromatography to give2-formyl-pyrrolidine-1-carboxylic acid tert-butyl ester as a pale yellowoil (2.687 g).

To a suspension of 2-formyl-pyrrolidine-1-carboxylic acid tert-butylester (2.68 g) in methanol (30 mL) at room temperature was added asolution of methylamine (831 mg) in methanol (3 mL). The reactionmixture was stirred at room temperature for 72 h and then sodiumborohydride (760 mg) and molecular sieves were added. After stirring atroom temperature for 2 h, the reaction mixture was filtered and thefiltrate reduced in vacuo. The residue was redissolved indichloromethane (30 mL) and washed with saturated sodium bicarbonatesolution (30 mL). The combined organics were washed with brine (30 mL),dried (MgSO₄) and reduced in vacuo to give2-methylaminomethyl-pyrrolidine-1-carboxylic acid tert-butyl ester as apale yellow oil (2.56 g).

To a solution of6-bromomethyl-2-chloro-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (420 mg)and 2-methylaminomethyl-pyrrolidine-1-carboxylic acid tert-butyl ester(310 mg) in acetonitrile (10 mL) was added potassium carbonate (250 mg).The reaction mixture was heated at 80° C. for 4 h and then allowed tocool to room temperature. The mixture was then partitioned betweendichloromethane (20 mL) and saturated aqueous sodium bicarbonatesolution (20 mL) and the organic layer washed with brine (20 mL), dried(MgSO4), reduced in vacuo and purified on column chromatography to give2-{[(2-chloro-4-morpholin-4-yl-thieno[3,2-d]pyrimidin-6-ylmethyl)-methyl-amino]-methyl}-pyrrolidine-1-carboxylicacid tert-butyl ester as a white solid (487 mg).

To a solution of2-{[(2-chloro-4-morpholin-4-yl-thieno[3,2-d]pyrimidin-6-ylmethyl)-methyl-amino]-methyl}-pyrrolidine-1-carboxylicacid tert-butyl ester (480 mg) in dichloromethane (10 mL) was addedhydrogen chloride (3 mL of a 2.0 M solution in diethyl ether). Themixture was stirred at room temperature for 16 h and then reduced invacuo to give(2-chloro-4-morpholin-4-yl-thieno[3,2-d]pyrimidin-6-ylmethyl)-methyl-pyrrolidin-2-ylmethyl-aminehydrochloride salt as a yellow solid (380 mg).

To a stirring solution of(2-chloro-4-morpholin-4-yl-thieno[3,2-d]pyrimidin-6-ylmethyl)-methyl-pyrrolidin-2-ylmethyl-aminehydrochloride salt (380 mg) in dichloromethane (10 mL) was addedtriethylamine (0.30 mL) and methane sulfonyl chloride (71 μL). Themixture was stirred at room temperature for 2 h and then partitionedbetween dichloromethane (20 mL) and saturated aqueous sodium bicarbonatesolution (20 mL). The organics were washed with brine (20 mL), dried,reduced in vacuo and purified by column chromatography to give(2-chloro-4-morpholin-4-yl-thieno[3,2-d]pyrimidin-6-ylmethyl)-(1-methanesulfonyl-pyrrolidin-2-ylmethyl)-methyl-amineas an off-white solid (124 mg).

(2-Chloro-4-morpholin-4-yl-thieno[3,2-d]pyrimidin-6-ylmethyl)-(1-methanesulfonyl-pyrrolidin-2-ylmethyl)-methyl-aminewas reacted with4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1H-indazole in generalprocedure A. Purification on silica yielded the title compound.

NMR: CDCl₃: 1.88-1.96 (2H, m); 1.99-2.03 (1H, m); 2.04-2.12 (1H, m);2.40 (3H, s); 2.52 (1H, dd, J=12.50 and 9.21); 2.72 (1H, dd, J=12.52 and4.55); 2.88 (3H, s); 3.28-3.41 (2H, m); 3.84-3.92 (7H, m); 4.02-4.10(4H, m); 7.46 (1H, s); 7.49 (1H, t, J=8.14); 7.62 (1H, d, J=8.28); 8.28(1H, d, J=7.26); 9.01 (1H, s); 10.10 (1H, s).

MS: ESI+: MH+ 542

58: To a solution of 1-N—BOC-3-pyrrolidinone (3.0 g) in methanol (30 ml)was added a solution of freshly prepared methylamine (0.75 g) inmethanol (3.1 ml). The reaction mixture was stirred for 1 hour and thensodium borohydride (0.61 g) was added. After stirring for 4 hours thereaction mixture was then diluted with dichloromethane, washed withsodium bicarbonate solution, dried (Mg₂SO₄) and the solvent removed invacuo to give 3-methylamino-pyrrolidine-1-carboxylic acid tert-butylester (3.18 g).

To a solution of 3-methylamino-pyrrolidine-1-carboxylic acid tert-butylester (0.50 g) in dichloromethane (10 ml) was added triethylamine (0.38ml) followed by methanesulfonic acid (0.21 ml). After stirring for 24hours, the reaction mixture was diluted with dichloromethane, washedwith sodium bicarbonate solution, dried (MgSO₄) and the solvent removedin vacuo. The residue was purified by flash chromatography to yield3-(methanesulfonyl-methyl-amino)-pyrrolidine-1-carboxylic acidtert-butyl ester (0.52 g). Treatment of this compound with HCl indichloromethane/methanol yieldedN-Methyl-N-pyrrolidin-3-yl-methanesulfonamide hydrochloride salt (0.41g).

To a solution of6-bromomethyl-2-chloro-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (500 mg)and N-Methyl-N-pyrrolidin-3-yl-methanesulfonamide hydrochloride salt(370 mg) in acetonitrile (10 mL) was added potassium carbonate (490 mg).The reaction mixture was heated at 80° C. for 16 h and then allowed tocool to room temperature. The mixture was then partitioned betweendichloromethane (20 mL) and saturated aqueous sodium bicarbonatesolution (20 mL) and the organic layer washed with brine (20 mL), dried(MgSO₄), reduced in vacuo and purified on column chromatography to giveN-methyl-N-[1-(2-methyl-4-morpholin-4-yl-thieno[3,2-d]pyrimidin-6-ylmethyl)-pyrrolidin-3-yl]-methanesulfonamideas a pale yellow solid (395 mg).

N-methyl-N-[1-(2-methyl-4-morpholin-4-yl-thieno[3,2-d]pyrimidin-6-ylmethyl)-pyrrolidin-3-yl]-methanesulfonamidewas reacted with4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1H-indazole in generalprocedure A. Purification on silica yielded the title compound.

NMR: CDCl₃: 1.88-1.98 (1H, m); 2.12-2.26 (1H, m); 2.44 (1H, q, J=8.28);2.62-2.70 (1H, m); 2.89 (3H, s); 2.86 (1H, dd, J=10.24 and 3.98); 2.92(3H, s); 2.96-3.01 (1H, m); 3.84-3.98 (6H, m); 4.02-4.10 (4H, m);4.52-4.63 (1H, m); 7.34 (1H, s); 7.50 (1H, t, J=8.20); 7.61 (1H, d,J=8.21); 8.26 (1H, d, J=7.23); 9.01 (1H, s); 10.11 (1H, s).

MS: ESI+: MH+ 528

60: To a solution of 1-N—BOC-3-pyrrolidinone (3.0 g) in methanol (30 ml)was added a solution of freshly prepared methylamine (0.75 g) inmethanol (3.1 ml). The reaction mixture was stirred for 1 hour and thensodium borohydride (0.61 g) was added. After stirring for 4 hours thereaction mixture was then diluted with dichloromethane, washed withsodium bicarbonate solution, dried (Mg₂SO₄) and the solvent removed invacuo to give 3-methylamino-pyrrolidine-1-carboxylic acid tert-butylester (3.18 g).

To a mixture of6-bromomethyl-2-chloro-4-morpholino-4-yl-thieno[3,2,-d]pyrimidine (0.50g) and 3-methylamino-pyrrolidine-1-carboxylic acid tert-butyl ester(0.34 g) in acetonitrile (10 ml) was added potassium carbonate (0.30 g)and heated to 80° C. for 3 hours. The reaction mixture was then dilutedwith dichloromethane, washed with sodium bicarbonate solution, dried(Mg₂SO₄) and the solvent removed in vacuo. The residue was purified byflash chromatography to yield3-[(2-Chloro-4-morpholin-4-yl-thieno[3,2,-d]pyrimidin-6-ylmethyl)-amino]-pyrrolidine-1-carboxylicacid tert-butyl ester (0.65 g). Treatment of this compound with HCl indichloromethane/methanol yielded(2-chloro-4-morpholin-4-yl-thieno[3,2,-d]pyrimidin-6-ylmethyl)-amino-pyrrolidin-3-aminehydrochloride salt (0.56 g).

To a suspension of(2-chloro-4-morpholin-4-yl-thieno[3,2,-d]pyrimidin-6-ylmethyl)-amino-pyrrolidin-3-aminehydrochloride salt (0.56 g) in dichloromethane (10 ml) was addedtriethylamine (0.42 ml) followed by methanesulfonyl chloride (0.12 ml).After stirring for 3 hours the reaction mixture was diluted withdichloromethane, washed with sodium bicarbonate solution, dried (Mg₂SO₄)and the solvent removed in vacuo. The residue was purified by flashchromatography to yield(2-chloro-4-morpholin-4-yl-thieno[3,2,-d]pyrimidin-6-ylmethyl)-(1-methanesulfonyl-pyrrolidin-3-yl)-methyl-amine(0.25 g).(2-Chloro-4-morpholin-4-yl-thieno[3,2,-d]pyrimidin-6-ylmethyl)-(1-methanesulfonyl-pyrrolidin-3-yl)-methyl-aminewas reacted with4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1H-indazole in generalprocedure A. Purification on silica yielded the title compound.

NMR: CDCl₃: 1.94-2.01 (1H, m); 2.20-2.28 (1H, m); 2.36 (3H, s); 2.85(3H, s); 3.20-3.38 (3H, m); 3.52-3.65 (2H, m); 3.72-3.95 (6H, m);4.02-4.07 (4H, m); 7.33 (1H, s); 7.49 (1H, t, J=8.21); 7.60 (1H, d,J=8.22); 8.24 (1H, d, J=7.20); 9.01 (1H, s); 10.12 (1H, s).

MS: ESI+: MH+ 528

74: Reductive amination of 1-Methanesulfonyl-piperidin-4-one (150 mg)with(2-Chloro-4-morpholin-4-yl-thieno[3,2-d]pyrimidin-6-ylmethyl)-methyl-amine(250 mg) under standard conditions followed by aqueous work-up andpurification on silica gave(2-chloro-4-morpholin-4-yl-thieno[3,2-d]pyrimidin-6-ylmethyl)-(1-methanesulfonyl-piperidin-4-yl)-methyl-amine(279 mg).

(2-Chloro-4-morpholin-4-yl-thieno[3,2-d]pyrimidin-6-ylmethyl)-(1-methanesulfonyl-piperidin-4-yl)-methyl-aminewas reacted with4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1H-indazole in GeneralProcedure A. Purification on silica yielded the desired compound.

NMR: (DMSO): 13.16 (bs, 1H); 8.87 (s, 1H); 8.21 (d, 1H, J=7.3 Hz); 7.65(d, 1H, J=8.3 Hz); 7.46 (m, 2H); 3.99 (m, 4H); 3.95 (s, 2H); 3.82 (m,4H); 3.61 (m, 2H); 2.84 (s, 3H); 2.72 (m, 2H); 2.62 (m, 1H); 2.29 (s,3H); 1.87 (m, 2H); 1.58 (m, 2H)

MS: (ESI+): MH+=542.3

72: To a suspension of piperazine-2-carboxylic acid dihydrochloride (10g) in 1,4-dioxane (100 mL) and water (50 mL) at 0° C. was added 17M NaOHsolution in portions followed by di-tert-butyldicarbonate (11.8 g). Theresulting mixture was warmed to R.T. and stirred for 5 h. Triethylamine(13.7 mL) and methanesulfonyl chloride (3.8 mL) were added this mixturewas stirred overnight at R.T. The reaction mixture was concentrated invacuo, diluted with 2M HCl and extracted with EtOAC. Combined extractswere dried (MgSO4), filtered and concentrated to give4-methanesulfonyl-piperazine-1,3-dicarboxylic acid 1-tert-butyl ester(8.46 g).

To a solution of 4-methanesulfonyl-piperazine-1,3-dicarboxylic acid1-tert-butyl ester (8.4 g, crude) in DMF (50 mL) was added K₂CO₃ (7.5 g)and iodomethane (8.5 mL) The mixture was stirred overnight at R.T. Anaqueous work-up followed by purification on silica gave4-methanesulfonyl-piperazine-1,3-dicarboxylic acid 1-tert-butyl ester3-methyl ester (3.267 g). A solution of4-methanesulfonyl-piperazine-1,3-dicarboxylic acid 1-tert-butyl ester3-methyl ester (3.2 g) in dry THF (20 mL) was added via cannular to amixture of lithium aluminium hydride (0.75 g) in THF (30 mL) at 0° C.and under N₂ atmosphere. The resultant mixture was then warmed to R.T.and stirred for 2.5 h. The reaction was carefully quenched with aqueousammonium chloride (5 mL) then filtered over Celite. An aqueous work-upfollowed by purification on silica gave3-hydroxymethyl-4-methanesulfonyl-piperazine-1-carboxylic acidtert-butyl ester (1.13 g).

3-Formyl-4-methanesulfonyl-piperazine-1-carboxylic acid tert-butyl esterwas prepared from3-hydroxymethyl-4-methanesulfonyl-piperazine-1-carboxylic acidtert-butyl ester following a procedure in J. Med. Chem. 2005, 48(2), pp4009-4024.

Reductive amination of3-formyl-4-methanesulfonyl-piperazine-1-carboxylic acid tert-butyl ester(160 mg) with dimethylamine hydrochloride (67 mg) according to GeneralProcedure C followed by an aqueous work-up and purification on silicagave 3-dimethylaminomethyl-4-methanesulfonyl-piperazine-1-carboxylicacid tert-butyl ester (160 mg). This was treated with 2M HCl to givedesired (1-methanesulfonyl-piperazin-2-ylmethyl)-dimethyl-aminedihydrochloride (140 mg).

To a mixture of6-bromomethyl-2-chloro-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (140 mg)and (1-methanesulfonyl-piperazin-2-ylmethyl)-dimethyl-aminedihydrochloride (140 mg) in dry MeCN (6 mL) was added K₂CO₃ (190 mg).The mixture was stirred at 80° C. for 4 h. An aqueous work-up followedby purification on silica gave[4-(2-chloro-4-morpholin-4-yl-thieno[3,2-d]pyrimidin-6-ylmethyl)-1-methanesulfonyl-piperazin-2-ylmethyl]-dimethyl-amine(115 mg).

[4-(2-Chloro-4-morpholin-4-yl-thieno[3,2-d]pyrimidin-6-ylmethyl)-1-methanesulfonyl-piperazin-2-ylmethyl]-dimethyl-aminewas reacted with4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1H-indazole in GeneralProcedure A. Purification on silica yielded the desired compound.

400 MHz; CDCl3

2.30 (7H, m); 2.37 (2H, m); 2.53 (1H, m); 2.83-3.07 (6H, m); 3.27 (1H,m); 3.68 (1H, d, J=12.6 Hz); 3.84 (3.84 (2H, m); 3.94 (4H, t, J=4.7 Hz);4.10 (4H, t, J=4.7 Hz); 7.40 (1H, s); 7.52 (1H, t, J=7.7 Hz); 7.60 (1H,d, J=8.3 Hz); 8.28 (1H, d, J=7.4 Hz); 9.02 (1H, s); 10.15 (1H, br s).

MS: (ESI+) M+H (571)

70:2-Chloro-6-(4-methyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidinewas reacted with 3-amino-4-methylbenzeneboronic acid in generalprocedure A. Purification by flash chromatography on silica yielded2-Methyl-5-[6-(4-methyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidin-2-yl]-phenylamine.To a solution of2-Methyl-5-[6-(4-methyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidin-2-yl]-phenylamine(154 mg) in chloroform (10 ml) and acetic acid (2 ml) was added isoamylnitrite (55 μL). The reaction mixture was stirred at room temperaturefor 3 days. The reaction mixture was diluted with chloroform and washedwith a 50/50 mixture of saturated sodium bicarbonate solution and brine,dried (MgSO₄) and the solvents were removed in vacuo to give a cruderesidue. This was purified by flash chromatography to yield the desiredproduct.

NMR: 400 MHz ¹H NMR DMSO: 13.15 (bs, 1H); 8.57 (s, 1H); 8.20 (d, 1H);8.10 (s, 1H) 7.81 (d, 1H); 7.40 (s, 1H); 3.99 (m, 4H); 3.82 (m, 4H+CH2);2.35 (m, 8H), 2.16 (s, 3H)

MS: (ESI+): 450.2

62: To a solution of 4-hydroxymethyl-piperidine-1-carboxylic acidtert-butyl ester (2.0 g) in anhydrous tetrahydrofuran (50 ml) was addedcarbon tetrabromide (6.2 g) and triphenylphosphine (4.88 g). thereaction mixture was stirred at room temperature for 3 days. Thereaction mixture was filtered through celite. The filtrate was taken upin ethyl acetate, washed with water then brine, dried (MgSO4) and thesolvent removed in vacuo give a crude product. This was purified usingflash chromatography which yielded Bromomethyl-piperidine-1-carboxylicacid tert-butyl ester (1.287 g).

To a solution of pyrazole (68 mgs) in anhydrous dimethylformamide wasadded sodium hydride (44 mgs). The reaction mixture was stirred at 50°C. for 25 minutes. 4-Bromomethyl-piperidine-1-carboxylic acid tert-butylester (280 mgs) in anhydrous dimethylformamide was added. The reactionmixture was stirred at 70° C. under argon for 2.5 hours. The reactionmixture was quenched with water (1 ml) and the solvents were removed invacuo. The crude residue was partitioned between dichloromethane andwater, dried (MgSO₄) and the solvents removed in vacuo to give a crudeproduct. This was purified using flash chromatography to yield4-Pyrazol-1-ylmethyl-piperidine-1-carboxylic acid tert-butyl ester (148mg).

To a solution of 4-Pyrazol-1-ylmethyl-piperidine-1-carboxylic acidtert-butyl ester (215 mg) in anhydrous dichloromethane (5 ml) was added2M hydrogen chloride in ether (4.1 ml). The reaction mixture was stirredat room temperature for 6 hours. The solvents were removed in vacuo toyield 4-Pyrazol-1-ylmethyl-piperidine hydrochloride salt.

To a solution of 4-Pyrazol-1-ylmethyl-piperidine hydrochloride salt in1,2-dichloroethane (5 ml) was added2-Chloro-4-morpholin-4-yl-thieno[3,2-d]pyrimidine-6-carbaldehyde (230mg) and glacial acetic acid (50 μL). The reaction mixture was stirred atroom temperature for 6 hours. Sodium triacetoxyborohydride (224 mg) andtriethylamine (113 μL) were added. The reaction mixture was stirred atroom temperature overnight. The reaction mixture was diluted withdichloromethane, washed with a 50/50 mixture of saturated sodiumbicarbonate solution and brine, dried (MgSO₄) and the solvents removedin vacuo to give a crude product. This was purified by flashchromatography to yield2-Chloro-4-morpholin-4-yl-6-(4-pyrazol-1-ylmethyl-piperidin-1-ylmethyl)-thieno[3,2-d]pyrimidine(154 mg).

2-Chloro-4-morpholin-4-yl-6-(4-pyrazol-1-ylmethyl-piperidin-1-ylmethyl)-thieno[3,2-d]pyrimidinewas reacted with4-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)-1H-indazole in generalprocedure A. Purification by flash chromatography on silica yielded thedesired product.

NMR: 400 MHz 1H NMR in DMSO: 13.15 (bs, 1H); 8.87 (s, 1H); 8.21 (d, 1H,J=6.7 HZ); 7.67 (d, 1H, J=6.2 Hz); 7.64 (s, 1H); 7.44 (m, 3H); 6.20 (t,1H); 4.01 (m, 4H+CH2); 3.83 (m, 4H+CH2); 2.91 (m, 2H); 2.04 (m, 2H);1.98 (m, 2H); 1.45 (m, 2H); 1.25 (m, 2H)

MS: (ESI+): 512.2

61: To a solution of 4-hydroxymethyl-piperidine-1-carboxylic acidtert-butyl ester (2.0 g) in anhydrous tetrahydrofuran (50 ml) was addedcarbon tetrabromide (6.2 g) and triphenylphosphine (4.88 g). thereaction mixture was stirred at room temperature for 3 days. Thereaction mixture was filtered through celite. The filtrate was taken upin ethyl acetate, washed with water then brine, dried (MgSO4) and thesolvent removed in vacuo give a crude product. This was purified usingflash chromatography which yielded Bromomethyl-piperidine-1-carboxylicacid tert-butyl ester (1.287 g).

To a solution of 2-pyrrolidone (86 mg) in anhydrous dimethylformamide (5ml) was added sodium hydride (45 mg). the reaction mixture was stirredunder nitrogen at 50° C. for 35 minutes.4-Bromomethyl-piperidine-1-carboxylic acid tert-butyl ester (86 mg) inanhydrous dimethylformamide (5 ml) was added. The reaction mixture wasstirred at 70° C. overnight. The solvents were removed in vacuo and thecrude residue was partitioned between dichloromethane and water, thecombined organic extracts were washed with brine, dried (MgSO4) and thesolvents removed in vacuo to give a crude product. This was purifiedusing flash chromatography to yield4-(2-Oxo-pyrrolidin-1-ylmethyl)-piperidine-1-carboxylic acid tert-butylester (99 mg).

To a solution of 4-(2-Oxo-pyrrolidin-1-ylmethyl)-piperidine-1-carboxylicacid tert-butyl ester in dichloromethane was added 2M hydrogen chloridein ether (1.78 ml). The reaction mixture was stirred at room temperaturefor 6 hours. The solvents were removed in vacuo to yield1-Piperidin-4-ylmethyl-pyrrolidin-2-one hydrochloride salt.

To a solution of 1-Piperidin-4-ylmethyl-pyrrolidin-2-one hydrochloridesalt in anhydrous 1,2-dichloroethane was added triethylamine (47 μL),the reaction mixture was stirred at room temperature for 2 hours.2-Chloro-4-morpholin-4-yl-thieno[3,2-d]pyrimidine-6-carbaldehyde (99 mg)and glacial acetic acid were added, the reaction mixture was stirred atroom temperature for 4 hours. Sodium triacetoxyborohydride (96 mg) wasadded. The reaction mixture was stirred at room temperature overnight.The reaction mixture was diluted with dichloromethane, washed with a50/50 mixture of saturated sodium bicarbonate solution and brine, dried(MgSO4) and the solvents removed in vacuo to give a crude residue. Thiswas purified using column chromatography to give2-[1-(2-Chloro-4-morpholin-4-yl-thieno[3,2-d]pyrimidin-6-ylmethyl)-piperidin-4-ylmethyl]-cyclopentanone(73 mg).

2-[1-(2-Chloro-4-morpholin-4-yl-thieno[3,2-d]pyrimidin-6-ylmethyl)-piperidin-4-ylmethyl]-cyclopentanonewas reacted with 4-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)-1H-indazole in procedure A. Purification by flashchromatography on silica yielded the desired product.

NMR: 1H NMR 400 MHz, d6 DMSO: 13.15 (bs, 1H); 8.87 (s, 1H); 8.21 (d, 1H,J=7.4 Hz); 7.65 (d, 1H, J=8.3 Hz); 7.46 (t, 1H, J=8.3 Hz); 4.01 (m, 4H);3.83 (m, 4H+CH2); 3.06 (m, 2H); 2.91 (m, 2H); 2.20 (t, 1H, J=7.8 Hz);2.06 (t, 1H, J=11.2 Hz); 1.90 (m, 2H); 1.56 (m, 3H); 1.19 (m, 2H).

MS: (ESI+): 532.3

82:2-chloro-6-(4-methanesulfonyl-piperidin-1-ylmethyl)-4-morpholin-4-yl-thieno[2,3-d]pyrimidinewas reacted with 2-methoxy-5-pyrimidine-boronic acid in GeneralProcedure A. Purification on silica yielded the desired compound.

NMR: (CDCl₃): 2.64-2.67 (m, 4H, 2×CH2), 2.80 (s, 3H, CH3), 3.27-3.30 (m,4H, 2×CH2), 3.81 (s, 2H, CH2), 3.87-3.89 (m, 4H, 2×CH2), 3.95-3.97 (m,4H, 2×CH2), 4.09 (s, 3H, CH3), 7.14 (s, H, ArH), 9.45 (s, 2H, 2×ArH).

MS: (ESI+): MH+=506.16

83:2-chloro-6-(4-methanesulfonyl-piperidin-1-ylmethyl)-4-morpholin-4-yl-thieno[2,3-d]pyrimidinewas reacted with 2-dimethylamino-pyrimidine-5-boronic acid in GeneralProcedure A. Purification on silica yielded the desired compound.

NMR: (CDCl₃): 2.63-2.66 (m, 4H, 2×CH2), 2.79 (s, 3H, CH3), 3.25-3.28 (m,10H, 2×CH2+2×CH3), 3.79 (s, 2H, CH2), 3.84-3.87 (m, 4H, 2×CH2),3.91-3.94 (m, 4H, 2×CH2), 7.101 (s, H, ArH), 9.28 (s, 2H, 2×ArH).

MS: (ESI+): MH+=519.27

EXAMPLE 5 Further Compounds of the Invention

The following further compounds of the invention were prepared. Thecompound numbering corresponds to that used in Table 1B.

140: To 190 mg of2-Chloro-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[2,3-d]pyrimidinein 1 mL 1M KOAc and 2 mL acetonitrile was added 109.8 mg (1.02 eq) of7-azaindole-5-boronic acid pinacol ester and 50.8 mg (0.1 eq) ofPd(PPh₃)₄ as per General Procedure A to give 170.7 mg of the desiredproduct after RP-HPLC purification (75% yield). MS (Q1) 514.2 (M)+.152: To 200 mg of2-Chloro-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[2,3-d]pyrimidinein 2 mL 1M Sodium carbonate in water and 2 mL acetonitrile was added 270mg (1.5 eq) of3-((2-(trimethylsilyl)ethoxy)methyl)-2-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3H-imidazo[4,5-b]Pyridineand 54 mg (0.05 eq) of Pd (PPh₃)₄ as per General Procedure A. Thisinsoluble intermediate was filtered off, washed with water, concentratedin vacuo and dissolved in 20 mL THF followed by the addition of 2.8 mL(6.0 eq) of 1.0 M Tetra-n-butylammonium fluoride in THF. After heatingthe reaction to 80° C. with a reflux condenser attached overnight,complete reaction was confirmed by LCMS. The reaction was diluted withwater, extracted with EtOAc, concentrated in vacuo and gave 55.2 mg ofthe desired product after RP-HPLC purification (21% yield). MS (Q1)529.2 (M)+.132: To 96 mg (0.23 mM) of2-chloro-6-(4-methyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidinein 1 mL 1M KOAc and 1.5 mL acetonitrile was added 73.2 mg (1.3 eq) of4-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)-1H-indazole and 26.6 mg(0.1 mM) of Pd (PPh₃)₄ as per General Procedure A to Give 23.4 mg of thedesired product after RP-HPLC purification (17% yield). MS (Q1) 492.4(M)+.131: 590 mg of crude HCl salt of2-chloro-7-methyl-4-morpholino-6-((piperazin-1-yl)methyl)thieno[3,2-d]pyrimidinewas treated with 430 mg of L-Lactic Acid via Procedure B. 60 mg of thiscrude intermediate was reacted with4-(4,4,5,5-tertamethyl-1,3,2-dioxaborolan-2-yl)1H-indazole via ProcedureA to give 32.5 mg of the desired product after reverse phase. HPLCpurification. MS (Q1) 522.3 (M)+.134: 200 mg of2-chloro-4-morpholinothieno[3,2-d]pyrimidine-6-carbaldehyde was usedaccording to procedure C with (S)-4-N-trityl-2-methyl-piperazine. Thecrude material was then dissolved in 10 mL of methanol and reacted with0.5 mL of concentrated HCl for several hours before basifying with NaOHand extracting into EtOAc. After evaporation the crude reaction mixturecontaining 200 mg of2-chloro-6-(((S)-2-methylpiperazin-1-yl)methyl-4-morpholinothieno[3,2-d]pyrimidinewas reacted with lactic acid via Procedure B. 120 mg of(S)-1-((S)-4-((2-chloro-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)-3-methylpiperazin-1-yl)-2-hydroxypropan-1-onewas reacted with4-(4,4,5,5-tertamethyl-1,3,2-dioxaborolan-2-yl)1H-indazole via ProcedureA to give 47.5 mg of the desired product after reverse phase HPLCpurification. MS (Q1) 522.3 (M)+.148: 250 mg of tert-butyl4-((2-chloro-7-methyl-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazine-1-carboxylatewas reacted with5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[2,3-b]pyridinevia Procedure A. This crude intermediate was subjected to Procedure D.

The crude HCl salt of7-methyl-4-morpholino-6-((piperazin-1-yl)methyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yl)thieno[3,2-d]pyrimidinewas reacted with L-Lactic acid via Procedure B to give 86.7 mg of thedesired product after reverse phase HPLC purification. MS (Q1) 522.2(M)+.

150: 100 mg of tert-butyl4-((2-chloro-7-methyl-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazine-1-carboxylatewas reacted with quinolin-3-yl-3-boronic ester via Procedure A. Thiscrude intermediate was subjected to Procedure D.

The crude HCl salt of3-(7-methyl-4-morpholino-6-((piperazin-1-yl)methyl)thieno[3,2-d]pyrimidin-2-yl)quinolinewas reacted with L-Lactic acid via Procedure B to give 21.6 mg of thedesired product after reverse phase HPLC purification. MS (Q1) 533.2(M)+.

149: 250 mg of tert-butyl4-((2-chloro-4-morpholinothieno[2,3-d]pyrimidin-6-yl)methyl)piperazine-1-carboxylatewas reacted with5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[2,3-b]pyridinevia Procedure A. This crude intermediate was subjected to Procedure D.

The crude HCl salt of4-morpholino-6-((piperazin-1-yl)methyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yl)thieno[2,3-d]pyrimidinewas reacted with L-Lactic acid via Procedure B to give 58.5 mg of thedesired product after reverse phase HPLC purification. MS (Q1) 508.2(M)+.

151: 100 mg of tert-butyl4-((2-chloro-4-morpholinothieno[2,3-d]pyrimidin-6-yl)methyl)piperazine-1-carboxylatewas reacted with quinolin-3-yl-3-boronic ester via Procedure A. Thiscrude intermediate was subjected to Procedure D.

The crude HCl salt of3-(4-morpholino-6-((piperazin-1-yl)methyl)thieno[2,3-d]pyrimidin-2-yl)quinolinereacted with L-Lactic acid via Procedure B to give 68 mg of the desiredproduct after reverse phase HPLC purification. MS (Q1) 519.2 (M)+.

153: 100 mg of tert-butyl4-((2-chloro-4-morpholinothieno[2,3-d]pyrimidin-6-yl)methyl)piperazine-1-carboxylatewas reacted with3-((2(trimethylsilyl)ethoxy)methyl)-2-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3H-imidazo[4,5-b]pyridinevia Procedure A. Crude intermediate tert-butyl4-((2-(1-((2-(trimethylsilyl)ethoxy)methyl)-2-methyl-1H-benzo[d]imidazol-6-yl)-4-morpholinothieno[2,3-d]pyrimidin-6-yl)methyl)piperazine-1-carboxylatewas then refluxed overnight with 2 equivalents oftetrabutylammoniumfluoride in THF to remove the SEM protecting group.The crude material was then extracted with water and ethyl acetate. Theorganic layer was concentrated to dryness and then subjected toProcedure D.

The crude HCl salt of2-(2-methyl-1H-benzo[d]imidazol-5-yl)-4-morpholino-6-((piperazin-1-yl)methyl)thieno[2,3-d]pyrimidinewas reacted with L-Lactic Acid via Procedure B to give 14.1 mg of thedesired product after reverse phase HPLC purification. MS (Q1) 523.2(M)+.

142:2-chloro-6-((4-(methylsulfonyl)piperazin-1-yl)methyl)-4-morpholinofuro[3,2-d]pyrimidine(1 eq), azaindole boronic ester (1.7 eq) andbis(triphenylphosphine)palladium(II) dichloride (0.1 eq) in 1M Na₂CO₃aqueous solution (3 eq) and an equal volume of acetonitrile (3 eq) washeated to 130° C. in a sealed microwave reactor for 10 min. Uponcompletion, the reaction mixture was concentrated and crude mixture waspurified by reverse phase HPLC to yield 12 mg of5-(4-morpholinofuro[2,3-d]pyrimidin-2-yl)pyrimidin-2-amine. MS (Q1) 498(M)⁺.141:2-chloro-6-((4-(methylsulfonyl)piperazin-1-yl)methyl)-4-morpholinofuro[2,3-d]pyrimidine(1 eq), 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazole (1.7eq) and bis(triphenylphosphine)palladium(II) dichloride (0.1 eq) in 1MKOAc aqueous solution (3 eq) and an equal volume of acetonitrile (3 eq)was heated to 140° C. in a sealed microwave reactor for 10 min. Uponcompletion, the reaction mixture was concentrated and crude mixture waspurified by reverse phase HPLC to yield 16 mg of2-(1H-indazol-4-yl)-6-((4-methylsulfonylpiperazin-1-yl)methyl)-4-morpholinofuro[2,3-d]pyrimidine.MS (Q1) 498 (M)⁺.128:2-chloro-6-((4-(methylsulfonyl)piperazin-1-yl)methyl)-4-morpholinofuro[3,2-d]pyrimidine(1 eq), indole boronic ester (1.7 eq) andbis(triphenylphosphine)palladium(II) dichloride (0.1 eq) in 1M Na₂CO₃aqueous solution (3 eq) and an equal volume of acetonitrile (3 eq) washeated to 140° C. in a sealed microwave reactor for 10 min. Uponcompletion, the reaction mixture was concentrated and crude mixture waspurified by reverse phase HPLC to yield 12 mg of5-(4-morpholinofuro[2,3-d]pyrimidin-2-yl)pyrimidin-2-amine. MS (Q1) 497(M)⁺.133: Prepared from the appropriate intermediate according to GeneralProcedure A using5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[2,3-b]pyridine.The compound is obtained after reverse phase HPLC purification (49 mg).MS (Q1) 514 (M)+130: To 2-chloro-4-morpholinothieno[3,2-d]pyrimidine-6-carbaldehyde (100mg, 0.35 mmol) in 1,2-dichloroethane (2 mL) was added AcOH (20 μL, 0.35mmol) and 4-Amino-1-BOC-piperidine (210 mg, 1.05 mmol). The resultingsolution stirred overnight at room temperature then Na(OAc)₃BH (90 mg,0.42 mmol) was added and the reaction stirred 4 h at room temperature.The reaction was quenched with water and extracted with DCM then EtOAc.The combined organics were dried over Na₂SO₄, filtered, and concentratedin vacuo. The crude product was dissolved in MeOH (5 mL) and AcOH (80μL), then formaldehyde (37%, 31 μL) and NaCNBH₃ (26 mg, 0.42 mmol) wereadded. The reaction mixture was allowed to stir overnight thenadditional formaldehyde (37%, 56 μL) was added to drive the reaction tocompletion.

After 1 h at room temperature the reaction was complete and quenchedwith saturated aqueous K₂CO₃ and diluted with EtOAc. The aqueous layerwas extracted with EtOAc and the combined organics were dried overNa₂SO₄, filtered, and concentrated in vacuo. The crude product wasdissolved in CH₂Cl₂ (10 mL), MeOH (10 mL), and Et₂O (5 mL) and 4 M HClin dioxane (10 mL) was added. The resulting mixture stirred at roomtemperature for 3 days then was concentrated in vacuo. The residue wasdissolved in CH₂Cl₂ (20 mL) and Et₃N (5 mL) was added. Excess water wasadded to the solution. The organic phase was separated and the aqueouslayer was extracted with EtOAc. The combined organics were dried overNa₂SO₄, filtered, and concentrated in vacuo. The crude material wascarried onto the next step without purification. Compound 130 wasproduced by Suzuki coupling with4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazole according toGeneral Procedure A (6 mg). MS (Q1) 464 (M)+

EXAMPLE 6 Additional Compounds of the Invention

The following additional compounds of the invention were prepared. Thecompound numbering corresponds to that used in Table 1B above.

129: To N—BOC-piperazine (1.3 g) in dry DCM (10 ml) was addedtriethylamine (1.2 mL) and cyclopropanesulphonyl chloride (1.04 g) andthe reaction mixture was stirred at room temperature for 16 hours. Thereaction mixture was then diluted with DCM, washed with water, dried(MgSO₄) and reduced in vacuo. The residue was dissolved in methanol (10mL) and 4M HCL in dioxane was added (20 mL). After stirring overnightthe solvent was reduced in vacuo to yield1-cyclopropanesulfonyl-piperazine hydrochloride.

2-chloro-4-morpholin-4-yl-thieno[3,2-d]pyrimidine-6-carbaldehyde wastreated with 1-cyclopropanesulfonyl-piperazine hydrochloride usingGeneral Procedure C (reductive amination) to yield2-chloro-6-(4-cyclopropanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine.

2-chloro-6-(4-cyclopropanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidinewas reacted with4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1H-indazole in generalprocedure A. Purification by column chromatography yielded the titlecompound.

(400 Mhz, CDCl3): 1.00-1.02 (2H, m, CH2), 1.19-1.23 (2H, m, CH2), 2.29(1H, m, CH), 2.69 (4H, m, CH2), 3.40 (4H, m, CH2), 3.91-3.94 (6H, m,CH2), 4.08-4.11 (4H, m, CH2), 7.41 (1H, s, ar), 7.49-7.53 (1H, m, ar),7.60 (1H, d (J8.30), ar), 8.29 (1H, d J (7.05), ar), 9.02 (1H, s, ar),10.10 (1H, b, NH)

(M+H)+ 540.34

137:2-Chloro-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidinewas reacted with5-(4,4,5,5-tetramethyl-[1.3.2]dioxaborolan-2-yl)-1H-indazole(commercially available) in general procedure A. Purification by columnchromatography yielded the title compound.

NMR: CDCl₃: 2.58-2.62 (4H, m, CH₂), 2.74 (1H, s, Me), 3.22-3.25 (4H, m,CH₂), 3.82 (2H, s, CH₂), 3.82-3.86 (4H, m, CH₂), 4.00-4.02 (4H, m, CH₂),7.28 (1H, s, Ar), 7.48 (1H, d, J 8.2, Ar), 8.09 (1H, s, Ar), 8.48 (1H,d, J 8.2, Ar), 8.82 (1H, d, J 7.5, Ar) and 10.01 (1H, s, NH).

MS: (ESI+): MH+ 514.17

143:(2-chloro-4-morpholin-4-yl-thieno[3,2-d]pyrimidin-6-ylmethyl)-methyl-aminewas made by treating2-chloro-4-morpholin-4-yl-thieno[3,2-d]pyrimidine-6-carbaldehyde(intermediate 10) and 40% methylamine in water according to GeneralProcedure C (reductive amination).

(2-Chloro-4-morpholin-4-yl-thieno[3,2-d]pyrimidin-6-ylmethyl)-(1-isopropyl-piperidin-4-yl)-methyl-aminewas made by treating(2-chloro-4-morpholin-4-yl-thieno[3,2-d]pyrimidin-6-ylmethyl)-methyl-amineand 1-isopropyl-4-piperidone according to the General Procedure C(reductive amination).

A suspension of(2-chloro-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-ylmethyl)-(1-isopropyl-piperidin-4-yl)-methyl-amine(63 mg, 0.149 mmol),4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1H-indazole (44 mg,0.179 mmol), 1M Na₂CO₃ (0.5 ml, 0.5 mmol) and Pd(PPh₃)₂Cl₂ (11 mg, 0.015mmol) in acetonitrile (3 ml) was heated in a microwave at 140° C. for 25mins. The reaction was then acidified with 2N HCl (aq) extracted withethyl acetate, the water layer separated and basified with K₂CO₃ (sat.aq) resulting in an impure precipitate. This was purified on aluminausing 5% methanol in dichloromethane as the eluent, (11 mg, 15%).

NMR (CDCl3, 400 MHz), 0.96 (6H, d, J=6.4), 1.54-1.60 (2H, m), 1.77-1.80(2H, m), 2.04-2.09 (2H, m), 2.30 (3H, s), 2.40-2.46 (1H, m), 2.62-2.68(1H, m), 2.88-2.92 (2H, m), 3.84 (4H, t, J=4.4), 3.87 (2H, s), 4.02 (4H,t, J=4.8), 7.19 (1H, s), 7.43 (1H, t, J=7.6), 7.50 (1H, d, J=8.4), 8.20(1H, dd, J=7.2, 0.8), 8.95 (1H, d, J=0.8), 10.2 (1H, br s).

MS: (ESI+): MH+=506.

145: Intermediate F (1.00 g) was reacted with tert-butyl-1-piperazinecarboxylate (0.85 g) in General Procedure Z. Aqueous work-up andpurification on silica gave4-(2-chloro-4-morpholin-4-yl-thieno[2,3-d]pyrimidine-6-ylmethyl)-piperazine-1-carboxylicacid tert-butyl ester (1.61 g).

4-(2-Chloro-4-morpholin-4-yl-thieno[2,3-d]pyrimidine-6-ylmethyl)-piperazine-1-carboxylicacid tert-butyl ester (1.61 g) was treated with an excess of hydrogenchloride in diethyl ether at room temperature overnight. Removal ofvolatiles and basification with aqueous sodium hydrogen chlorideafforded2-chloro-4-morpholin-4-yl-6-piperazin-1-ylmethyl-thieno[2,3-d]pyrimidine(0.90 g).

To2-chloro-4-morpholin-4-yl-6-piperazin-1-ylmethyl-thieno[2,3-d]pyrimidine(187 mg) in anhydrous DCM (5 ml) and triethylamine (111 ul) was addedcyclopropanesulfonyl chloride (65 ul) at 0° C. The reaction mixture wasallowed to warm up to room temperature over 4 hours. Aqueous work-up andpurification on silica gave2-chloro-4-morpholin-4-yl-6-[4-(cyclopropane-2-sulfonyl)-piperazin-1-ylmethyl]-thieno[2,3-d]pyrimidine(159 mg).2-Chloro-4-morpholin-4-yl-6-[4-(cyclopropane-2-sulfonyl)-piperazin-1-ylmethyl]-thieno[2,3-d]pyrimidinewas reacted with 7-azaindole-5-boronic acid pinacol ester in GeneralProcedure A. Purification on silica yielded the desired compound.

NMR (CDCl3): 1.00-1.05 (2H, m), 1.18-1.22 (2H, m), 2.28-2.32 (1H, m),2.65-2.69 (4H, m), 3.37-3.41 (4H, m), 3.83 (2H, s), 3.92-3.96 (4H, m),4.00-4.04 (4H, m), 6.62-6.64 (1H, m), 7.18 (1H, s), 7.37-7.39 (1H, m),9.02 (1H, d), 9.37 (1H, br), 9.46 (1H, d)

MS (ESI+): MH+ 540.21 (15%)

146: To2-chloro-4-morpholin-4-yl-6-piperazin-1-ylmethyl-thieno[2,3-d]pyrimidine(150 mg) in anhydrous DCM (4 ml) and triethylamine (90 ul) was added2-thiophenesulfonyl chloride (101 ul) at 0° C. The reaction mixture wasallowed to warm up to room temperature over 4 hours. Aqueous work-up andpurification on silica gave2-chloro-4-morpholin-4-yl-6-[4-(thiophene-2-sulfonyl)-piperazin-1-ylmethyl]-thieno[2,3-d]pyrimidine(208 mg).2-Chloro-4-morpholin-4-yl-6-[4-(thiophene-2-sulfonyl)-piperazin-1-ylmethyl]-thieno[2,3-d]pyrimidinewas reacted with 7-azaindole-5-boronic acid pinacol ester in GeneralProcedure A. Purification on silica yielded the desired compound.

NMR (CDCl3): 2.67-2.70 (4H, m), 3.15-3.18 (4H, m), 3.79 (2H, s),3.91-3.95 (4H, m), 3.99-4.03 (4H, m), 6.61-6.63 (1H, m), 7.15 (1H, s),7.18-7.20 (1H, m), 7.33-7.36 (1H, m), 7.54-7.57 (1H, m), 7.66-7.68 (1H,m), 8.91 (1H, br), 8.99 (1H, d), 9.44 (1H, d)

MS (ESI+): MH+ 582 (10%)

138:4-[6-(4-Methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidin-2-yl]-benzene-1,2-diamine(150 mg, described above)) was heated in dry THF (4 ml) with CDI (195mg) at 40° C. for 5 hours and then stirred at room temperatureovernight. Added water, precipitate was filtered, washed with water anddried. The residue was purified by flash chromatography to give thetitle compound (43 mg).

NMR (DMSO): 2.49-2.52 (4H, m), 2.90 (3H, s), 3.15-3.18 (4H, m),3.80-3.83 (4H, m), 3.92 (2H, s), 3.95-3.97 (4H, m), 7.00 (1H, d, J=8.2),7.39 (1H, s), 7.99 (1H, s), 8.12 (1H, d, J=8.2), 10.65 (1H, br), 10.80(1H, br)

MS (ESI+): MH+ 530.36

139: A solution of (3-acetamido-2-nitrophenyl)boronic acid (300 mg) in2M aqueous hydrochloric acid solution (4 mL) was heated at 80° C. for 20min. After cooling to room temperature, the solvent was reduced in vacuoto give a brown solid which was redissolved in 1,4-dioxane (5 mL).Pinacol (316 mg) was added and the mixture heated at 100° C. for 30 min.After cooling to room temperature the solvent was reduced in vacuo togive a beige solid which was dissolved in acetic acid (5 mL). Palladiumon carbon (100 mg) was added and the mixture stirred under an atmosphereof hydrogen at 40° C. for 1 h. The reaction mixture was then filteredthrough Celite and the filtrate reduced in vacuo. Purification by columnchromatography gave2-amino-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline.

2-Chloro-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidinewas reacted with2-amino-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline ingeneral procedure A. Purification by column chromatography yielded3-[6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidin-2-yl]-benzene-1,2-diaminewhich was heated in formic acid at reflux for 4 h. After cooling to roomtemperature, the solution was poured into saturated aqueoussodiumhydrogen carbonate solution (20 mL) and extracted intodichloromethane (3×20 mL). The combined organics were washed withaqueous brine solution (2×20 mL), dried (MgSO₄), reduced in vacuo andpurified by column chromatography to give the title compound.

NMR: CDCl₃: 2.62-2.65 (4H, m, CH₂), 2.74 (3H, s, Me), 3.24-3.27 (4H, m,CH₂), 3.84 (2H, s, CH₂), 3.85-3.87 (4H, m, CH₂), 4.01-4.05 (4H, m, CH₂),7.30-7.32 (2H, m, Ar), 7.86 (1H, d, J 7.9, Ar), 8.10 (1H, s, Ar) and8.32 (1H, d, J 7.9, Ar).

MS: (ESI+): MH+ 514.22

144: A solution of 2,3-diamino-5-bromopyridine (1.34 g) in formic acid(7 mL) was heated at reflux for 3 h. After cooling to room temperature,the solvent was reduced in vacuo to give an off-white solid which wasrecrystallised from methanol-water to give6-bromo-3H-imidazo[4,5-b]pyridine as a pale orange solid.

To a solution of 6-bromo-3H-imidazo[4,5-b]pyridine (1.0 g) in THF (20mL) at 0° C. was added sodium hydride (187 mg) and the reaction stirredat 0° C. for 1 h. Then, 2-(trimethylsilyl)ethoxymethyl chloride (0.94mL) was added and the reaction stirred at room temperature for 16 h. Thereaction was quenched with water (20 mL) and extracted into ethylacetate (2×20 mL). The combined organics were washed with aqueous brinesolution (2×20 mL), dried (MgSO₄), reduced in vacuo and purified bycolumn chromatography to give6-bromo-3-(2-trimethylsilanyl-ethoxymethyl)-3H-imidazo[4,5-b]pyridine.

To a solution of6-bromo-3-(2-trimethylsilanyl-ethoxymethyl)-3H-imidazo[4,5-b]pyridine(350 mg) in 1,4-dioxane (10 mL) was added bis(tributyltin) (1.08 mL),tetrakis(triphenylphosphine)palladium (0) (62 mg) and lithium chloride(136 mg) and the reaction heated at reflux for 16 h. After cooling toroom temperature, the reaction mixture was filtered through Celite,washing with ethyl acetate. The filtrate was washed with water (2×30mL), aqueous brine solution (2×20 mL), dried (MgSO₄), reduced in vacuoand purified by column chromatography to give6-tributylstannanyl-3-(2-trimethylsilanyl-ethoxymethyl)-3H-imidazo[4,5-b]pyridineas a colourless oil.

To a solution of2-chloro-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine(450 mg) in DMF (6 mL) was added sodium thiomethoxide (183 mg) and thereaction heated at 100° C. for 16 h. After cooling to room temperaturethe reaction mixture was poured into ice water and the resultingprecipitate filtered and air dried to give6-(4-methanesulfonyl-piperazin-1-ylmethyl)-2-methylsulfanyl-4-morpholin-4-yl-thieno[3,2-d]pyrimidineas a white solid.

To a solution of6-(4-methanesulfonyl-piperazin-1-ylmethyl)-2-methylsulfanyl-4-morpholin-4-yl-thieno[3,2-d]pyrimidine(90 mg) in 1,2-dimethoxyethane (10 mL) was added6-tributylstannanyl-3-(2-trimethylsilanyl-ethoxymethyl)-3H-imidazo[4,5-]pyridine(219 mg) and copper(I)bromide-dimethylsulfide (84 mg) and the reactionstirred at room temperature for 10 min. Then,tetrakis(triphenylphosphine)palladium (0) (12 mg) was added and thereaction heated at reflux for 16 h. After cooling to room temperature,the reaction mixture was diluted with ethyl acetate (20 mL) and washedwith water (2×30 mL), aqueous brine solution (2×20 mL), dried (MgSO₄),reduced in vacuo and purified by column chromatography to give6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-2-[3-(2-trimethylsilanyl-ethoxymethyl)-3H-imidazo[4,5-b]pyridin-6-yl]-thieno[3,2-d]pyrimidineas a white solid.

To a solution of6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-2-[3-(2-trimethylsilanyl-ethoxymethyl)-3H-imidazo[4,5-b]pyridin-6-yl]-thieno[3,2-d]pyrimidine(70 mg) in THF (10 mL) was added tetrabutylammonium fluoride (0.16 mL ofa 1 M solution in THF) and the reaction heated at reflux for 1 h. Aftercooling to room temperature, the reaction was diluted withdichloromethane (20 mL) and washed with water (2×30 mL), aqueous brinesolution (2×20 mL), dried (MgSO₄), reduced in vacuo and purified bycolumn chromatography to give the title compound.

NMR: CDCl₃: 2.61-2.64 (4H, m, CH₂), 2.76 (3H, s, Me), 3.22-3.25 (4H, m,CH₂), 3.80 (2H, s, CH₂), 3.81-3.84 (4H, m, CH₂), 4.02-4.05 (4H, m, CH₂),7.31 (1H, s, Ar), 8.21 (1H, s, Ar), 9.09 (1H, s, Ar) and 9.50 (1H, s,Ar).

MS: (ESI+): MH+ 515.19

147: To a solution2-chloro-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[2,3-d]pyrimidine(450 mg) in DMF (6 mL) was added sodium thiomethoxide (183 mg) and thereaction heated at 1100° C. for 16 h. After cooling to room temperaturethe reaction mixture was poured into ice water and the resultingprecipitate filtered and air dried to give6-(4-methanesulfonyl-piperazin-1-ylmethyl)-2-methylsulfanyl-4-morpholin-4-yl-thieno[2,3-d]pyrimidineas a white solid.

To a solution of6-(4-methanesulfonyl-piperazin-1-ylmethyl)-2-methylsulfanyl-4-morpholin-4-yl-thieno[2,3-d]pyrimidine(90 mg) in 1,2-dimethoxyethane (10 mL) was added6-tributylstannanyl-3-(2-trimethylsilanyl-ethoxymethyl)-3H-imidazo[4,5-]pyridine(219 mg) and copper(I)bromide-dimethylsulfide (84 mg) and the reactionstirred at room temperature for 10 min. Then,tetrakis(triphenylphosphine)palladium (0) (12 mg) was added and thereaction heated at reflux for 16 h. After cooling to room temperature,the reaction mixture was diluted with ethyl acetate (20 mL) and washedwith water (2×30 mL), aqueous brine solution (2×20 mL), dried (MgSO₄),reduced in vacuo and purified by column chromatography to give6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-2-[3-(2-trimethylsilanyl-ethoxymethyl)-3H-imidazo[4,5-b]pyridin-6-yl]-thieno[2,3-d]pyrimidineas a white solid.

To a solution of6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-2-[3-(2-trimethylsilanyl-ethoxymethyl)-3H-imidazo[4,5-b]pyridin-6-yl]-thieno[2,3-d]pyrimidine(70 mg) in THF (10 mL) was added tetrabutylammonium fluoride (0.16 mL ofa 1 M solution in THF) and the reaction heated at reflux for 1 h. Aftercooling to room temperature, the reaction was diluted withdichloromethane (20 mL) and washed with water (2×30 mL), aqueous brinesolution (2×20 mL), dried (MgSO₄), reduced in vacuo and purified bycolumn chromatography to give the title compound.

NMR: CDCl₃: 2.58-2.61 (4H, m, CH₂), 2.72 (3H, s, Me), 3.21-3.23 (4H, m,CH₂), 3.76 (2H, s, CH₂), 3.80-3.82 (4H, m, CH₂), 3.92-3.94 (4H, m, CH₂),7.10 (1H, s, Ar), 8.15 (1H, s, Ar), 9.09 (1H, s, Ar) and 9.49 (1H, s,Ar).

MS: (ESI+): MH+ 515.14

135: Intermediate G (500 mg) was reacted with2-nitro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (613 mg)in a General Procedure A. Aqueous work-up and purification by flashchromatography gave4-[6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidin-2-yl]-2-nitro-phenylamine(633 mg).

4-[6-(4-Methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidin-2-yl]-2-nitro-phenylamine(200 mg) was stirred under hydrogen balloon with palladium on carbon(10%, 70 mg) in a mixture of MeOH and DCM (1:1, 10 ml) at roomtemperature overnight. The reaction mixture was then filtered throughCelite®, volatiles removed in vacuo, and the residue purified by flashchromatography to give4-[6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidin-2-yl]-benzene-1,2-diamine(99 mg).

4-[6-(4-Methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidin-2-yl]-benzene-1,2-diamine(95 mg) was refluxed in formic acid (1 mL) for 1 hour. The reactionmixture was basified with aqueous sodium hydrogen carbonate andextracted into DCM. Flash chromatography and recrystallisation from hotDCM/hexane gave the title compound (32 mg).

NMR (CDCl3): 2.67-2.71 (4H, m), 2.81 (3H, s), 3.29-3.33 (4H, m), 3.89(2H, s), 3.89-3.93 (4H, m), 4.08-4.12 (4H, m), 7.35 (1H, s), 7.70-7.80(1H, br), 8.10 (1H, s), 8.48 (1H, d, J=8.6), 8.80 (1H, br)

MS (ESI+): MH+ 514.20 (100%)

136: 2-Nitro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline(1.00 g) was stirred under hydrogen balloon with palladium on carbon(10%, 150 mg) in a mixture of MeOH and DCM (1:1, 10 ml) at roomtemperature overnight. The reaction mixture was then filtered throughCelite®, volatiles removed in vacuo, and the residue purified by flashchromatography to give4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzene-1,2-diamine (890mg).

Intermediate G (750 mg) was reacted with4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzene-1,2-diamine (815mg) in a General Procedure A. Purification by flash chromatographyafforded4-[6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidin-2-yl]-benzene-1,2-diamine(535 mg).

4-[6-(4-Methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidin-2-yl]-benzene-1,2-diamine(102 mg) was refluxed in acetic acid (1 mL) for 1 hour. The reactionmixture was basified with aqueous sodium hydrogen carbonate andextracted into DCM. Flash chromatography and diethyl ether triturationgave the title compound (47 mg).

NMR (CDCl3/MeOD): 2.56 (3H, s), 2.63-2.66 (4H, m), 2.78 (3H, s),3.24-3.27 (4H, m), 3.85 (2H, s), 3.85-3.87 (4H, m), 4.02-4.05 (4H, m),7.29 (1H, s), 7.60 (1H, br), 8.22 (1H, d, J=1.5), 8.30 (1H, br)

MS (ESI+): MH+ 528.33

154:2-Chloro-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[2,3-d]pyrimidinewas reacted with 2-aminopyrimidine-5-boronic acid pinacol ester ingeneral procedure A. Purification by column chromatography yielded5-[6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[2,3-d]pyrimidin-2-yl]-pyrimidin-2-ylamine.

To a solution of5-[6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[2,3-d]pyrimidin-2-yl]-pyrimidin-2-ylamine(70 mg) in chloroacetaldehyde (2 mL) was added sodium hydrogen carbonate(300 mg) and the mixture was stirred at room temperature for 72 h. Themixture was then diluted with dichloromethane (10 mL) and washed withaqueous brine solution (2×10 mL), dried (MgSO₄), reduced in vacuo andpurified by column chromatography to give the title compound.

NMR: CDCl₃: 2.60-2.63 (4H, m), 2.54 (3H, s), 3.21-3.24 (4H, m), 3.76(2H, s), 3.83-3.85 (4H, m), 3.91-3.94 (4H, m), 7.53 (1H, s, Ar), 7.78(1H, s, Ar), 9.36 (1H, d, J 2.2, Ar) and 9.50 (1H, d, J 2.2, Ar).

MS: (ESI+): MH+ 515.19

155: To 1-BOC-homopiperazine (0.8 ml) was added methane sulphonylchloride (0.34 ml) and triethylamine (0.68 ml). The reaction mixture wasstirred at room temperature for 4 hours. The reaction mixture was thenpartitioned between dichloromethane and water. The combined organicextracts were then washed with brine and dried (MgSO₄). The solvent wasremoved in vacuo to yield 1.23 g of crude4-methanesulfonyl-[1,4]diazepane-1-carboxylic acid tert-butyl ester.

Crude 4-methanesulfonyl-[1,4]diazepane-1-carboxylic acid tert-butylester (1.23 g) was stirred in anhydrous methanol (10 ml). 2M hydrogenchloride in ether (22 ml) was added. The reaction mixture was stirred atroom temperature. After 5 minutes a precipitate formed, addition ofanhydrous methanol (5 ml) caused this to dissolve. The reaction mixturewas stirred overnight at room temperature. The solvents were removed invacuo to yield 1.06 g of 1-methanesulfonyl-[1,4]diazepane hydrochloridesalt.

Reaction between2-chloro-4-morpholin-4-yl-thieno[2,3-d]pyrimidine-6-carbaldehyde and1-methanesulfonyl-[1,4]diazepane hydrochloride salt using GeneralProcedure C (reductive amination) yielded2-chloro-6-(4-methanesulfonyl-[1,4]diazepan-1-ylmethyl)-4-morpholin-4-yl-thieno[2,3-d]pyrimidine.

2-Chloro-6-(4-methanesulfonyl-[1,4]diazepan-1-ylmethyl)-4-morpholin-4-yl-thieno[2,3-d]pyrimidinewas reacted with4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1H-indazole in generalprocedure A. Purification by column chromatography yielded the titlecompound.

(400 MHz CDCl3): 3.38-3.44 (4H, m, CH2), 3.86-3.92 (10H, m, CH2), 7.10(1H, s, ar), 7.42-7.46 (1H, m, ar), 7.53 (1H, d (J=8.33), ar), 8.25 (1H,d (J=6.65), ar), 8.96 (1H, s, ar), 10.00 (H, b, NH)

MH+=528.24

156: To 1-BOC-homopiperazine (0.8 ml) was added methane sulphonylchloride (0.34 ml) and triethylamine (0.68 ml). The reaction mixture wasstirred at room temperature for 4 hours. The reaction mixture was thenpartitioned between dichloromethane and water. The combined organicextracts were then washed with brine and dried (MgSO₄). The solvent wasremoved in vacuo to yield 1.23 g crude4-methanesulfonyl-[1,4]diazepane-1-carboxylic acid tert-butyl ester.

Crude 4-Methanesulfonyl-[1,4]diazepane-1-carboxylic acid tert-butylester (1.23 g) was stirred in anhydrous methanol (10 ml). 2M hydrogenchloride in ether (22 ml) was added. The reaction mixture was stirred atroom temperature. After 5 minutes a precipitate formed, addition ofanhydrous methanol (5 ml) caused this to dissolve. The reaction mixturewas stirred overnight at room temperature. The solvents were removed invacuo to yield 1.06 g of 1-methanesulfonyl-[1,4]diazepane hydrochloridesalt.

Reaction between2-chloro-4-morpholin-4-yl-thieno[3,2-d]pyrimidine-6-carbaldehyde and1-methanesulfonyl-[1,4]diazepane hydrochloride salt using procedure Cyielded2-chloro-6-(4-methanesulfonyl-[1,4]diazepan-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine.This compound was subjected to procedure A to yield the desired finalcompound which was purified using flash chromatography.

NMR: (400 MHz, CDCl3): 1.26 (3H, s, CH3), 1.96 (2H, m, CH2), 2.86-2.88(4H, m, CH2), 3.49-3.52 (4H, m, CH2), 3.92-3.94 (4H, m, CH2), 4.03 (2H,s, CH2), 4.08-4.11 (4H, m, CH2), 7.38 (1H, s, ar), 7.51-7.53 (1H, m,ar), 7.58 (1H, d, ar), 8.28 (1H, d, J (7.41), ar), 9.02 (1H, s, ar),10.05 (1H, b, NH)

(M+H)+ 528.23

157: 2-Nitro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline(1.00 g) was stirred under hydrogen balloon with palladium on carbon(10%, 150 mg) in a mixture of MeOH and DCM (1:1, 10 ml) at roomtemperature overnight. The reaction mixture was then filtered throughCelite®, volatiles removed in vacuo, and the residue purified by flashchromatography to give4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzene-1,2-diamine (890mg).

Intermediate G (750 mg) was reacted with4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzene-1,2-diamine (815mg) in a General Procedure A. Purification by flash chromatographyafforded4-[6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidin-2-yl]-benzene-1,2-diamine(535 mg).4-[6-(4-Methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidin-2-yl]-benzene-1,2-diamine(102 mg) was refluxed in acetic acid (1 mL) for 1 hour. The reactionmixture was basified with aqueous sodium hydrogen carbonate andextracted into DCM. Flash chromatography and diethyl ether triturationgave the title compound (47 mg).

NMR (CDCl3/MeOD): 2.56 (3H, s), 2.63-2.66 (4H, m), 2.78 (3H, s),3.24-3.27 (4H, m), 3.85 (2H, s), 3.85-3.87 (4H, m), 4.02-4.05 (4H, m),7.29 (1H, s), 7.60 (1H, br), 8.22 (1H, d, J=1.5), 8.30 (1H, br)

MS (ESI+): MH+ 528.33

158:2-Chloro-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidinewas reacted with5-(4,4,5,5-tetramethyl-[1.3.2]dioxaborolan-2-yl)-1H-indazole(commercially available) in general procedure A. Purification by columnchromatography yielded the title compound.

NMR: CDCl₃: 2.58-2.62 (4H, m, CH₂), 2.74 (1H, s, Me), 3.22-3.25 (4H, m,CH₂), 3.82 (2H, s, CH₂), 3.82-3.86 (4H, m, CH₂), 4.00-4.02 (4H, m, CH₂),7.28 (1H, s, Ar), 7.48 (1H, d, J 8.2, Ar), 8.09 (1H, s, Ar), 8.48 (1H,d, J 8.2, Ar), 8.82 (1H, d, J 7.5, Ar) and 10.01 (1H, s, NH).

159: A solution of4-(6-((4-methylsulfonyl)piperazin-1-yl)methyl)-4-morpholinothieno[2,3-d]pyrimidin-2-yl)benzene-1,2-diamine(87.5 mg, 0.20 mMol) in 1 mL of formic acid was refluxed for severalhours, then cooled to room temperature and concentrated in vacuo to givea dark solid. This residue was taken into DMF at 100 mM, and purified byprep RP-HPLC to give 36.5 mg of the desired product in a 36.5% yield MS(Q1) 514.0 (M)+160: A solution of4-(6-((4-methylsulfonyl)piperazin-1-yl)methyl)-4-morpholinothieno[2,3-d]pyrimidin-2-yl)benzene-1,2-diamine(87.5 mg, 0.20 mMol) in 1 mL of acetic acid was refluxed for severalhours, then cooled to room temperature and concentrated in vacuo to givea dark solid. This residue was taken into DMF at 100 mM, and purified byprep RP-HPLC to give 31.5 mg of the desired product in a 30% yield MS(Q1) 528.5 (M)+161:12-chloro-6-((4-(methylsulfonyl)piperazin-1-yl)methyl)-4-morpholinothieno[2,3-d]pyrimidineand 3,5-diaminophenyl boronic acid were used in General procedure ASuzuki Coupling to produce4-(6-((4-methylsulfonyl)piperazin-1-yl)methyl)-4-morpholinothieno[2,3-d]pyrimidin-2-yl)benzene-1,2-diaminein 78% yield MS (Q1) 514.2 (M)+

EXAMPLE 7 Biological Testing

Compounds of the invention, prepared as described in the precedingExamples, were submitted to the following series of biological assays:

(i) PI3K Biochemical Screening

Compound inhibition of PI3K was determined in a radiometric assay usingpurified, recombinant enzyme and ATP at a concentration of 1 uM. Allcompounds were serially diluted in 100% DMSO. The kinase reaction wasincubated for 1 hour at room temperature, and the reaction wasterminated by the addition of PBS. IC₅₀ values were subsequentlydetermined using sigmoidal dose-response curve fit (variable slope). Allof the compounds tested had an IC₅₀ against PI3K of 50 uM or less.

(ii) Cellular Proliferation Inhibition

Cells were seeded at optimal density in a 96 well plate and incubatedfor 4 days in the presence of test compound. Alamar Blue™ wassubsequently added to the assay medium, and cells were incubated for 6hours before reading at 544 nm excitation, 590 nm emission. EC₅₀ valueswere calculated using a sigmoidal dose response curve fit. All thecompounds tested had an EC₅₀s of 50 uM or less in the range of celllines utilized.

(iii) Caco-2 Permeability

Caco-2 cells were seeded onto Millipore Multiscreen plates at 1×10⁵cells/cm², and were cultured for 20 days. Assessment of compoundpermeability was subsequently conducted. The compounds were applied tothe apical surface (A) of cell monolayers and compound permeation intothe basolateral (B) compartment was measured. This was performed in thereverse direction (B-A) to investigate active transport. A permeabilitycoefficient value, P_(app), for each compound, a measure of the rate ofpermeation of the compound across the membrane, was calculated.Compounds were grouped into low (P_(app)</=1.0×10⁶ cm/s) or high(P_(app)>/=1.0×10⁶ cm/s) absorption potential based on comparison withcontrol compounds with established human absorption.

For assessment of a compound's ability to undergo active efflux, theratio of basolateral (B) to apical (A) transport compared with A to Bwas determined. Values of B-A/A-B>/=1.0 indicated the occurrence ofactive cellular efflux. All of the compounds tested through the Caco-2permeability screen had P_(app) values >/=1.0×10⁶ cm/s. One compoundassessed through the bidirectional assay, PI540, had an B-A/A-Basymmetry index of less than 1.0, indicating that the compound does notundergo active cellular efflux.

(iv) Hepatocyte Clearance

Suspensions of cryopreserved human hepatocytes were used. Incubationswere performed at compound concentration of 1 mM or 3 μM at a celldensity of 0.5×10⁶ viable cells/mL. The final DMSO concentration in theincubation was 0.25%. Control incubations were also performed in theabsence of cells to reveal any non-enzymatic degradation. Duplicatesamples (50 μL) were removed from the incubation mixture at 0, 5, 10,20, 40 and 60 minutes (control sample at 60 minutes only) and added tomethanol—containing internal standard (100 μL)—to terminate thereaction. Tolbutamide, 7-hydroxycoumarin, and testosterone were used ascontrol compounds. Samples were centrifuged and the supernatants at eachtime point pooled for analysis by LC-MSMS. From a plot of ln peak arearatio (parent compound peak area/internal standard peak area) againsttime, intrinsic clearance (CL_(int)) was calculated as follows: CL_(int)(μl/min/million cells)=V×k, where k is the elimination rate constant,obtained from the gradient of ln concentration plotted against time; Vis a volume term derived from the incubation volume and is expressed asuL 10⁶ cells⁻¹.

Compounds were classified with low (CL</=4.6 μL/min/10⁶ cells), medium(CL>/=4.6; </=25.2 μl/min/10⁶ cells) and high (>/=25.2 μl/min/10⁶ cells)clearance. The majority of the tested compounds of the invention weredetermined to have low hepatocyte clearance.

(v) Cytochrome P450 Inhibition

Compounds of the invention were screened against five CYP450 targets(1A2, 2C9, 2C19, 2D6, 3A4) at 10 concentrations in duplicate, with a topconcentration of 100 uM being used. Standard inhibitors (furafylline,sulfaphenazole, tranylcypromine, quinidine, ketoconazole) were used ascontrols. Plates were read using a BMG LabTechnologies PolarStar influorescence mode. The majority of the tested compounds assessed in thisassay displayed weak activity (IC₅₀>/=5 uM) against all isoforms ofCYP450.

(vi) Cytochrome P450 Induction

Freshly isolated human hepatocytes from a single donor were cultured for48 hours prior to addition of test compound at three concentrations andwere incubated for 72 hours. Probe substrates for CYP3A4 and CYP1A2 wereadded for 30 minutes and 1 hour before the end of the incubation. At 72hours, cells and media were removed and the extent of metabolism of eachprobe substrate quantified by LC-MS/MS. The experiment was controlled byusing inducers of the individual P450s incubated at one concentration intriplicate. The compounds of the invention assessed in this assay showednegligible effects on induction of cytochrome P450 enzymes.

(vii) Plasma Protein Binding

Solutions of test compound (5 um, 0.5% final DMSO concentration) wereprepared in buffer and 10% plasma (v/v in buffer). A 96 well HT dialysisplate was assembled so that each well was divided in two by asemi-permeable cellulose membrane. The buffer solution was added to oneside of the membrane and the plasma solution to the other side;incubations were then conducted at 37° C. over 2 hours in triplicate.The cells were subsequently emptied, and the solutions for each batch ofcompounds were combined into two groups (plasma-free andplasma-containing) then analysed by LC-MSMS using two sets ofcalibration standards for plasma-free (6 points) and plasma-containingsolutions (7 points). The fraction unbound value for each compound wascalculated: highly protein bound compounds (>/=90% bound) had anFu</=0.1. The compounds of the invention assessed in this assay had Fuvalues >/=0.1.

(viii) hERG Channel Blockage

Compounds of the invention were evaluated for their ability to modulaterubidium efflux from HEK-294 cells stably expressing hERG potassiumchannels using established flux methodology. Cells were prepared inmedium containing RbCl and were plated into 96-well plates and grownovernight to form monolayers. The efflux experiment was initiated byaspirating the media and washing each well with 3×100 μL ofpre-incubation buffer (containing low [K⁺]) at room temperature.Following the final aspiration, 50 μL of working stock (2×) compound wasadded to each well and incubated at room temperature for 10 minutes. 50μL of stimulation buffer (containing high [K+]) was then added to eachwell giving the final test compound concentrations. Cell plates werethen incubated at room temperature for a further 10 minutes. 80 μL ofsupernatant from each well was then transferred to equivalent wells of a96-well plate and analysed via atomic emission spectroscopy. Compoundswere screened as 10pt duplicate IC₅₀ curves, n=2, from a topconcentration of 100 μM.

EXAMPLE 8 p110 Isoform Selectivity Scintillation Proximity Binding Assay

The ability of representative compounds from Tables 1a and 1b to inhibitthe lipid kinase activity of purified preparations of human PI3Kisoforms alpha, beta, delta, and gamma was determined by a radiometricscintillation proximity assay (SPA, GE Healthcare, AmershamBiosciences). Concentration dependent inhibition at 50% (IC₅₀ μMol) wasdetermined for all four isoforms (alpha) and fold potency over beta,delta, and gamma relative to alpha was calculated for a selection ofcompounds in Table 2. Each compound has a p110 alpha IC₅₀<1 μMol.

TABLE 2 Compound alpha/beta alpha/delta alpha/gamma 2 >10 <10 >10 4 >10<10 >10 7 >10 <10 >10 16 >10 <10 >10 23 >10 <10 >10 24 >10 <10 >1027 >10 <10 >10 28 >10 <10 >10 29 >10 <10 >10 34 >10 <10 >10 54 <10<10 >10 57 >10 <10 >10 58 >10 <10 >10 59 >10 <10 >10 60 >10 <10 >1062 >10 <10 >10 65 <10 <10 >10 66 <10 <10 >10 89 >10 >10 >10 90 >10<10 >10 94 >10 <10 >10 95 >10 >10 >10 133 >10 <10 >10 139 <10 <10 <10140 >10 >10 >10 141 <10 <10 >10 142 >10 <10 >10 144 <10 <10 >10147 >10 >10 >10 157 >10 <10 >10

EXAMPLE 9 Tablet Composition

Tablets, each weighing 0.15 g and containing 25 mg of a compound of theinvention are manufactured as follows:

Composition for 10,000 Tablets

Active compound (250 g)

Lactose (800 g)

Corn starch (415 g)

Talc powder (30 g)

Magnesium stearate (5 g)

The active compound, lactose and half of the corn starch are mixed. Themixture is then forced through a sieve 0.5 mm mesh size. Corn starch (10g) is suspended in warm water (90 ml). The resulting paste is used togranulate the powder. The granulate is dried and broken up into smallfragments on a sieve of 1.4 mm mesh size. The remaining quantity ofstarch, talc and magnesium is added, carefully mixed and processed intotablets.

EXAMPLE 10 Injectable Formulation

Formulation A Active compound 200 mg Hydrochloric Acid Solution 0.1M orSodium Hydroxide Solution 0.1M q.s. to pH 4.0 to 7.0 Sterile water q.s.to  10 ml

The compound of the invention is dissolved in most of the water (35° 40°C.) and the pH adjusted to between 4.0 and 7.0 with the hydrochloricacid or the sodium hydroxide as appropriate. The batch is then made upto volume with water and filtered through a sterile micropore filterinto a sterile 10 ml amber glass vial (type 1) and sealed with sterileclosures and overseals.

Formulation B Active Compound 125 mg Sterile, Pyrogen-free, pH 7Phosphate Buffer, q.s. to 25 ml Active compound 200 mg Benzyl Alcohol0.10 g Glycofurol 75 1.45 g Water for injection q.s to 3.00 ml

The active compound is dissolved in the glycofurol. The benzyl alcoholis then added and dissolved, and water added to 3 ml. The mixture isthen filtered through a sterile micropore filter and sealed in sterile 3ml glass vials (type 1).

EXAMPLE 11 Syrup Formulation

Active compound 250 mg Sorbitol Solution 1.50 g Glycerol 2.00 g Sodiumbenzoate 0.005 g Flavour 0.0125 ml Purified Water q.s. to 5.00 ml

The compound of the invention is dissolved in a mixture of the glyceroland most of the purified water. An aqueous solution of the sodiumbenzoate is then added to the solution, followed by addition of thesorbitol solution and finally the flavour. The volume is made up withpurified water and mixed well.

The invention claimed is:
 1. A compound which is fused pyrimidine offormula (Ib′):

wherein X is O or S; Y is N or —CH—; R² is H, halo or C₁-C₆ alkyl; eachR′ is, independently, H, C₁-C₆ alkyl or hydroxy-C₁-C₆ alkyl, or twogroups R′ on the same carbon atom form an oxo (═O) group; or when Y isN, two groups R′ on different carbon atoms together form a —CH₂—bridgehead; each R″ is, independently, H or C₁-C₆ alkyl, or two groupsR″ on the same carbon atom form an oxo (═O) group; Z is R¹⁰ or-(alk)_(q)-NR¹¹R¹²; R¹⁰ is H, a C₃-C₆ cycloalkyl group, C₁-C₆ alkylwhich is unsubstituted, or CF₃; R¹¹ and R¹² are each independentlyselected from H, C₁-C₆ alkyl which is unsubstituted and -(alk)_(q)-OR,or R¹¹ and R¹² together form, with the N atom to which they areattached, a 5- or 6-membered saturated N-containing heterocyclic groupcontaining 0 or 1 additional heteroatoms selected from O, N and S; q is0 or 1; r is 0 or 1; alk is C₁-C₆ alkylene; and and R³ is selected from:(a) a group of the following formula:

wherein B is a phenyl ring which is unsubstituted or substituted and Zis selected from H, —OR, —SR, CH₂OR, —CO₂R, CF₂OH, CH(CF₃)OH, C(CF₃)₂OH,—(CH₂)_(q)OR, —(CH₂)_(q)NR₂, —C(O)N(R)₂, —NR₂, —NRC(O)R, —S(O)_(m)N(R)₂,—OC(O)R, OC(O)N(R)₂, —NRS(O)_(m)R, —NRC(O)N(R)₂, CN, halogen and —NO₂,wherein each R is independently selected from H, C₁-C₆ alkyl, C₃-C₁₀cycloalkyl and a 5- to 12-membered aryl or heteroaryl group, the groupbeing unsubstituted or substituted, m is 1 or 2 and q is 0, 1 or 2; (b)a heteroaryl group which contains 1, 2, 3 or 4 ring nitrogen atoms and0, 1 or 2 additional heteroatoms selected from O and S, which group isbicyclic and which is unsubstituted or substituted; and (c) a benzenering which is unsubstituted or substituted and which is fused to aheteroaryl group as defined above; or a pharmaceutically acceptable saltthereof.
 2. A compound which is a fused pyrimidine of formula (Ib):

wherein X is O or S; R¹ is a group of formula:

R² is H, halo or C₁-C₆ alkyl R⁴ and R⁵ form, together with the N atom towhich they are attached, a group selected from piperazine, piperidine,pyrrolidine, oxazolidinone, diazepan and2,5-diaza-bicyclo[2,2,1]-heptane, which group is unsubstituted orsubstituted by -[(alk)_(q)-NR]_(r)—S(O)₂-(alk)_(q)-Z or—C(O)-(alk)_(q)-S(O)₂Z wherein Z is R¹⁰ or —NR¹¹R¹², or by unsubstitutedC₁-C₆ alkyl, hydroxyl-C₁-C₆ alkyl, oxo (═O), -(alk)_(q)-OR,—C(O)—C(R′)₂—N(R)₂, —C(R)₂—C(O)—N(R)₂, —C(O)—(NR)_(q)-(alk)_(q)-OR,—C(O)-cyclyl, —C(O)R, —C(O)OR, —C(O)-Tet or —NR¹³R¹⁴; or one of R⁴ andR⁵ is C₁-C₆ alkyl, -(alk)_(q)-Heterocyclyl or -(alk)_(q)-OR and theother is a piperazine, piperidine, pyrrolidine, sulphonylpyran or-(alk)_(q)-Heterocyclyl group, wherein said piperazine, piperidine,pyrrolidine, sulphonylpyran or Heterocyclyl is unsubstituted orsubstituted by C₁-C₆ alkyl, -(alk)_(q)-OR or —S(O)₂R¹⁰; R is H or C₁-C₆alkyl which is unsubstituted; each R′ is, independently, H or C₁-C₆alkyl which is unsubstituted, or the two groups R′ form, together withthe C atom to which they are attached, a cyclyl group; R¹⁰ is H, cyclyl,C₁-C₆ alkyl which is unsubstituted or CF₃; R¹¹ and R¹² are eachindependently selected from H, C₁-C₆ alkyl which is unsubstituted and-(alk)_(q)-OR, or R¹¹ and R¹² together form, with the N atom to whichthey are attached, a 5- or 6-membered saturated N-containingheterocyclic group containing 0 or 1 additional heteroatoms selectedfrom O, N and S; R¹³ and R¹⁴ are each independently selected from C₁-C₆alkyl, —S(O)₂R¹⁰, and -(alk)_(q)-OR; Tet is a tetrahydrofuranyl ortetrahydropyranyl group, which group is unsubstituted or substituted;Heterocyclyl is a 5- or 6-membered saturated N-containing heterocyclicgroup containing 0 or 1 additional heteroatoms selected from O, N and S;Cyclyl is a C₃-C₆ cycloalkyl group; each q is independently 0 or 1; r is0 or 1; alk is C₁-C₆ alkylene; and R³ is selected from: (a) a group ofthe following formula:

wherein B is a phenyl ring which is unsubstituted or substituted, and Zis selected from H, —OR, —SR, CH₂OR, —CO₂R, CF₂OH, CH(CF₃)OH, C(CF₃)₂OH,—(CH₂)_(q)OR, —(CH₂)_(q)NR₂, —C(O)N(R)₂, —NR₂, —NRC(O)R, —S(O)_(m)N(R)₂,—OC(O)R, OC(O)N(R)₂, —NRS(O)_(m)R, —NRC(O)N(R)₂, CN, halogen and —NO₂,wherein each R is independently selected from H, C₁-C₆ alkyl, C₃-C₁₀cycloalkyl and a 5- to 12-membered aryl or heteroaryl group, the groupbeing unsubstituted or substituted, m is 1 or 2 and q is 0, 1 or 2; (b)a heteroaryl group which contains 1, 2, 3 or 4 ring nitrogen atoms and0, 1 or 2 additional heteroatoms selected from O and S, which group isbicyclic and which is unsubstituted or substituted; and (c) a benzenering which is unsubstituted or substituted and which is fused to aheteroaryl group as defined above; or a pharmaceutically acceptable saltthereof; with the proviso that: (i) when X in formula (Ib) is S, then R³is other than an indole group.
 3. A compound which is a fused pyrimidineof formula (Ib):

wherein X is O or S; R¹ is a group of formula:

R² is H, halo or C₁-C₆ alkyl R⁴ and R⁵ form, together with the N atom towhich they are attached, a group selected from piperazine, pyrrolidine,oxazolidinone, diazepan and 2,5-diaza-bicyclo[2,2,1]-heptane, whichgroup is unsubstituted or substituted by-[(alk)_(q)-NR]_(r)—S(O)₂-(alk)_(q)-Z or —C(O)-(alk)_(q)-S(O)₂Z whereinZ is R¹⁰ or —NR¹¹R¹², or by unsubstituted C₁-C₆ alkyl,—C(O)—C(R′)₂—N(R)₂, —C(O)-cyclyl, —C(O)R, —C(O)-Tet or —NR¹³R¹⁴; or oneof R⁴ and R⁵ is C₁-C₆ alkyl, -(alk)_(q)-Heterocyclyl or -(alk)_(q)-ORand the other is a piperazine, piperidine, pyrrolidine, sulphonylpyranor -(alk)_(q)-Heterocyclyl group, wherein said piperazine, piperidine,pyrrolidine, sulphonylpyran or Heterocyclyl is unsubstituted orsubstituted by C₁-C₆ alkyl, -(alk)_(q)-OR or —S(O)₂R¹⁰; R is H or C₁-C₆alkyl which is unsubstituted; each R′ is, independently, H or C₁-C₆alkyl which is unsubstituted, or the two groups R′ form, together withthe C atom to which they are attached, a cyclyl group; R¹⁰ is H, cyclyl,C₁-C₆ alkyl which is unsubstituted or CF₃; R¹¹ and R¹² are eachindependently selected from H, C₁-C₆ alkyl which is unsubstituted and-(alk)_(q)-OR, or R¹¹ and R¹² together form, with the N atom to whichthey are attached, a 5- or 6-membered saturated N-containingheterocyclic group containing 0 or 1 additional heteroatoms selectedfrom O, N and S; R¹³ and R¹⁴ are each independently selected from C₁-C₆alkyl, —S(O)₂R¹⁰, and -(alk)_(q)-OR; Tet is a tetrahydrofuranyl ortetrahydropyranyl group, which group is unsubstituted or substituted;Heterocyclyl is a 5- or 6-membered saturated N-containing heterocyclicgroup containing 0 or 1 additional heteroatoms selected from O, N and S;Cyclyl is a C₃-C₆ cycloalkyl group; each q is independently 0 or 1; r is0 or 1; alk is C₁-C₆ alkylene; and R³ is 1H-indazol-4-yl; or apharmaceutically acceptable salt thereof.
 4. A compound according toclaim 2 wherein R¹ is (4-methylsulfonylpiperazin-1-yl)methyl.
 5. Acompound according to claim 2 wherein R² is H.
 6. A compound accordingto claim 2 wherein R³ is selected from:

where W is CR¹⁰ or N; each R¹⁰ is independently selected from H, C₁-C₆alkyl, C₁-C₆ alkoxy, C₁-C₆ acyl, —C(O)NR′R″, —S(O)_(t)NR′R″, aryl,heteroaryl, sulphonyl and halogen; R′ and R″ are each independently H orC₁-C₆ alkyl; and t is 1 or
 2. 7. A compound according to claim 2 whereinR³ is 1H-indazol-4-yl.
 8. A compound selected from:2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-((4-methylsulfonylpiperazin-1-yl)methyl)-4-morpholinothieno[2,3-d]pyrimidine;(3-(6-((4-methylpiperazin-1-yl)methyl)-4-morpholinothieno[2,3-d]pyrimidin-2-yl)phenyl)methanol;2-(1H-indazol-4-yl)-6-((4-N,N-dimethylaminosulfonylpiperidin-1-yl)methyl)-4-morpholinothieno[2,3-d]pyrimidine;2-(1H-indazol-4-yl)-6-((4-methylsulfonylpiperidin-1-yl)methyl)-4-morpholinothieno[2,3-d]pyrimidine;2-(1H-indazol-4-yl)-6-((4-methylpiperazin-1-yl)methyl)-4-morpholinothieno[2,3-d]pyrimidine;2-(1H-indazol-4-yl)-6-((4-methylsulfonylpiperazin-1-yl)methyl)-4-morpholinothieno[2,3-d]pyrimidine;4-[6-(4-Methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[2,3-d]pyrimidin-2-yl]-isoquinoline;3-[6-(4-Methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[2,3-d]pyrimidin-2-yl]-quinoline;2-(1H-Indazol-4-yl)-6-((S)-4-methanesulfonyl-3-methyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[2,3-d]pyrimidine;2-(1H-Indazol-4-yl)-4-morpholin-4-yl-6-[4-(propane-2-sulfonyl)-piperazin-1-ylmethyl]-thieno[2,3-d]pyrimidine;2-(1H-Indazol-4-yl)-6-((R)-4-methanesulfonyl-3-methyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[2,3-d]pyrimidine;2-(1H-Indazol-4-yl)-6-((2S,6R)-4-methanesulfonyl-2,6-dimethyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[2,3-d]pyrimidine;2-(1H-Indazol-4-yl)-4-morpholin-4-yl-thieno[2,3-d]pyrimidin-6-ylmethyl]-methyl-(1-methyl-piperidin-4-yl)-amine;2-{4-[2-(1H-Indazol-4-yl)-4-morpholin-4-yl-thieno[2,3-d]pyrimidin-6-ylmethyl]-piperazin-1-yl}-N,N-dimethyl-acetamide;2-{4-[2-(1H-Indazol-4-yl)-4-morpholin-4-yl-thieno[2,3-d]pyrimidin-6-ylmethyl]-piperazin-1-yl}-N-methyl-isobutyramide;2-(1H-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-5-methyl-4-morpholin-4-yl-thieno[2,3-d]pyrimidine;(S)-1-(4-((2-(1H-indazol-4-yl)-4-morpholinothieno[2,3-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxypropan-1-one;(R)-1-(4-((2-(1H-indazol-4-yl)-4-morpholinothieno[2,3-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxypropan-1-one;1-(4-((2-(1H-indazol-4-yl)-4-morpholinothieno[2,3-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxy-2-methylpropan-1-one;1-(4-((2-(1H-indazol-4-yl)-4-morpholinothieno[2,3-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxyethanone;1-(4-((2-(1H-indazol-4-yl)-4-morpholinothieno[2,3-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-methoxyethanone;(4-((2-(1H-indazol-4-yl)-4-morpholinothieno[2,3-d]pyrimidin-6-yl)methyl)piperazin-1-yl)(tetrahydrofuran-2-yl)methanone;1-(4-((2-(1H-indazol-4-yl)-4-morpholinothieno[2,3-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-amino-2-methylpropan-1-one;(4-((2-(1H-indazol-4-yl)-4-morpholinothieno[2,3-d]pyrimidin-6-yl)methyl)piperazin-1-yl)(1-aminocyclopropyl)methanone;1-(4-((2-(1H-indazol-4-yl)-4-morpholinothieno[2,3-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-aminoethanone;(S)-1-(4-((2-(1H-indazol-4-yl)-4-morpholinothieno[2,3-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-aminopropan-1-one;(R)-1-(4-((2-(1H-indazol-4-yl)-4-morpholinothieno[2,3-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-aminopropan-1-one;and1-(4-((2-(1H-indazol-4-yl)-4-morpholinothieno[2,3-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-(methylsulfonyl)ethanone;6-((4-methylsulfonylpiperazin)1-yl)methyl)-4-morpholino-2-(1H-pyrrolo[2,3-b]pyridin)5-yl)thieno[2,3-d]pyrimidine;2-(1H-indazol-4-yl)-6-[((4-methylsulfonylpiperazin-1-yl)methyl)-4-morpholinofuro[2,3-d]pyrimidine;6-((4-isopropylsulfonylpiperazin-1-yl)methyl)-4-morpholino-2-(1H-pyrrolo[2,3-b]pyridin-5-yl)thieno[2,3-d]pyrimidine;6-(6-((4-methylsulfonylpiperazin)1-yl)methyl)-4-morpholinothieno[2,3-d]pyrimidin-2-yl)-3H-imidazo[4,5-b]pyridine;(S)-2-hydroxy-1-(4-((4-morpholino-2-(1H-pyrrolo[2,3-b]pyridin-5-yl)thieno[2,3-d]pyrimidin-6-yl)methyl)piperazin-1-yl)propan-1-one;(S)-2-hydroxy-1-(4-((4-morpholino-2-(quinolin-3-yl)thieno[2,3-d]pyrimidin-6-yl)methyl)piperazin-1-yl)propan-1-one;2-methyl-6-(6((4-methylsulfonylpiperazin-1-yl)methyl)-4-morpholinothieno[2,3-d]pyrimidin-2-yl)-3H-imidazo[4,5-b]pyridine;(S)-2-hydroxy-1-(4-((2-(2-methyl-3H-imidazo[4,5-b]pyridin-6-yl)-4-morpholinothieno[2,3-d]pyrimidin-6-yl)methyl)piperazin-1-yl)propan-1-one;6-(6-((4-methylsulfonylpiperazin-1-yl)methyl)-4-morpholinothieno[2,3-d]pyrimidin-2-yl)imidazo[1,2-a]pyrimidine;2-(1H-Indazol-4-yl)-6-(4-methanesulfonyl-[1,4]diazepan-1-ylmethyl)-4-morpholin-4-yl-thieno[2,3-d]pyrimidine;2-(1H-benzo[d]imidazol-5-yl)-6-((4-(methylsulfonyl)piperazin-1-yl)methyl)-4-morpholinothieno[2,3-d]pyrimidine;2-(2-methyl-1H-benzo[d]imidazol-5-yl)-6-(4-(methylsulfonyl)piperazin-1-yl)methyl)-4-morpholinothieno[2,3-d]pyrimidine;4-(6-((4-(methylsulfonyl)piperazin-1-yl)methyl)-4-morpholinothieno[2,3-d]pyrimidin-2-yl)benzene-1,2-diamine;4-(6-((4-(methylsulfonyl)piperazin-1-yl)methyl)-2-(pyrido[2,3-b]pyrazin-7-yl)thieno[2,3-d]pyrimidin-4-yl)morpholine;4-(6-((4-(methylsulfonyl)piperazin-1-yl)methyl)-2-(1H-pyrazolo[3,4-b]pyridin-5-yl)thieno[2,3-d]pyrimidin-4-yl)morpholine;4-(6-((4-(methylsulfonyl)piperazin-1-yl)methyl)-2-(1H-pyrazolo[3,4-c]pyridin-4-yl)thieno[2,3-d]pyrimidin-4-yl)morpholine;4-(6-((4-(methylsulfonyl)piperazin-1-yl)methyl)-2-(5,6,7,8-tetrahydroquinolin-3-yl)thieno[2,3-d]pyrimidin-4-yl)morpholine;andN,1-dimethyl-N-((4-morpholino-2-(quinolin-3-yl)thieno[2,3-d]pyrimidin-6-yl)methyl)piperidin-4-amine;and the pharmaceutically acceptable salts thereof.
 9. A pharmaceuticalcomposition which comprises a pharmaceutically acceptable carrier ordiluent and, as an active ingredient, a compound as claimed in claim 2.10. A composition according to claim 9, further comprising achemotherapeutic agent.
 11. A composition according to claim 9 which isformulated for oral administration.
 12. A kit comprising: (a) a firstpharmaceutical composition comprising a compound as defined in claim 2;(b) a second pharmaceutical composition that comprises a compound havinganti-hyperproliferative activity; and (c) instructions for thesimultaneous, sequential or separate administration of said first andsecond pharmaceutical compositions to a patient in need thereof; whereinsaid first and second pharmaceutical compositions are contained inseparate containers.